
<html lang="en"     class="pb-page"  data-request-id="295d646e-d262-4842-9f51-b7fa2b0953f5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-9;article:article:10.1021/acs.jmedchem.9b01392;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor" /></meta><meta name="dc.Creator" content="Qibin  Su" /></meta><meta name="dc.Creator" content="Erica  Banks" /></meta><meta name="dc.Creator" content="Geraldine  Bebernitz" /></meta><meta name="dc.Creator" content="Kirsten  Bell" /></meta><meta name="dc.Creator" content="Cassandra F.  Borenstein" /></meta><meta name="dc.Creator" content="Huawei  Chen" /></meta><meta name="dc.Creator" content="Claudio E.  Chuaqui" /></meta><meta name="dc.Creator" content="Nanhua  Deng" /></meta><meta name="dc.Creator" content="Andrew D.  Ferguson" /></meta><meta name="dc.Creator" content="Sameer  Kawatkar" /></meta><meta name="dc.Creator" content="Neil P.  Grimster" /></meta><meta name="dc.Creator" content="Linette  Ruston" /></meta><meta name="dc.Creator" content="Paul D.  Lyne" /></meta><meta name="dc.Creator" content="Jon A.  Read" /></meta><meta name="dc.Creator" content="Xianyou  Peng" /></meta><meta name="dc.Creator" content="Xiaohui  Pei" /></meta><meta name="dc.Creator" content="Stephen  Fawell" /></meta><meta name="dc.Creator" content="Zhanlei  Tang" /></meta><meta name="dc.Creator" content="Scott  Throner" /></meta><meta name="dc.Creator" content="Melissa M.  Vasbinder" /></meta><meta name="dc.Creator" content="Haoyu  Wang" /></meta><meta name="dc.Creator" content="Jon  Winter-Holt" /></meta><meta name="dc.Creator" content="Richard  Woessner" /></meta><meta name="dc.Creator" content="Allan  Wu" /></meta><meta name="dc.Creator" content="Wenzhan  Yang" /></meta><meta name="dc.Creator" content="Michael  Zinda" /></meta><meta name="dc.Creator" content="Jason G.  Kettle" /></meta><meta name="dc.Description" content="JAK1, JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways is associated with a wide variety of..." /></meta><meta name="Description" content="JAK1, JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways is associated with a wide variety of..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 16, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01392" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01392" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01392" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01392" /></link>
        
    
    

<title>Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01392" /></meta><meta property="og:title" content="Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0013.jpeg" /></meta><meta property="og:description" content="JAK1, JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways is associated with a wide variety of diseases. Particularly, pSTAT3 is observed in response to the treatment with inhibitors of oncogenic signaling pathways such as EGFR, MAPK, and AKT and is associated with resistance or poorer response to agents targeting these pathways. Among the JAK family kinases, JAK1 has been shown to be the primary driver of STAT3 phosphorylation and signaling; therefore, selective JAK1 inhibition can be a viable means to overcome such treatment resistances. Herein, an account of the medicinal chemistry optimization from the promiscuous kinase screening hit 3 to the candidate drug 21 (AZD4205), a highly selective JAK1 kinase inhibitor, is reported. Compound 21 has good preclinical pharmacokinetics. Compound 21 displayed an enhanced antitumor activity in combination with an approved EGFR inhibitor, osimertinib, in a preclinical non-small-cell lung cancer (NSCLC) xenograft NCI-H1975 model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01392"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01392">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01392&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01392&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01392&amp;href=/doi/10.1021/acs.jmedchem.9b01392" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 4517-4527</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01336" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01573" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of (2<i>R</i>)-<i>N</i>-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1<i>H</i>-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Qibin Su</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qibin Su</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#dcadb5beb5b2f2afa99cbdafa8aebda6b9b2b9bfbdf2bfb3b1"><span class="__cf_email__" data-cfemail="93e2faf1fafdbde0e6d3f2e0e7e1f2e9f6fdf6f0f2bdf0fcfe">[email protected]</span></a>. Tel.: +1 781-839-4175.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qibin++Su">Qibin Su</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3394-3614" title="Orcid link">http://orcid.org/0000-0003-3394-3614</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erica Banks</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erica Banks</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erica++Banks">Erica Banks</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Geraldine Bebernitz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Geraldine Bebernitz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Geraldine++Bebernitz">Geraldine Bebernitz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kirsten Bell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kirsten Bell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kirsten++Bell">Kirsten Bell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cassandra F. Borenstein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cassandra F. Borenstein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cassandra+F.++Borenstein">Cassandra F. Borenstein</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huawei Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huawei Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huawei++Chen">Huawei Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claudio E. Chuaqui</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claudio E. Chuaqui</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claudio+E.++Chuaqui">Claudio E. Chuaqui</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nanhua Deng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nanhua Deng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nanhua++Deng">Nanhua Deng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew D. Ferguson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew D. Ferguson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+D.++Ferguson">Andrew D. Ferguson</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1018-9631" title="Orcid link">http://orcid.org/0000-0002-1018-9631</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sameer Kawatkar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sameer Kawatkar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sameer++Kawatkar">Sameer Kawatkar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil P. Grimster</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil P. Grimster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil+P.++Grimster">Neil P. Grimster</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0088-1250" title="Orcid link">http://orcid.org/0000-0003-0088-1250</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linette Ruston</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linette Ruston</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linette++Ruston">Linette Ruston</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul D. Lyne</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul D. Lyne</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+D.++Lyne">Paul D. Lyne</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jon A. Read</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jon A. Read</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, R&D, AstraZeneca R&D, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jon+A.++Read">Jon A. Read</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xianyou Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xianyou Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xianyou++Peng">Xianyou Peng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaohui Pei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaohui Pei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaohui++Pei">Xiaohui Pei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen Fawell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Fawell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Fawell">Stephen Fawell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhanlei Tang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhanlei Tang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhanlei++Tang">Zhanlei Tang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott Throner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott Throner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Throner">Scott Throner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melissa M. Vasbinder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melissa M. Vasbinder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melissa+M.++Vasbinder">Melissa M. Vasbinder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haoyu Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haoyu Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haoyu++Wang">Haoyu Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jon Winter-Holt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jon Winter-Holt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jon++Winter-Holt">Jon Winter-Holt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Woessner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Woessner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Woessner">Richard Woessner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Allan Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Allan Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Sciences, R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Allan++Wu">Allan Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenzhan Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenzhan Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Early Product Development, Pharmaceutical Sciences, R&D, Boston, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenzhan++Yang">Wenzhan Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Zinda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Zinda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Zinda">Michael Zinda</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jason G. Kettle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason G. Kettle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Oncology R&D, AstraZeneca R&D, Cambridge CB4 0WG, U.K.</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason+G.++Kettle">Jason G. Kettle</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7373-0758" title="Orcid link">http://orcid.org/0000-0001-7373-0758</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01392&amp;href=/doi/10.1021%2Facs.jmedchem.9b01392" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 4517–4527</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 16, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 August 2019</li><li><span class="item_label"><b>Published</b> online</span>16 April 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 May 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01392</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4517%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DQibin%2BSu%252C%2BErica%2BBanks%252C%2BGeraldine%2BBebernitz%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D9%26contentID%3Dacs.jmedchem.9b01392%26title%3DDiscovery%2Bof%2B%25282R%2529-N-%255B3-%255B2-%255B%25283-Methoxy-1-methyl-pyrazol-4-yl%2529amino%255Dpyrimidin-4-yl%255D-1H-indol-7-yl%255D-2-%25284-methylpiperazin-1-yl%2529propenamide%2B%2528AZD4205%2529%2Bas%2Ba%2BPotent%2Band%2BSelective%2BJanus%2BKinase%2B1%2BInhibitor%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4527%26publicationDate%3DMay%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01392"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2866</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01392" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Qibin&quot;,&quot;last_name&quot;:&quot;Su&quot;},{&quot;first_name&quot;:&quot;Erica&quot;,&quot;last_name&quot;:&quot;Banks&quot;},{&quot;first_name&quot;:&quot;Geraldine&quot;,&quot;last_name&quot;:&quot;Bebernitz&quot;},{&quot;first_name&quot;:&quot;Kirsten&quot;,&quot;last_name&quot;:&quot;Bell&quot;},{&quot;first_name&quot;:&quot;Cassandra&quot;,&quot;last_name&quot;:&quot;F. Borenstein&quot;},{&quot;first_name&quot;:&quot;Huawei&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Claudio&quot;,&quot;last_name&quot;:&quot;E. Chuaqui&quot;},{&quot;first_name&quot;:&quot;Nanhua&quot;,&quot;last_name&quot;:&quot;Deng&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;D. Ferguson&quot;},{&quot;first_name&quot;:&quot;Sameer&quot;,&quot;last_name&quot;:&quot;Kawatkar&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;P. Grimster&quot;},{&quot;first_name&quot;:&quot;Linette&quot;,&quot;last_name&quot;:&quot;Ruston&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;D. Lyne&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;A. Read&quot;},{&quot;first_name&quot;:&quot;Xianyou&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Xiaohui&quot;,&quot;last_name&quot;:&quot;Pei&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Fawell&quot;},{&quot;first_name&quot;:&quot;Zhanlei&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Throner&quot;},{&quot;first_name&quot;:&quot;Melissa&quot;,&quot;last_name&quot;:&quot;M. Vasbinder&quot;},{&quot;first_name&quot;:&quot;Haoyu&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jon&quot;,&quot;last_name&quot;:&quot;Winter-Holt&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Woessner&quot;},{&quot;first_name&quot;:&quot;Allan&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Wenzhan&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Zinda&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;G. Kettle&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;4517-4527&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01392&quot;},&quot;abstract&quot;:&quot;JAK1, JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways is associated with a wide variety of diseases. Particularly, pSTAT3 is observed in response to the treatment with inhibitors of oncogenic signaling pathways such as EGFR, MAPK, and AKT and is associated with resistance or poorer response to agents targeting these pathways. Among the JAK family kinases, JAK1 has been shown to be the primary driver of STAT3 phosphorylation and signaling; therefore, selective JAK1 inhibition can be a viable means to overcome such treatment resistances. Herein, an account of the medicinal chemistry optimization from the promiscuous kinase screening hit 3 to the candidate drug 21 (AZD4205), a highly selective JAK1 kinase inhibitor, is reported. Compound 21 has good preclinical pharmacokinetics. Compound 21 displayed an enhanced antitumor activity in combination with an approved EGFR inhibitor, osimertinib, in a preclinical&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01392&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01392" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01392&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01392" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01392&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01392" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01392&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01392&amp;href=/doi/10.1021/acs.jmedchem.9b01392" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01392" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01392" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01392%26sid%3Dliteratum%253Aachs%26pmid%3D32297743%26genre%3Darticle%26aulast%3DSu%26date%3D2020%26atitle%3DDiscovery%2Bof%2B%25282R%2529-N-%255B3-%255B2-%255B%25283-Methoxy-1-methyl-pyrazol-4-yl%2529amino%255Dpyrimidin-4-yl%255D-1H-indol-7-yl%255D-2-%25284-methylpiperazin-1-yl%2529propenamide%2B%2528AZD4205%2529%2Bas%2Ba%2BPotent%2Band%2BSelective%2BJanus%2BKinase%2B1%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D9%26spage%3D4517%26epage%3D4527%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292017" title="Solvents">Solvents</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/jmcmar.2020.63.issue-9/20200514/jmcmar.2020.63.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">JAK1, JAK2, JAK3, and TYK2 belong to the JAK (Janus kinase) family. They play critical roles in cytokine signaling. Constitutive activation of JAK/STAT pathways is associated with a wide variety of diseases. Particularly, pSTAT3 is observed in response to the treatment with inhibitors of oncogenic signaling pathways such as EGFR, MAPK, and AKT and is associated with resistance or poorer response to agents targeting these pathways. Among the JAK family kinases, JAK1 has been shown to be the primary driver of STAT3 phosphorylation and signaling; therefore, selective JAK1 inhibition can be a viable means to overcome such treatment resistances. Herein, an account of the medicinal chemistry optimization from the promiscuous kinase screening hit <b>3</b> to the candidate drug <b>21</b> (AZD4205), a highly selective JAK1 kinase inhibitor, is reported. Compound <b>21</b> has good preclinical pharmacokinetics. Compound <b>21</b> displayed an enhanced antitumor activity in combination with an approved EGFR inhibitor, osimertinib, in a preclinical non-small-cell lung cancer (NSCLC) xenograft NCI-H1975 model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08608" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08608" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">JAK1 together with JAK2, JAK3, and TYK2 belongs to the JAK (Janus-associated kinase) family of cytoplasmic tyrosine kinases that play important roles in cytokine- and growth factor-mediated signal transduction.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Consequently, the JAK family kinases are strongly associated with both cancer<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and inflammatory diseases.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Currently, there are several approved JAK inhibitors to treat human diseases: tofacitinib (Xeljanz, a pan-JAK inhibitor from Pfizer)<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> for rheumatoid arthritis, ruxolitinib (<b>1</b>, Jakafi, a selective JAK1/2 inhibitor from Incyte)<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> for intermediate- or high-risk myeloproliferative neoplasms, and baricitinib (Olumiant, a JAK1/2 inhibitor)<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> for the treatment of rheumatoid arthritis, together with peficitinib (Smyraf, a pan-JAK inhibitor)<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> approved in Japan for treatment of rheumatoid arthritis. Both compounds have demonstrated clinical benefit in a range of disease areas but have additionally been associated with a number of side effects. Specifically, tofacitinib’s adverse events have included nonserious infections, reduction of leukocyte cell count number, and rare but severe incidences of perforation of the stomach or intestine. With ruxolitinib treatment, thrombocytopenia and anemia were observed.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> These toxicities are believed to be associated with inhibition of JAK2. Thus, the pharmaceutical industry has been motivated to evaluate second-generation inhibitors, which possess increased JAK isoform selectivity in the hope that treatment with such agents may maintain similar efficacy to established therapies but with fewer undesirable side effects. To this end, JAK1 selective inhibitors (e.g., ABT494,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> PF-04965842,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and filgotinib<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a>) are currently being studied in human clinical trials for the treatment of autoimmune or inflammatory diseases.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a></div><div class="NLM_p last">We have a long-standing interest in studying JAK inhibition in the area of oncology.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref20 ref21 ref22">(16−22)</a> There is growing evidence to suggest that dysregulation of constitutively activated JAK/STAT signaling is associated with a wide variety of malignancies.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In particular, increased activation of STAT3 through phosphorylation at Y705 (pSTAT3) is reported in up to 70% of human tumors including ovarian, breast, liver, prostate, colorectal, head and neck, esophageal, pancreatic, bladder, and non-small-cell lung cancers.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31">(24−31)</a> In addition, such elevated pSTAT3 has also been observed in response to chemotherapy treatment and is associated with resistance or poor response to the treatment with agents targeting oncogenic signaling pathways such as EGFR, MAPK, and AKT.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> Among the JAK family kinases, JAK1 has been shown to be the primary driver of STAT3 phosphorylation and signaling.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> JAK2, however, is essential for signal transduction downstream of erythropoietin, thrombopoietin, and other related receptors that control erythrocyte and megakaryocyte expansion.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Taken together, it is believed that a JAK1 selective inhibitor may enable higher target coverage of the JAK1-STAT3 signaling by sparing toxicities such as thrombocytopenia and anemia, associated with JAK2 inhibition, thereby maximizing the clinical benefit of such agents in oncology<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and other therapeutic areas.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Herein, an account of the medicinal chemistry optimization from the promiscuous kinase screening hit <b>3</b> to the candidate drug <b>21</b> (AZD4205), a highly selective JAK1 kinase inhibitor, is reported. Detailed biological and pharmacokinetic evaluation of this compound is also included.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During the course of our discovery program, a patent application describing JAK1 selective inhibitors, such as compound <b>2</b>, were reported.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> We synthesized and tested this compound in house. To our surprise, although derived from the same chemical class as <b>1</b>, a dual JAK1/2 inhibitor (JAK1 IC<sub>50</sub> = 0.02 μM, no selectivity of JAK1 over JAK2), compound <b>2</b> displayed a high degree of JAK1 selectivity (JAK1 IC<sub>50</sub> = 0.02 μM, 120-fold selectivity of JAK1 over JAK2). To rationalize the observed selectivity, an X-ray crystal structure of <b>2</b> bound to the kinase domain of JAK1 was solved (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) X-ray crystal structure of <b>2</b> (yellow carbon atoms) bound to JAK1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SM8">6SM8</a>) reveals a p-loop JAK1 selectivity pocket. Selected residues are shown as sticks. Hydrogen bonds are shown as dashed lines. (B) Overlay of <b>3</b> (green carbon atoms) with the X-ray crystal structure of JAK1 in complex with compound <b>2</b> suggested that substitutions of the 7-position of indole ring can reach the p-loop selectivity pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Analysis of the X-ray structure revealed a bidentate interaction between pyrrolopyrimidine moiety of <b>2</b> with hinge residues Glu957 and Leu959. The pyrrolopyrimidine and the pyrazole ring form hydrophobic interactions with Leu881, Val889, and Leu1010. The nitrile group occupies a small pocket, formed by the isobutyl side chain of Leu101 and Gly1020, and may stabilize the conformation of the pyrrolidine ring while possibly contributing to desolvation of this hydrophobic region. However, most interestingly, a well-ordered p-loop region with clear electron density is seen in the crystal structure. In general, the p-loop in kinases is very flexible. Also, it is common to observe poor or no electron density visible for this region even in high-resolution protein kinase structures.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The presence of such a well-ordered p-loop region suggests a stabilizing interaction between the terminal chloro-cyano-phenyl group of <b>2</b> and the hydrophobic pocket defined by the side chains of protein residues Gly884, His885, Phe886, and Gly1028 of JAK1. We hypothesized that this stabilization contributes to the JAK1 selectivity of <b>2</b> because, in this region, there is a productive π–π stacking interaction between the chloro-cyano-phenyl group of <b>2</b> and the imidazole side chain of His885 in JAK1, which is absent in JAK2, where the corresponding residue is an asparagine.</div><div class="NLM_p">Our program started with a high-throughput screen of the AstraZeneca compound collection against JAK1 to generate three-point IC<sub>50</sub> values. The resulting hits were followed up in a five-point IC<sub>50</sub> dose–response versus JAK1 and JAK2 at the corresponding <i>K</i><sub>m</sub> ATP concentrations (55 and 15 μM, respectively) to identify potent and selective starting points. In the lead optimization phase, we increased the ATP concentration to a more physiologically relevant level in our biochemical assays (5 mM) to assess the inhibitors’ JAK1 potency and their selectivity toward JAK2. Herein, all the biochemical potencies are reported under the 5 mM ATP conditions.</div><div class="NLM_p">From the screening campaign, compound <b>3</b> was identified as a potent JAK1 inhibitor (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, IC<sub>50</sub> = 0.07 μM) with moderate selectivity over JAK2 (JAK2 IC<sub>50</sub> = 0.38 μM, 5-fold selectivity). Docking of <b>3</b> into the JAK1 protein showed that the indole NH binds the carboxylate moiety of Asp1021, while the 2-amino pyrimidine forms interactions with the hinge residue Leu959. Intriguingly, when superimposing<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> the docked pose of <b>3</b> onto the X-ray structure of <b>2</b>, we postulated that the 7-position of the indole may direct substituents toward the p-loop, thereby accessing the JAK1 selectivity pocket (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). Consequently, we designed 7-substituted indole analogs containing an appropriate linker to direct an aryl group to the selectivity pocket and achieve the desired π–π interaction with His885 in the hopes of increasing the isoform selectivity of newly generated compounds. To test this hypothesis, with a consideration of ease of synthesis, <b>4</b>, bearing an amido-linker, was synthesized and evaluated in the JAK1 and JAK2 biochemical assays. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <b>4</b> displayed an increased JAK1 potency (IC<sub>50</sub> = 0.004 μM) and, more importantly, improved selectivity (50-fold) toward JAK2, as compared to <b>3</b> (5-fold).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biochemical Potencies of <b>1</b>, JAK1 Selective Inhibitor <b>2</b>, and In-House Screening Hit <b>3</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0008.gif" alt="" id="gr8" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">selectivity over JAK2 (fold)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">0.07</td><td class="colsep0 rowsep0" align="char" char=".">0.38</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Biochemical potency was measured at 5 mM ATP concentration.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Selectivity expressed as the ratio of JAK2 IC<sub>50</sub> over JAK1 IC<sub>50</sub>. All experimental values represent the geometric mean of at least two independent experiments and have SEM within 0.2 log units. For experimental details, see the Supporting Information of ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of JAK1 Selective 4-Pyrimidine Indoles with Varied Linkers and Solvent Tails</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0009.gif" alt="" id="gr9" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">selectivity over JAK2 (fold)</th><th class="colsep0 rowsep0" align="center" char=".">solubility (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td><td class="colsep0 rowsep0" align="char" char=".">50</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">122</td><td class="colsep0 rowsep0" align="char" char=".">41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">0.043</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.56</td><td class="colsep0 rowsep0" align="char" char=".">140</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">115</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Biochemical potency was measured at 5 mM ATP concentration. Selectivity expressed as the ratio of JAK2 IC<sub>50</sub> over JAK1 IC<sub>50</sub>. All experimental values represent the geometric mean of at least two independent experiments and have SEM within 0.2 log units. For experimental details, see the Supporting Information of ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Solubility was measured at pH 7.4.</p></div></div></div><div class="NLM_p">With this encouraging result, we then turned our attention to explore the SAR of solvent tail groups (denoted as in <b>4</b>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). It has been reported that <i>ortho</i>-substitution on similar solvent tails may reduce JAK2 activity, thus improving selectivity between JAK1 and JAK2.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Capitalizing on this observation, we designed and synthesized <b>5</b> with a 3-methoxy-1-methyl amino-pyrazole solvent tail. Indeed, <b>5</b> retained a high level of JAK1 potency (IC<sub>50</sub> = 0.018 μM) with increased JAK2 selectivity (122-fold). The cyclopropyl amide has also been shown to be a viable hinge binding motif for JAK1,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and compound <b>6</b> exhibited favorable JAK1 potency (IC<sub>50</sub> = 0.043 μM) with an encouraging degree of selectivity over JAK2 (60-fold).</div><div class="NLM_p">We then explored the linkers while keeping the 2-methoxy-1-methyl-aminopyrazole solvent tail group constant. Compound <b>7</b>, with a benzylic amine linker, exhibited favorable JAK1 potency (IC<sub>50</sub> = 0.004 μM), but with low solubility (<0.1 μM). With the reversed amide linker, compound <b>8</b> displayed diminished JAK1 potency (IC<sub>50</sub> = 0.26 μM). This suggested that the amido-linker in <b>5</b> is critical for achieving a high level of JAK1 potency. We therefore elected to use this linker for further SAR exploration.</div><div class="NLM_p">Having leads with promising selectivity between JAK1 and JAK2, we were keen to further evaluate their broader kinase selectivity. To this end, <b>5</b> was tested as representative of the chemical series in a panel of 293 kinases at a single-point concentration (1 μM). To our disappointment, <b>5</b> promiscuously inhibited a broad set of kinases in this panel (80 out of 289 members tested with over 50% inhibitory effect at this concentration. For details, see SI Table 1).</div><div class="NLM_p">To gain additional structural insights, an X-ray structure of <b>5</b> bound to the JAK1 kinase domain was obtained. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> (6SMB), <b>5</b> displayed the expected binding mode: the amino pyrimidine moiety forms a two-point binding interaction with the kinase hinge, consistent with our docked pose for compound <b>3</b>. Notably, a distinct bidentate hydrogen bond interaction of the indole NH and amide moiety with the carboxylate side chain of Asp1021 was observed. Gratifyingly, the interaction between the pyridyl group in <b>5</b> and imidazole side chain of His885 was also observed and stabilized the p-loop region, with clear electron density in the X-ray structure, thus presumably rendering isoform selectivity in a similar manner to that described for <b>2</b>. In addition to the p-loop stabilization, the methoxy functionality on the pyrazole solvent tail group, which also potentially contributes to this isoform selectivity, points toward a small hydrophobic pocket defined by the phenyl ring of Phe958 (side chain) and backbone of Pro960, Ser961, and Gly962 in JAK1. The corresponding pocket in JAK2 is formed by the side chain of Tyr931 and the amide backbones of Pro933, Tyr834, and Gly934. We reasoned that the pocket with a tyrosine residue in JAK2 was more sterically demanding than the one defined by phenylalanine in JAK1. The methoxy-pyrazole solvent tail of <b>5</b> is therefore less well tolerated when bound to the JAK2 protein, thus leading to diminished activity.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of <b>5</b>-JAK1 complex (6SMB). The aminopyrimidine moiety maintains the key hydrogen bonds to the hinge. The amido-indole forms a bidentate hydrogen bond interaction with the side chain carboxylate of Asp1021. The methyl pyridine group forms several hydrophobic interactions in addition to a cation−π interaction with Lys908. Hydrogen bonds are shown as dashed lines. Compound <b>5</b> (yellow carbon atoms) overlays with the X-ray crystal structure of JAK1 in complex with compound <b>2</b> (green carbon atoms).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With this structural information in hand, we set out to improve the broader kinome selectivity of the series while also attempting to identify leads with better physical properties and improved metabolic stability. In protein kinases, the p-loop regions are flexible with highly diversified structures.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> We reasoned that a selective kinase inhibitor might be obtained by further exploiting the interaction in this area of the protein. We synthesized over 300 amide analogs of <b>6</b> using a diverse reagent set, comprising aromatic and aliphatic carboxylic acids, while keeping the cyclopropyl amide solvent tail group constant.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> All compounds synthesized were tested in our JAK1 and JAK2 biochemical assays, and in parallel, their solubility and human microsome clearance (CL<sub>int</sub>) were measured. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> shows the JAK1 biochemical potency versus human microsomal CL<sub>int</sub>, with points colored by the ratio of the IC<sub>50</sub>s of JAK1 over JAK2 and sized by measured solubility at pH 7.4. While most of compounds in the library displayed low solubility or low JAK2 selectivity, we found that compound <b>9</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) had a favorable balance of JAK1 potency and selectivity (JAK1 IC<sub>50</sub> = 180 nM and more than 166-fold selectivity), with good aqueous solubility (>1000 μM) and low human microsome CL<sub>int</sub> (4.4 μL/min/mg). Given the low kinome selectivity of lead compound <b>5</b>, we next tested <b>9</b> in the kinase panel described previously. Remarkably, <b>9</b> displayed an improved kinase selectivity (with only 6 out of 293 kinases tested over 50% inhibition at single dose concentration of 1 μM; see complete kinome screen data in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_001.pdf" class="ext-link">SI Table 2</a>, Supporting Information).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plot of JAK1 biochemical potency vs human microsome CL<sub>int</sub>. Compound <b>9</b> was identified with a favorable balance of potency and properties. Dots were colored by ratio of IC<sub>50</sub>’s of JAK1 over JAK2 and sized by measured solubility at pH 7.4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure, JAK Enzymatic Activity, and Solubility of Compounds <b>9–14</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0010.gif" alt="" id="gr10" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">selectivity over JAK2 (fold)</th><th class="colsep0 rowsep0" align="center" char=".">solubility (μM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">0.18</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>166</td><td class="colsep0 rowsep0" align="char" char=".">>930</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>27</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>65</td><td class="colsep0 rowsep0" align="char" char=".">230</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>18</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>12</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>13</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Biochemical potency was measured at 5 mM ATP concentration. Selectivity expressed as the ratio of JAK2 IC<sub>50</sub> over JAK1 IC<sub>50</sub>. All experimental values represent the geometric mean of at least two independent experiments and have SEM within 0.2 log units. For experimental details, see the Supporting Information of ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Solubility measured at pH 7.4.</p></div></div></div><div class="NLM_p">As compound <b>9</b> bears a significant structural difference from <b>5</b>, an X-ray structure of <b>9</b>-bound JAK1 protein was obtained to elucidate its binding mode (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The interaction at the hinge and the bidentate interaction of the indole NH and amide NH toward Asp1021 of JAK1 are all maintained. Interestingly, an additional salt-bridge interaction between the chiral piperazine moiety and Asp1003 is also evident in the crystal structure. While the X-ray structure also shows a stabilized p-loop with clear electron density, the ligand does not form direct π–π interactions with the loop residues due to lack of an aromatic ring in this region. As Asp1003 is actually conserved between JAK2 and JAK1, we believe that it is the combination of the additional polar interaction, p-loop stabilization, and the selective nature of the solvent tail group that contributes to the favorable JAK1/2 selectivity of <b>9</b>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray structure of <b>9</b>-JAK1 complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GGH">6GGH</a>). In addition to the retained interactions with the hinge and Aps1021, compound <b>9</b> also forms a salt-bridge interaction between the piperazine moiety and Asp1003. Hydrogen bonds are shown as dashed lines. Compound <b>9</b> (orange carbon atoms) overlays with the X-ray crystal structure of JAK1 in complex with compound <b>5</b> (yellow carbon atoms).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Encouraged by the profile of <b>9</b>, we set out to explore the SAR around the chiral basic amides. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the <i>R</i> configuration in <b>9</b> is preferred (JAK1 IC<sub>50</sub> = 0.18 μM) over its enantiomer <b>10</b> (JAK1 IC<sub>50</sub> = 1.1 μM). Achiral compounds, such as <b>11</b> and <b>12</b>, exhibited weaker JAK1 activity (IC<sub>50</sub> = 0.46 and 1.7 μM, respectively). As suggested in the crystal structure, the distal basic center of the chiral amide in <b>9</b> is essential for JAK1 potency. Removal of the basic centers significantly lowered JAK1 potency (<b>13</b>, IC<sub>50</sub> = 2.4 μM; <b>14</b>, IC<sub>50</sub> = 2.2 μM). Gratifyingly, even though the analogs in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> have various levels of JAK1 potency, they consistently displayed high aqueous solubility, indicating that the chemical series has favorable physical properties.</div><div class="NLM_p">Establishing that the initial <i>R</i>-methyl piperazine was the preferred amine, we set out to explore SAR of the solvent tail groups with this newly identified piperazine amide. Having learned that a small <i>ortho</i>-substitution played a critical role in achieving a high level of JAK2 selectivity, we scanned additional <i>ortho</i>-substituted aromatic rings. A series of compounds with a high level of JAK1 selectivity were obtained by deploying this tactic (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Compound <b>15</b> with a 2-methylpyridine solvent tail displayed a high degree of JAK1/2 selectivity, albeit at the expense of JAK1 potency (<b>15</b>, JAK1 IC<sub>50</sub> = 0.13 μM). In contrast, installation of a less sterically demanding <i>ortho</i>-substituent, such as F, restored JAK1 potency while maintaining a high JAK1 selectivity (<b>16</b>, JAK1 IC<sub>50</sub> = 0.027 μM, >1000-fold selectivity versus JAK2). As previously described, the <i>ortho</i>-methoxy pyrazole solvent tail was well tolerated (<b>17</b>, JAK1 IC<sub>50</sub> = 0.010 μM, 540-fold selectivity versus JAK2). Having high JAK1 biochemical potency, these compounds were subsequently evaluated in a cellular assay, measuring the inhibition of phosphorylation of STAT3 (pSTAT3), a downstream substrate of JAK1, in an NCI-H1975 cell line. We found that <b>15</b> inhibited pSTAT3 with IC<sub>50</sub> = 0.18 μM. Compound <b>16</b> displayed a promising JAK1 cellular potency (IC<sub>50</sub> = 0.08 μM); however, disappointingly, the compound was found to inhibit the hERG ion channel (IC<sub>50</sub> = 10 μM). Compound <b>17</b> exhibited a potent cellular activity (IC<sub>50</sub> = 0.13 μM) without any detectable hERG activity (IC<sub>50</sub> > 100 μM).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure and JAK Enzymatic and Cellular Activity and <b>15–17</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0011.gif" alt="" id="gr11" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">selectivity over JAK2 (folds)</th><th class="colsep0 rowsep0" align="center" char=".">pSTAT3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">>30</td><td class="colsep0 rowsep0" align="char" char=".">>230</td><td class="colsep0 rowsep0" align="char" char=".">0.18</td><td class="colsep0 rowsep0" align="char" char=".">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">>1111</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">540</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="char" char=".">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Measured at 5 mM ATP concentration. Selectivity expressed as the ratio of JAK2 IC<sub>50</sub> over JAK1 IC<sub>50</sub>. All values represent the geometric mean of at least two independent experiments and have SEM within 0.2 log units.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Cellular mode of action assay measuring the inhibition of pSTAT3 in NCI-H1975 cells. For experimental details, see the Supporting Information of ref <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>.</p></div></div></div><div class="NLM_p">We next examined the SAR of pyrimidine C5-subsituents. JAK1 possesses a methionine gatekeeper residue; therefore, hydrophobic substituents or hydrogen may be favorable at the C-5 position. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, increasing hydrophobicity of the substituents led to higher JAK1 potency (<b>18</b>, <b>19</b>, and <b>20</b>; IC<sub>50</sub> = 7, 19, and 8 nM respectively); however, we also observed the same trend with JAK2 potency. In addition, <b>18</b> and <b>20</b> exhibited improved cellular potencies (IC<sub>50</sub> = 0.06 and 0.094 μM, respectively) but also displayed moderate hERG ion channel activities (IC<sub>50</sub> = 22 and 15 μM, respectively). Overall, <b>21</b>, with a C5-H substituent exhibited the desired balance of favorable JAK1 potency, selectivity versus JAK2, and no detectable hERG activity. We therefore selected it for further profiling.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Structure and JAK Enzymatic and Cellular Activity of <b>18–21</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0012.gif" alt="" id="gr12" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center" char=".">JAK1 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">JAK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">selectivity over JAK2 (folds)</th><th class="colsep0 rowsep0" align="center" char=".">pSTAT3 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">1.80</td><td class="colsep0 rowsep0" align="char" char=".">257</td><td class="colsep0 rowsep0" align="char" char=".">0.060</td><td class="colsep0 rowsep0" align="char" char=".">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">6.60</td><td class="colsep0 rowsep0" align="char" char=".">347</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">1.57</td><td class="colsep0 rowsep0" align="char" char=".">196</td><td class="colsep0 rowsep0" align="char" char=".">0.094</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">0.070</td><td class="colsep0 rowsep0" align="char" char=".">>15</td><td class="colsep0 rowsep0" align="char" char=".">>214</td><td class="colsep0 rowsep0" align="char" char=".">0.130</td><td class="colsep0 rowsep0" align="char" char=".">>100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Measured at 5 mM ATP concentration. Selectivity expressed as the ratio of JAK2 IC<sub>50</sub> over JAK1 IC<sub>50</sub>. All values represent the geometric mean of at least two independent experiments and have SEM within 0.2 log units.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Cellular mode of action assay measuring the inhibition of pSTAT3 in NCI-H1975 cells. For experimental details, see the Supporting Information of <a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a>.</p></div></div></div><div class="NLM_p">Having <b>21</b> with high selectivity between JAK1 and JAK2, first, we tested <b>21</b> in the biochemical assays of other JAK family kinases with a high concentration of ATP and found that <b>21</b> is inactive toward JAK3 (IC<sub>50</sub> > 30 μM) with only moderate activity toward TYK2 (IC<sub>50</sub> = 2.8 μM). Next, in a panel of 293 kinases at a single-point concentration (1 μM), we found that <b>21</b> showed a high level of selectivity, only inhibiting one other kinase (FLT4) over 75% at this concentration (for details, see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_001.pdf" class="ext-link">SI Table 3</a>, Supporting Information).</div><div class="NLM_p">Compound <b>21</b> displayed high metabolic stability in hepatocyte CL<sub>int</sub> assays across species, with high solubility at pH 6.5 (>1000 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compound <b>21</b> did not inhibit any of the isoforms of human cytochrome P450s up to a concentration of 30 μM. Compound <b>21</b> also displayed high permeability (<i>P</i><sub>app</sub> = 7.5 1 × 10<sup>–6</sup> cm/s) with a low efflux ratio (2.6) in a Caco-2 assay (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compound <b>21</b> displayed favorable pharmacokinetic properties across species (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), showing a low <i>in vivo</i> clearance (20 mL/min/kg) with a moderate half-life (6 h) and excellent oral bioavailability (100%) in rats. We similarly observed that <b>21</b> has low <i>in vivo</i> clearance (9 mL/min/kg) with prolonged half-life (9 h) and high oral availability (71%) in dogs.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Preclinical ADME and Calculated Properties of <b>21</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">calculated properties</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">log<i>D</i> at pH 7.4<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">solubility at pH 6.5 (μM)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">hepatocyte<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> CL<sub>int</sub> ((μL/min)/10<sup>–6</sup> cells) (rat, dog, human)</th><th class="colsep0 rowsep0" align="center">human cytochrome P450 inhibition IC<sub>50</sub> (μM) (all isoforms)</th><th class="colsep0 rowsep0" align="center">permeability Caco-2 A to B <i>P</i><sub>app</sub> (1 × 10<sup>–6</sup> cm/s) (efflux ratio)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">MW</th><th class="colsep0 rowsep0" align="center">PSA</th><th class="colsep0 rowsep0" align="center">log<i>P</i></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">1.7</td><td class="colsep0 rowsep0" align="center">605</td><td class="colsep0 rowsep0" align="center"><1.9, 2.0, <1</td><td class="colsep0 rowsep0" align="center">>30</td><td class="colsep0 rowsep0" align="center">7.5 (2.6)</td><td class="colsep0 rowsep0" align="center">489</td><td class="colsep0 rowsep0" align="center">106</td><td class="colsep0 rowsep0" align="center">1.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Measured using shake-flask methodology with a buffer/octanol volume ratio of 100:1 at pH 7.4.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">High-throughput solubility using DMSO stock solution was measured in pH 7.4 phosphate buffer at 37 °C.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Intrinsic clearance measured from fresh hepatocytes from the indicated species.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Permeability was measured in both the apical to basolateral (A to B) and basolateral to apical (B to A) direction. Efflux ratio (ER) determined as the ratio of both permeabilities (B to A permeability divided by A to B permeability).</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Properties of <b>21</b> in Rats and Dogs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">preclinical species</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center"><i>F</i>%</th><th class="colsep0 rowsep0" align="center">AUC (μM h)</th><th class="colsep0 rowsep0" align="center">CL<sub>obs</sub> (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>dss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">rat<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" rowspan="2" align="left">100%</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" rowspan="2" align="center">20</td><td class="colsep0 rowsep0" rowspan="2" align="center">8.7</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">1.7.</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">dog<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" rowspan="2" align="left">71%</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" rowspan="2" align="center">9.0</td><td class="colsep0 rowsep0" rowspan="2" align="center">6.3</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p.o.</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Han Wistar rat male; 10 mg/kg p.o. (0.1% HPMC); 5 mg/kg i.v. (40% DMA/40% PEG/20% saline).</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Beagle dog male; 20 mg/kg p.o. (0.1% HPMC, pH 2); 10 mg/kg i.v. (20% TEG/D5W).</p></div></div></div><div class="NLM_p">With advanced compound <b>21</b> in hand, we were keen to evaluate its preclinical <i>in vivo</i> antitumor activity and, furthermore, to test the hypothesis that inhibition of JAK1 could be a viable therapeutic approach to enhance antitumor activity in combination with the approved therapies targeting oncogenic signaling pathways. To see the additive effect, we evaluated <b>21</b> (dosed at 50 mpk BID) in a mouse non-small-cell lung cancer (NSCLC) xenograft NCI-H1975 model in combination with the approved third-generation mutant EGFR selective kinase inhibitor, osimertinib, <b>22</b> at a low dose of 2.5 mpk.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> NCI-H1975 cells were implanted subcutaneously in female NCr nude mice (Taconic Laboratories). Ten days after cell implantation, mice were randomized into groups of six to eight mice (average tumor volume, 189 mm<sup>3</sup>; range, 152 to 250 mm<sup>3</sup>) and dosed orally with either vehicle (20% captisol), <b>21</b>, <b>22</b>, or combinations of <b>21</b> plus <b>22</b> at the doses and schedules indicated in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> for 18 days. In the combination-treated groups, the addition of <b>21</b> enhanced the antitumor activity of <b>22</b> (green diamonds), compared to treatment with <b>22</b> alone (red squares). When compound <b>21</b> was administered as a single agent (blue triangles), it had only weak antitumor activity relative to vehicle control treatment (black circles). On the last day of treatment, the inhibition of tumor growth of the combination treatments was statistically significant (<i>p</i> < 0.05), compared to single agent <b>22</b> alone. All treatments were well tolerated, with no significant weight loss or other outward signs observed over the course of treatment (data not shown).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>21</b> enhances the antitumor activity of low-dose <b>22</b> (osimertinib) in an NCI-H1975 (T790M) NSCLC xenograft model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A satellite group of the tumor bearing mice was treated for a single day with these compounds for pharmacodynamic analysis. We measured pSTAT3 (Y705) levels in tumor lysates as an <i>in vivo</i> biomarker of JAK1 kinase inhibition, as described previously,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and pEGFR (Y1173) levels as the biomarker of EGFR (T790M) inhibition.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> A single 2.5 mg/kg dose of <b>22</b> achieved a complete inhibition of pEGFR levels up to 24 h. With a 50 mg/kg dose of <b>21</b>, approximately 80% of the pSTAT3 inhibition was maintained up to 8 h after dosing (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The combined doses of <b>21</b> and <b>22</b> resulted in a robust knockdown of pSTAT3 and pEGFR, measured at 8 h after the dose. This correlated well with the observed enhanced antitumor activity in the mice xenograft efficacy study. Taken together, the increased antitumor activity of <b>21</b> plus <b>22</b> in combination compared to single agent <b>22</b>, as well as the correlation with pSTAT3 knockdown by <b>21</b>, is consistent with a role for STAT3 signaling in escaping from, or resistance to, EGFR inhibition in this model. The results support the hypothesis that inhibition of STAT3 signaling can enhance the antitumor activity of an EGFR inhibitor in T790M EGFR mutant NSCLC. As such, compound <b>21</b> displayed the best overall profile and was thus selected as the drug candidate to progress into the clinical development.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Plot of pSTAT3 and pEGFR signals in an NCI-H1975 mouse xenograft model with the treatment of <b>21</b> and <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37511" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37511" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described our efforts toward the development of a JAK1 selective inhibitor. Starting from a nonkinome selective screening hit <b>3</b>, structure based-design and a parallel synthesis approach were used to identify the potent and selective lead <b>9</b>. Further optimization led to the discovery of candidate drug <b>21</b> (AZD4205) with a high degree of JAK1 potency and favorable DMPK properties. The compound displayed an enhanced antitumor activity in combination with an approved EGFR inhibitor, osimertinib, in a preclinical NSCLC model. These findings warrant the further investigation of <b>21</b> in human clinical trials.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02458" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02458" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Suzuki reactions were used to couple the 7-nitro-indole boronic ester (<b>SI3</b>) to 2,4-dichloropyrimidines, differentially substituted at the C-5 position, to furnish 2-chloro-4-indole pyrimidines, i.e., <b>SI5</b>. Subsequently, acid-mediated aniline displacement yielded the desired nitro intermediates. Reduction of the nitro group under mild conditions was followed by amidation to produce the desired compounds (for an example, the synthesis of <b>21</b> is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. For the synthesis of other compounds, see the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_001.pdf" class="ext-link">Supporting Information</a>).</div><figure id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Example Synthesis of Compound <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) Pd(dppf)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>; 83%; (ii) NaOH, 50 °C, 81%; (b) TsOH·H<sub>2</sub>O, 130 °C, 75%; (c) Fe, NH<sub>4</sub>Cl, 74%; (d) HATU, iPrEt<sub>2</sub>N, 48%.</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00737" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00737" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Information</h3><div class="NLM_p">All solvents used were commercially available in anhydrous grade. Reagents were utilized without further purification, unless otherwise stated. Evaporation of solvent was carried out using a rotary evaporator under reduced pressure at a bath temperature of up to 60 °C. Temperatures are given in degrees Celsius (°C), and operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18–30 °C. In general, the course of reactions was followed by thin-layer chromatography or mass spectroscopy, and reaction times are given for illustration only; where a synthesis is described as being analogous to that described in a previous example, the amounts used are the millimolar ratio equivalents to those used in the previous example. NMR data are in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 or 400 MHz using a deuterated solvent. The analytical mass spectra were run with an electron energy of 70 eV in the chemical ionization (CI) mode using a direct exposure probe, where the indicated ionization was effected by electron impact (EI), electrospray (ESP), or atmospheric pressure chemical ionization (APCI); values for <i>m</i>/<i>z</i> are given. Generally, only ions that indicate the parent mass are reported. Unless otherwise indicated, all final compounds were purified to ≥95% purity, as assessed by analytical HPLC using an Agilent 1100 equipped with Waters columns (Atlantis T3, 2.1 × 50 mm, 3 μm or Atlantis C18, 2.1 × 50 mm, 5 μm) eluted for >10 min with a gradient mixture of water and acetonitrile, with either formic acid or ammonium acetate added as a modifier, monitored at wavelengths of 220, 254, and 280 nm.</div><div class="NLM_p last">All experimental activities involving animals were carried out in accordance with AstraZeneca animal welfare protocols, which are consistent with The American Chemical Society Publications rules and ethical guidelines. For details of synthesis, please see the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01392" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01392?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01392</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Compound synthesis, characterization, crystallographic information, kinase panel selectivity data, additional DMPK data, compound purity data, and NMR spectra of selected compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of the compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_001.pdf">jm9b01392_si_001.pdf (1.91 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_002.csv">jm9b01392_si_002.csv (2.06 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01392" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qibin Su</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3394-3614" title="Orcid link">http://orcid.org/0000-0003-3394-3614</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1869717a7176366b6d58796b6c6a79627d767d7b79367b7775"><span class="__cf_email__" data-cfemail="96e7fff4fff8b8e5e3d6f7e5e2e4f7ecf3f8f3f5f7b8f5f9fb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erica Banks</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Geraldine Bebernitz</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kirsten Bell</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cassandra F. Borenstein</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huawei Chen</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudio E. Chuaqui</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nanhua Deng</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew D. Ferguson</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1018-9631" title="Orcid link">http://orcid.org/0000-0002-1018-9631</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sameer Kawatkar</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil P. Grimster</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0088-1250" title="Orcid link">http://orcid.org/0000-0003-0088-1250</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linette Ruston</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul D. Lyne</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon A. Read</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, R&D, AstraZeneca R&D, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xianyou Peng</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaohui Pei</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Fawell</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhanlei Tang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Throner</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melissa M. Vasbinder</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haoyu Wang</span> - <span class="hlFld-Affiliation affiliation">Pharmaron
Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jon Winter-Holt</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Cambridge CB4 0WG, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Woessner</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Allan Wu</span> - <span class="hlFld-Affiliation affiliation">Discovery
Sciences, R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenzhan Yang</span> - <span class="hlFld-Affiliation affiliation">Early Product
Development, Pharmaceutical Sciences, R&D, Boston, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Zinda</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason G. Kettle</span> - <span class="hlFld-Affiliation affiliation">Oncology
R&D, AstraZeneca R&D, Cambridge CB4 0WG, U.K.</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7373-0758" title="Orcid link">http://orcid.org/0000-0001-7373-0758</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Dr. Brian Aquila for insightful discussion, Dr. Michelle Lamb for proofreading the manuscript, Dr. Kun Song for preparing structure pictures, Sharon Tentarelli for the LC/MS support, and Holger Steuber for obtaining the X-ray crystal structures.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">JAK1</td><td class="NLM_def"><p class="first last">Janus kinase 1</p></td></tr><tr><td class="NLM_term">JAK2</td><td class="NLM_def"><p class="first last">Janus kinase 2</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">MF</td><td class="NLM_def"><p class="first last">idiopathic myelofibrosis</p></td></tr><tr><td class="NLM_term">mpk</td><td class="NLM_def"><p class="first last">mg/kg</p></td></tr><tr><td class="NLM_term">MPNs</td><td class="NLM_def"><p class="first last">myeloproliferative neoplasms</p></td></tr><tr><td class="NLM_term">PAGE</td><td class="NLM_def"><p class="first last">Polyacrylamide gel electrophoresis</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">PV</td><td class="NLM_def"><p class="first last">polycythemia vera</p></td></tr><tr><td class="NLM_term">SDS</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">pSTAT</td><td class="NLM_def"><p class="first last">phosphorylated signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">tSTAT</td><td class="NLM_def"><p class="first last">total signal transducers and activators of transcription</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raivola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span> <span> </span><span class="NLM_article-title">The regulation of JAKs in cytokine signaling and its breakdown in disease</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2018.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.cyto.2018.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=29685781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFegtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2019&pages=48-63&author=H.+M.+Hammar%C3%A9nauthor=A.+T.+Virtanenauthor=J.+Raivolaauthor=O.+Silvennoinen&title=The+regulation+of+JAKs+in+cytokine+signaling+and+its+breakdown+in+disease&doi=10.1016%2Fj.cyto.2018.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of JAKs in cytokine signaling and its breakdown in disease</span></div><div class="casAuthors">Hammaren, Henrik M.; Virtanen, Anniina T.; Raivola, Juuli; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-63</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The JAK-STAT signal transduction pathway is responsible for mediating signals of over fifty cytokines, growth factors and hormones.  Signaling through the JAK-STAT pathway is regulated on multiple levels, including intramol. regulation by the JAK pseudokinase domain, and intermol. regulation by a host of regulatory proteins.  The advent of accessible genomic tools have provided a wealth of information on disease-assocd. mutations in the JAK-STAT pathway and its regulatory components.  The vast no. of these mutations in diseases ranging from immunodeficiencies and obesity to many cancers highlight the importance of correct regulation of JAK-STAT signaling for biol. processes such as hematopoiesis, regulation of the immune system, metab., and growth.  Simultaneously, JAK inhibitors are gaining traction in clin. use, both for treatment of diseases driven by JAK mutations, and for a host of inflammatory disorders, in which proinflammatory cytokine signaling through the JAK-STAT pathway is an integral part of pathogenesis.  The elucidation of mol. mechanisms in the pathogenesis of complex diseases has also, however, brought the limitations of our current understanding on the regulation of cytokine signaling to the foreground.  Indeed, deeper understanding of these regulatory mechanisms are a prerequisite for the development of the next generation of pharmacol. modulators of the JAK-STAT pathway.  In this review we discuss the current state of knowledge of the intra- and intermol. regulation of the JAK-STAT pathway, with a focus on diseases arising from disruptions in the regulatory app.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RzQKF2IxZbVg90H21EOLACvtfcHk0lgm05Aj5CeVyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFegtLg%253D&md5=f640078513fdd7e86a122d5d1172f76b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2018.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2018.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%2BM.%26aulast%3DVirtanen%26aufirst%3DA.%2BT.%26aulast%3DRaivola%26aufirst%3DJ.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520regulation%2520of%2520JAKs%2520in%2520cytokine%2520signaling%2520and%2520its%2520breakdown%2520in%2520disease%26jtitle%3DCytokine%26date%3D2019%26volume%3D118%26spage%3D48%26epage%3D63%26doi%3D10.1016%2Fj.cyto.2018.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vakil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment</span>. <i>Clin. Lymphoma, Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S37</span>– <span class="NLM_lpage">S45</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.clml.2011.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=22035746" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=S37-S45&author=E.+Vakilauthor=A.+Tefferi&title=BCR-ABL1%2D%2Dnegative+myeloproliferative+neoplasms%3A+a+review+of+molecular+biology%2C+diagnosis%2C+and+treatment&doi=10.1016%2Fj.clml.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DVakil%26aufirst%3DE.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DBCR-ABL1--negative%2520myeloproliferative%2520neoplasms%253A%2520a%2520review%2520of%2520molecular%2520biology%252C%2520diagnosis%252C%2520and%2520treatment%26jtitle%3DClin.%2520Lymphoma%252C%2520Myeloma%2520Leuk.%26date%3D2011%26volume%3D11%26spage%3DS37%26epage%3DS45%26doi%3D10.1016%2Fj.clml.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, S. E.</span></span> <span> </span><span class="NLM_article-title">Biology and significance of the JAK/STAT signalling pathways</span>. <i>Growth Factors</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.3109/08977194.2012.660936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.3109%2F08977194.2012.660936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=22339650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=88-106&author=H.+Kiuauthor=S.+E.+Nicholson&title=Biology+and+significance+of+the+JAK%2FSTAT+signalling+pathways&doi=10.3109%2F08977194.2012.660936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and significance of the JAK/STAT signalling pathways</span></div><div class="casAuthors">Kiu, Hiu; Nicholson, Sandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-106</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Since its discovery 2 decades ago, the activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway by numerous cytokines and growth factors has resulted in it becoming 1 of the most well-studied intracellular signaling networks.  The field has progressed from the identification of the individual components to high-resoln. crystal structures of both JAK and STAT, and an understanding of the complexities of the mol. activation and deactivation cycle which results in a diverse, yet highly specific and regulated pattern of transcriptional responses.  While there is still more to learn, we now appreciate how disruption and deregulation of this pathway can result in clin. disease and look forward to adoption of the next generation of JAK inhibitors in routine clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2feFVqfQ77Vg90H21EOLACvtfcHk0lgm05Aj5CeVyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D&md5=d81b34c514392de2c2179229633e9a55</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3109%2F08977194.2012.660936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08977194.2012.660936%26sid%3Dliteratum%253Aachs%26aulast%3DKiu%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DS.%2BE.%26atitle%3DBiology%2520and%2520significance%2520of%2520the%2520JAK%252FSTAT%2520signalling%2520pathways%26jtitle%3DGrowth%2520Factors%26date%3D2012%26volume%3D30%26spage%3D88%26epage%3D106%26doi%3D10.3109%2F08977194.2012.660936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0ljbR-9W9iMQqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Franco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson-Viitanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis&doi=10.1056%2FNEJMoa1002028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0ljbR-9W9iMQqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127%26doi%3D10.1056%2FNEJMoa1002028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J. M.</span></span> <span> </span><span class="NLM_article-title">A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1111/bjd.14403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1111%2Fbjd.14403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=26800231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=1266-1276&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Ramanauthor=D.+Dischauthor=D.+E.+Schlichtingauthor=C.+Gaichauthor=W.+Maciasauthor=X.+Zhangauthor=J.+M.+Janes&title=A+randomized+phase+2b+trial+of+baricitinib%2C+an+oral+Janus+kinase+%28JAK%29+1%2FJAK2+inhibitor%2C+in+patients+with+moderate-to-severe+psoriasis&doi=10.1111%2Fbjd.14403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Raman, M.; Disch, D.; Schlichting, D. E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.  Objectives : To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.  Methods : Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 wk (Part A).  Dose adjustment for 12 addnl. weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score.  The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 wk for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population.  Results : At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75.  All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 wk and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-mg and 10-mg groups at 8 and 12 wk.  More than 81% of PASI-75 responders maintained their scores through 24 wk.  During Part A, study discontinuations due to adverse events (AEs) were 0%, 0%, 2·8%, 6·3% and 5·8% and treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, resp.  No opportunistic infections were obsd. in any treatment group.  Dose-dependent changes in lab. values were obsd.  Conclusions : Patients with moderate-to-severe psoriasis treated with baricitinib for 12 wk achieved significant improvements in PASI-75.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqVPv2558vrrVg90H21EOLACvtfcHk0lgzT3945g4xrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN&md5=37df34807683b4742548f192f99654f6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14403%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DRaman%26aufirst%3DM.%26aulast%3DDisch%26aufirst%3DD.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DGaich%26aufirst%3DC.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJanes%26aufirst%3DJ.%2BM.%26atitle%3DA%2520randomized%2520phase%25202b%2520trial%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520%2528JAK%2529%25201%252FJAK2%2520inhibitor%252C%2520in%2520patients%2520with%2520moderate-to-severe%2520psoriasis%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D174%26spage%3D1266%26epage%3D1276%26doi%3D10.1111%2Fbjd.14403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludivico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogulec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span> <span> </span><span class="NLM_article-title">Baricitinib in patients with refractory rheumatoid arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1056%2FNEJMoa1507247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27028914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1243-1252&author=M.+C.+Genoveseauthor=J.+Kremerauthor=O.+Zamaniauthor=C.+Ludivicoauthor=M.+Krogulecauthor=L.+Xieauthor=S.+D.+Beattieauthor=A.+E.+Kochauthor=T.+E.+Cardilloauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=S.+de+Bonoauthor=D.+E.+Schlichtingauthor=J.+S.+Smolen&title=Baricitinib+in+patients+with+refractory+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1507247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib in patients with refractory rheumatoid arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Kremer, Joel; Zamani, Omid; Ludivico, Charles; Krogulec, Marek; Xie, Li; Beattie, Scott D.; Koch, Alisa E.; Cardillo, Tracy E.; Rooney, Terence P.; Macias, William L.; de Bono, Stephanie; Schlichting, Douglas E.; Smolen, Josef S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1243-1252</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biol. disease-modifying antirheumatic drugs (DMARDs).  METHODS In this phase 3 study involving 527 patients with an inadequate response to or unacceptable side effects assocd. with one or more tumor necrosis factor inhibitors, other biol. DMARDs, or both, we randomly assigned the patients in a 1:1:1 ratio to baricitinib at a dose of 2 or 4 mg daily or placebo for 24 wk.  End points, tested hierarchically at week 12 to control type 1 error, were the American College of Rheumatol. 20% (ACR20) response (primary end point), the Health Assessment Questionnaire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based on C-reactive protein level (DAS28-CRP), and a Simplified Disease Activity Index (SDAI) score of 3.3 or less (on a scale of 0.1 to 86.0, with a score of 3.3 or less indicating remission).  Comparisons with placebo were made first with the 4-mg dose of baricitinib and then with the 2-mg dose.  RESULTS Significantly more patients receiving baricitinib at the 4-mg dose than those receiving placebo had an ACR20 response at week 12 (55% vs. 27%, P<0.001).  Differences between the higher-dose baricitinib group and the placebo group were also significant for the HAQ-DI score and the DAS28-CRP but not for an SDAI score of 3.3 or less.  Adverse-event rates through 24 wk were higher for patients receiving the 2-mg dose of baricitinib and those receiving the 4-mg dose than for patients receiving placebo (71% and 77%, resp., vs. 64%), including infections (44% and 40%, vs. 31%).  The rates of serious adverse events were 4%, 10%, and 7% in the three groups, resp.  Two nonmelanoma skin cancers and two major adverse cardiovascular events, including a fatal stroke, occurred in the higher-dose group.  Baricitinib was assocd. with a small redn. in neutrophil levels and increases in serum creatinine and low-d. lipoprotein cholesterol levels.  CONCLUSIONS In patients with rheumatoid arthritis and an inadequate response to biol. DMARDs, baricitinib at a daily dose of 4 mg was assocd. with clin. improvement at 12 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj72FQTLOsQLVg90H21EOLACvtfcHk0lgzT3945g4xrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E&md5=d7d317ee88fae38379b3b07c420349f6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507247%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DZamani%26aufirst%3DO.%26aulast%3DLudivico%26aufirst%3DC.%26aulast%3DKrogulec%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3Dde%2BBono%26aufirst%3DS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26atitle%3DBaricitinib%2520in%2520patients%2520with%2520refractory%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1243%26epage%3D1252%26doi%3D10.1056%2FNEJMoa1507247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubrzycka-Sienkiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardiel, M. H.</span></span> <span> </span><span class="NLM_article-title">Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">932</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1002/art.40054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1002%2Fart.40054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=28118538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVelsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=932-942&author=M.+C.+Genoveseauthor=M.+Greenwaldauthor=C.+Coddingauthor=A.+Zubrzycka-Sienkiewiczauthor=A.+J.+Kivitzauthor=A.+Wangauthor=K.+Shayauthor=X.+Wangauthor=J.+P.+Gargauthor=M.+H.+Cardiel&title=Peficitinib%2C+a+JAK+inhibitor%2C+in+combination+with+limited+conventional+synthetic+disease-modifying+antirheumatic+drugs+in+the+treatment+of+moderate-to-severe+rheumatoid+arthritis&doi=10.1002%2Fart.40054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Greenwald, Maria; Codding, Christine; Zubrzycka-Sienkiewicz, Anna; Kivitz, Alan J.; Wang, Annie; Shay, Kathyjo; Wang, Xuegong; Garg, Jay P.; Cardiel, Mario H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">932-942</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA).  Methods : In this randomized, double-blind, phase IIb trial, patients with RA (n = 289) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg or matching placebo once daily for 12 wk.  The primary end point was the percentage of patients who met the American College of Rheumatol. 20% improvement criteria (achieved an ACR20 response) at week 12.  Results : ACR20 response rates at week 12 were 22.0%, 36.8%, 48.3% (P < 0.05), 56.3% (P < 0.01), and 29.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, resp.  Patients in the peficitinib 100 mg and 150 mg groups achieved a rapid and statistically significant ACR20 response compared with those in the placebo group (P < 0.05), reaching statistical significance by week 2.  Overall, the incidence of adverse events (AEs) was similar between patients receiving peficitinib and those receiving placebo.  The most common AEs were upper respiratory tract infection (5% [n = 15]), nausea (4% [n = 12]), and urinary tract infection (4% [n = 10]).  There was 1 case of herpes zoster in the placebo group, and 1 serious infection (limb abscess) in the peficitinib 25 mg group.  There were no incidences of grade 2 or higher neutropenia or lymphopenia.  Conclusion : In patients with moderate-to-severe RA, orally administered once-daily peficitinib in combination with limited csDMARDs resulted in a dose-dependent ACR20 response rate over 12 wk with satisfactory tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAtngQf8klmrVg90H21EOLACvtfcHk0lgDG5ZMXrIbIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVelsr0%253D&md5=761c5b89cdbbe60108a1bceb1d699ecd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fart.40054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40054%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGreenwald%26aufirst%3DM.%26aulast%3DCodding%26aufirst%3DC.%26aulast%3DZubrzycka-Sienkiewicz%26aufirst%3DA.%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DShay%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGarg%26aufirst%3DJ.%2BP.%26aulast%3DCardiel%26aufirst%3DM.%2BH.%26atitle%3DPeficitinib%252C%2520a%2520JAK%2520inhibitor%252C%2520in%2520combination%2520with%2520limited%2520conventional%2520synthetic%2520disease-modifying%2520antirheumatic%2520drugs%2520in%2520the%2520treatment%2520of%2520moderate-to-severe%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D932%26epage%3D942%26doi%3D10.1002%2Fart.40054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez-Ureña, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poiley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubrzycka-Sienkiewicz, A.</span></span> <span> </span><span class="NLM_article-title">Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1002/art.39955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1002%2Fart.39955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27748083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVSrtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=709-719&author=A.+J.+Kivitzauthor=S.+R.+Gutierrez-Ure%C3%B1aauthor=J.+Poileyauthor=M.+C.+Genoveseauthor=R.+Kristyauthor=K.+Shayauthor=X.+Wangauthor=J.+P.+Gargauthor=A.+Zubrzycka-Sienkiewicz&title=Peficitinib%2C+a+JAK+inhibitor%2C+in+the+treatment+of+moderate-to-severe+rheumatoid+arthritis+in+patients+with+an+inadequate+response+to+methotrexate&doi=10.1002%2Fart.39955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate</span></div><div class="casAuthors">Kivitz, A. J.; Gutierrez-Urena, S. R.; Poiley, J.; Genovese, M. C.; Kristy, R.; Shay, K.; Wang, X.; Garg, J. P.; Zubrzycka-Sienkiewicz, A.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">709-719</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with methotrexate (MTX) in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to MTX.  Methods: In this multinational, phase IIb, randomized, double-blind, placebo-controlled, dose-ranging trial, patients with RA (n = 378) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg plus MTX, or matching placebo plus MTX once daily for 12 wk.  The primary end point was the percentage of patients who met the American College of Rheumatol. 20% improvement criteria (achieved an ACR20 response) at week 12.  Results: ACR20 response rates at week 12 were 43.9%, 61.5% (P < 0.05 vs. placebo), 46.4%, 57.7%, and 44.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, resp.  Significant decreases from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level were seen in the peficitinib 50 mg (P < 0.05) and 150 mg (P < 0.01) groups compared with placebo at week 12.  Overall, the incidence of adverse events (AEs) was similar between peficitinib and placebo.  The most common AEs were urinary tract infection (n = 22 [6%]), upper respiratory tract infection (n = 16 [4%]), and diarrhea (n = 16 [4%]).  There were 3 cases of herpes zoster infection (2 in the peficitinib 100 mg group and 1 in the 150 mg group) and 2 cases of serious infection (viral infection in the peficitinib 100 mg group and erysipelas in the 150 mg group).  Conclusion: The ACR20 response rate in the group receiving peficitinib 50 mg plus MTX was significantly different compared with the rate in patients receiving placebo, but there were no apparent dose-dependent responses, and the placebo response rate was high.  Peficitinib plus MTX in patients with moderate-to-severe RA was well tolerated, with limited safety signals emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsFnyDl8xZ4LVg90H21EOLACvtfcHk0lgDG5ZMXrIbIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVSrtro%253D&md5=20630f376b7459166317e00024145613</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fart.39955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39955%26sid%3Dliteratum%253Aachs%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DGutierrez-Ure%25C3%25B1a%26aufirst%3DS.%2BR.%26aulast%3DPoiley%26aufirst%3DJ.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKristy%26aufirst%3DR.%26aulast%3DShay%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGarg%26aufirst%3DJ.%2BP.%26aulast%3DZubrzycka-Sienkiewicz%26aufirst%3DA.%26atitle%3DPeficitinib%252C%2520a%2520JAK%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520moderate-to-severe%2520rheumatoid%2520arthritis%2520in%2520patients%2520with%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D709%26epage%3D719%26doi%3D10.1002%2Fart.39955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1080%2F13543776.2017.1252753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27774824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVagtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=127-143&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature+2013-2015%2C+part+1&doi=10.1080%2F13543776.2017.1252753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-143</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 1 covering A through to I.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhs64lbsS9rVg90H21EOLACvtfcHk0lgDG5ZMXrIbIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVagtr7I&md5=90dbe8bc6e86ac19fe512baf6ed82ef7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252753%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202013-2015%252C%2520part%25201%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D127%26epage%3D143%26doi%3D10.1080%2F13543776.2017.1252753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burmester, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerwein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Othman, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangan, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungerwirth, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2857</span>– <span class="NLM_lpage">2866</span>, <span class="refDoi"> DOI: 10.1002/art.39808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1002%2Fart.39808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27390150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGgsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=2857-2866&author=M.+C.+Genoveseauthor=J.+S.+Smolenauthor=M.+E.+Weinblattauthor=G.+R.+Burmesterauthor=S.+Meerweinauthor=H.+S.+Campauthor=L.+Wangauthor=A.+A.+Othmanauthor=N.+Khanauthor=A.+L.+Panganauthor=S.+Jungerwirth&title=Efficacy+and+safety+of+ABT-494%2C+a+selective+JAK-1+inhibitor%2C+in+a+phase+IIb+study+in+patients+with+rheumatoid+arthritis+and+an+inadequate+response+to+methotrexate&doi=10.1002%2Fart.39808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</span></div><div class="casAuthors">Genovese, Mark C.; Smolen, Josef S.; Weinblatt, Michael E.; Burmester, Gerd R.; Meerwein, Sebastian; Camp, Heidi S.; Wang, Li; Othman, Ahmed A.; Khan, Nasser; Pangan, Aileen L.; Jungerwirth, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2857-2866</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate the efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).  Methods : Three hundred RA patients receiving stable doses of MTX were randomly assigned equally to receive immediate-release ABT-494 at 3, 6, 12, or 18 mg twice daily, 24 mg once daily, or placebo for 12 wk.  The primary efficacy end point was the proportion of patients meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 12, as detd. using the last observation carried forward method.  Results : At week 12, the proportion of ACR20 responses was higher with ABT-494 (62%, 68%, 80%, 64%, and 76% for the 3, 6, 12, 18, and 24 mg doses, resp.) than with placebo (46%) (using nonresponder imputation) (P < 0.05 for the 6, 12, and 24 mg doses).  There was a significant dose-response relationship among all ABT-494 doses (P < 0.001).  The proportions of patients achieving ACR50 and ACR70 responses were significantly higher for all ABT-494 doses (except the 12 mg dose for the ACR70 response) than for placebo, as were changes in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP).  Rapid improvement was demonstrated by significant differences in ACR20 response rates and changes in the DAS28-CRP for all doses compared with placebo at week 2 (the first postbaseline visit).  The incidence of adverse events was similar across groups; most were mild, and infections were the most frequent.  One serious infection (community-acquired pneumonia) occurred with ABT-494 at 12 mg.  There were dose-dependent increases in high-d. lipoprotein (HDL) and low-d. lipoprotein (LDL) cholesterol, but the LDL cholesterol:HDL cholesterol ratios were unchanged through week 12.  Mean Hb levels remained stable at lower doses, but decreases were obsd. at higher doses.  Conclusion : This study evaluated a broad range of doses of ABT-494 in RA patients with an inadequate response to MTX.  ABT-494 demonstrated efficacy, with a safety and tolerability profile similar to that of other JAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0MsK02mgIbVg90H21EOLACvtfcHk0lixaKjqj2m7oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGgsL3I&md5=5d4bf383496b2153fede781caf6ba0c7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fart.39808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39808%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3DMeerwein%26aufirst%3DS.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DOthman%26aufirst%3DA.%2BA.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DPangan%26aufirst%3DA.%2BL.%26aulast%3DJungerwirth%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520ABT-494%252C%2520a%2520selective%2520JAK-1%2520inhibitor%252C%2520in%2520a%2520phase%2520IIb%2520study%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520and%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2016%26volume%3D68%26spage%3D2857%26epage%3D2866%26doi%3D10.1002%2Fart.39808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+a+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0lixaKjqj2m7oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520a%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smets, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeghinste, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van ’t Klooster, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyen, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">3568</span>– <span class="NLM_lpage">3577</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1201348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.4049%2Fjimmunol.1201348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=24006460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&author=L.+Van%0ARompaeyauthor=R.+Galienauthor=E.+M.+van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+van+%E2%80%99t+Kloosterauthor=J.+H.+M.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1%2C+for+the+treatment+of+inflammatory+diseases&doi=10.4049%2Fjimmunol.1201348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Van Rompaey, Luc; Galien, Rene; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Nelles, Luc; Smets, Bart; Lepescheux, Lien; Christophe, Thierry; Conrath, Katja; Vandeghinste, Nick; Vayssiere, Beatrice; De Vos, Steve; Fletcher, Stephen; Brys, Reginald; van 't Klooster, Gerben; Feyen, Jean H. M.; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3568-3577</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The JAKs receive continued interest as therapeutic targets for autoimmune, inflammatory, and oncol. diseases.  JAKs play crit. roles in the development and biol. of the hematopoietic system, as evidenced by mouse and human genetics.  JAK1 is crit. for the signal transduction of many type I and type II inflammatory cytokine receptors.  In a search for JAK small mol. inhibitors, GLPG0634 was identified as a lead compd. belonging to a novel class of JAK inhibitors.  It displayed a JAK1/JAK2 inhibitor profile in biochem. assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of ∼30-fold for JAK1- over JAK2-dependent signaling.  GLPG0634 dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro.  GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repression of Mx2 expression in leukocytes.  Oral dosing of GLPG0634 in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent redn. of the disease progression.  Paw swelling, bone and cartilage degrdn., and levels of inflammatory cytokines were reduced by GLPG0634 treatment.  Efficacy of GLPG0634 in the collagen-induced arthritis models was comparable to the results obtained with etanercept.  In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOIeLPk4kdvbVg90H21EOLACvtfcHk0liurAQiPnpu8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI&md5=01042ebac904fecbcdffe494e456c199</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201348%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3Dvan%2B%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%252C%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3568%26epage%3D3577%26doi%3D10.4049%2Fjimmunol.1201348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Ramos, M.</span></span> <span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+J.+Menetauthor=O.+Mammolitiauthor=M.+L%C3%B3pez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of γc cytokine (γc = common γ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0liurAQiPnpu8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DL%25C3%25B3pez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rompaey, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span> <span> </span><span class="NLM_article-title">Advances in the discovery of selective JAK inhibitors</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/B978-0-444-62652-3.00004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2FB978-0-444-62652-3.00004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=23384668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=153-223&author=C.+J.+Menetauthor=L.+V.+Rompaeyauthor=R.+Geney&title=Advances+in+the+discovery+of+selective+JAK+inhibitors&doi=10.1016%2FB978-0-444-62652-3.00004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of selective JAK inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Van Rompaey, Luc; Geney, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-223</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the advances in the discovery of selective JAK inhibitors.  JAK inhibitor includes JAK1, JAK2 and JAK3 and tyrosine kinase2.  Medicinal chem. and structural biol. fronts in designing and synthesizing selective or mixed JAK small-mol. inhibitors were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg_zxiK5GGLVg90H21EOLACvtfcHk0liurAQiPnpu8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D&md5=3d7e6f0481e3a891c84c49ece6421d74</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DRompaey%26aufirst%3DL.%2BV.%26aulast%3DGeney%26aufirst%3DR.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520selective%2520JAK%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D153%26epage%3D223%26doi%3D10.1016%2FB978-0-444-62652-3.00004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6524</span>– <span class="NLM_lpage">6528</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2009.10.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=19857966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6524-6528&author=S.+Ioannidisauthor=M.+L.+Lambauthor=A.+M.+Daviesauthor=L.+Almeidaauthor=M.+Suauthor=G.+Bebernitzauthor=M.+Yeauthor=K.+Bellauthor=M.+Alimzhanovauthor=M.+Zinda&title=Discovery+of+pyrazol-3-ylamino+pyrazines+as+novel+JAK2+inhibitors&doi=10.1016%2Fj.bmcl.2009.10.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Davies, Audrey M.; Almeida, Lynsie; Su, Mei; Bebernitz, Geraldine; Ye, Minwei; Bell, Kirsten; Alimzhanov, Marat; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6524-6528</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyridineethyl- and pyrimidineethyl-substituted pyrazoleaminopyrazines such as I (R = Me; X = N) and I (R = H; X = CH) are prepd. as selective JAK2 kinase inhibitors for potential use as anticancer agents; the GI50 values for their JAK2 and JAK3 kinase inhibition are detd.  The activities of selected pyridineethyl- and pyrimidineethyl-substituted pyrazoleaminopyrazines in a functional phosphorylation model in mice and their inhibition of aurora B kinase, cyclin-dependent kinase 2, and TrkA are detd.; the pharmacokinetics and pharmacodynamics of I (R = Me; X = N) and of I (R = H; X = CH) in rats and beagles are also detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY1tQ0K-v7orVg90H21EOLACvtfcHk0liomPe9SGdrtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLvE&md5=3029e4300eb84ea19f704264c8753df6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.054%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520pyrazol-3-ylamino%2520pyrazines%2520as%2520novel%2520JAK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6524%26epage%3D6528%26doi%3D10.1016%2Fj.bmcl.2009.10.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1669</span>– <span class="NLM_lpage">1673</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2010.01.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=20144546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlehsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1669-1673&author=S.+Ioannidisauthor=M.+L.+Lambauthor=L.+Almeidaauthor=H.+Guanauthor=B.+Pengauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Alimzhanovauthor=M.+Zinda&title=Replacement+of+pyrazol-3-yl+amine+hinge+binder+with+thiazol-2-yl+amine%3A+Discovery+of+potent+and+selective+JAK2+inhibitors&doi=10.1016%2Fj.bmcl.2010.01.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Almeida, Lynsie; Guan, Huiping; Peng, Bo; Bebernitz, Geraldine; Bell, Kirsten; Alimzhanov, Marat; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1669-1673</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Thiazol-2-yl amine was identified as an isosteric replacement for pyrazol-3-yl amine during the efforts to identify potent and selective JAK2 inhibitors.  The rationale, synthesis and biol. evaluation of several analogs I (X = N, CH; R1 = MeO, 4-morpholinyl, 4-methyl-1-piperazinyl; R2 = H, F; R3 = Me, CN) is reported, along with the in vivo evaluation of the lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE4-bwWDreyrVg90H21EOLACvtfcHk0liomPe9SGdrtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlehsbY%253D&md5=a9b1f0cdc19311aca0a314325a1cbc56</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.091%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DReplacement%2520of%2520pyrazol-3-yl%2520amine%2520hinge%2520binder%2520with%2520thiazol-2-yl%2520amine%253A%2520Discovery%2520of%2520potent%2520and%2520selective%2520JAK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1669%26epage%3D1673%26doi%3D10.1016%2Fj.bmcl.2010.01.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2958</span>– <span class="NLM_lpage">2961</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2011.03.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=21493067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVCmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2958-2961&author=T.+Wangauthor=S.+Ioannidisauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=M.+L.+Lambauthor=D.+A.+Scottauthor=M.+Suauthor=H.-J.+Zhangauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Zinda&title=In+vitro+and+in+vivo+evaluation+of+6-aminopyrazolyl-pyridine-3-carbonitriles+as+JAK2+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2011.03.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors</span></div><div class="casAuthors">Wang, Tao; Ioannidis, Stephanos; Almeida, Lynsie; Block, Michael H.; Davies, Audrey M.; Lamb, Michelle L.; Scott, David A.; Su, Mei; Zhang, Hai-Jun; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2958-2961</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis and biol. evaluation of a series of 6-aminopyrazolylpyridine-3-carbonitriles as JAK2 kinase inhibitors was reported.  Biochem. screening, followed by profile optimization, resulted in JAK2 inhibitors exhibiting good kinase selectivity, pharmacokinetic properties, phys. properties and pharmacodynamic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGzJYyPhqN_bVg90H21EOLACvtfcHk0lj-6CcJVMxfBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVCmtb0%253D&md5=e9b8a9e58e36a6976490bdb84a8043b6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.053%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%25206-aminopyrazolyl-pyridine-3-carbonitriles%2520as%2520JAK2%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2958%26epage%3D2961%26doi%3D10.1016%2Fj.bmcl.2011.03.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrace, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3105</span>– <span class="NLM_lpage">3110</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2013.02.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=23562594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlOhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3105-3110&author=H.+Guanauthor=M.+L.+Lambauthor=B.+Pengauthor=S.+Huangauthor=N.+Degraceauthor=J.+Readauthor=S.+Hussainauthor=J.+Wuauthor=C.+Rivardauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=M.+Zindaauthor=S.+Ioannidis&title=Discovery+of+novel+Jak2-Stat+pathway+inhibitors+with+extended+residence+time+on+target&doi=10.1016%2Fj.bmcl.2013.02.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target</span></div><div class="casAuthors">Guan, Huiping; Lamb, Michelle L.; Peng, Bo; Huang, Shan; DeGrace, Nancy; Read, Jon; Hussain, Syeed; Wu, Jiaquan; Rivard, Caroline; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Minwei; Zinda, Michael; Ioannidis, Stephanos</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3105-3110</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncol.  In this Letter, the authors communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivs.  The rationale, synthesis and biol. evaluation of these derivs. are reported.  Two lead analogs from this series, (I) and (II), displayed prolonged residence time on Jak2, at enzymic level.  Although (I) and (II) exhibited moderate selectivity in a selected kinase panel, the authors chose to test these inhibitors in vivo as a consequence to their long residence time.  However, extended inhibition of Jak2 due to the long residence time, in the form of inhibiting phosphorylation of downstream Stat5, was not recapitulated in an in vivo setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEqzh5WfofE7Vg90H21EOLACvtfcHk0lj-6CcJVMxfBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlOhtrk%253D&md5=dee4662399d073c0d1a5f8dddcd9682a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.111%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DDegrace%26aufirst%3DN.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520Jak2-Stat%2520pathway%2520inhibitors%2520with%2520extended%2520residence%2520time%2520on%2520target%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3105%26epage%3D3110%26doi%3D10.1016%2Fj.bmcl.2013.02.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/jm401546n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401546n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=144-158&author=Q.+Suauthor=S.+Ioannidisauthor=C.+Chuaquiauthor=L.+Almeidaauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Blockauthor=T.+Howardauthor=S.+Huangauthor=D.+Huszarauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=J.+Shiauthor=M.+Suauthor=M.+Yeauthor=M.+Zinda&title=Discovery+of+1-methyl-1H-imidazole+derivatives+as+potent+Jak2+inhibitors&doi=10.1021%2Fjm401546n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors</span></div><div class="casAuthors">Su, Qibin; Ioannidis, Stephanos; Chuaqui, Claudio; Almeida, Lynsie; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Block, Michael; Howard, Tina; Huang, Shan; Huszar, Dennis; Read, Jon A.; Rivard Costa, Caroline; Shi, Jie; Su, Mei; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure based design, synthesis, and biol. evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described.  Using the C-ring fragment from our first clin. candidate AZD1480 (I), optimization of the series led to the discovery of compd. II, a potent, orally bioavailable Jak2 inhibitor.  Compd. II displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells.  Compd. II demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczgU5RpFv1bVg90H21EOLACvtfcHk0li9bn11T1V9BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL&md5=88c57119ec77d084a91a1123fd9dea86</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm401546n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401546n%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25201-methyl-1H-imidazole%2520derivatives%2520as%2520potent%2520Jak2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D144%26epage%3D158%26doi%3D10.1021%2Fjm401546n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deegan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toader, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Identification of azabenzimidazoles as potent JAK1 selective inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2015.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=26614408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFagsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=60-67&author=M.+M.+Vasbinderauthor=M.+Alimzhanovauthor=M.+Augustinauthor=G.+Bebernitzauthor=K.+Bellauthor=C.+Chuaquiauthor=T.+Deeganauthor=A.+D.+Fergusonauthor=K.+Goodwinauthor=D.+Huszarauthor=A.+Kawatkarauthor=S.+Kawatkarauthor=J.+Readauthor=J.+Shiauthor=S.+Steinbacherauthor=H.+Steuberauthor=Q.+Suauthor=D.+Toaderauthor=H.+Wangauthor=R.+Woessnerauthor=A.+Wuauthor=M.+Yeauthor=M.+Zinda&title=Identification+of+azabenzimidazoles+as+potent+JAK1+selective+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of azabenzimidazoles as potent JAK1 selective inhibitors</span></div><div class="casAuthors">Vasbinder, Melissa M.; Alimzhanov, Marat; Augustin, Martin; Bebernitz, Geraldine; Bell, Kirsten; Chuaqui, Claudio; Deegan, Tracy; Ferguson, Andrew D.; Goodwin, Kelly; Huszar, Dennis; Kawatkar, Aarti; Kawatkar, Sameer; Read, Jon; Shi, Jie; Steinbacher, Stefan; Steuber, Holger; Su, Qibin; Toader, Dorin; Wang, Haixia; Woessner, Richard; Wu, Allan; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-67</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have identified a class of azabenzimidazoles as potent and selective JAK1 inhibitors.  Investigations into the SAR are presented along with the structural features required to achieve selectivity for JAK1 vs. other JAK family members.  An example from the series demonstrated highly selective inhibition of JAK1 vs. JAK2 and JAK3, along with inhibition of pSTAT3 in vivo, enabling it to serve as a JAK1 selective tool compd. to further probe the biol. of JAK1 selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQjKE058gZrVg90H21EOLACvtfcHk0li9bn11T1V9BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFagsLrL&md5=49f2cc63e15dcdf539fb7195a9c6224a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DVasbinder%26aufirst%3DM.%2BM.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DDeegan%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGoodwin%26aufirst%3DK.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DKawatkar%26aufirst%3DA.%26aulast%3DKawatkar%26aufirst%3DS.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSteuber%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520azabenzimidazoles%2520as%2520potent%2520JAK1%2520selective%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D60%26epage%3D67%26doi%3D10.1016%2Fj.bmcl.2015.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deegan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Throner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toader, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of a novel series of highly selective JAK1 kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5235</span>– <span class="NLM_lpage">5244</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00076</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00076" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKktbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5235-5244&author=N.+P.+Grimsterauthor=E.+Andersonauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=C.+Chuaquiauthor=T.+Deeganauthor=A.+D.+Fergusonauthor=T.+Geroauthor=A.+Harschauthor=D.+Huszarauthor=A.+Kawatkarauthor=J.+G.+Kettleauthor=P.+Lyneauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=L.+Rustonauthor=P.+Schroederauthor=J.+Shiauthor=Q.+Suauthor=S.+Thronerauthor=D.+Toaderauthor=M.+Vasbinderauthor=R.+Woessnerauthor=H.+Wangauthor=A.+Wuauthor=M.+Yeauthor=W.+Zhengauthor=M.+Zinda&title=Discovery+and+optimization+of+a+novel+series+of+highly+selective+JAK1+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.8b00076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors</span></div><div class="casAuthors">Grimster, Neil P.; Anderson, Erica; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Chuaqui, Claudio; Deegan, Tracy; Ferguson, Andrew D.; Gero, Thomas; Harsch, Andreas; Huszar, Dennis; Kawatkar, Aarti; Kettle, Jason G.; Lyne, Paul; Read, Jon A.; Rivard Costa, Caroline; Ruston, Linette; Schroeder, Patricia; Shi, Jie; Su, Qibin; Throner, Scott; Toader, Dorin; Vasbinder, Melissa; Woessner, Richard; Wang, Haixia; Wu, Allan; Ye, Minwei; Zheng, Weijia; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5235-5244</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) have been demonstrated to be crit. in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases.  The JAK family consists of four highly homologous members: JAK1-3 and TYK2.  The development of small-mol. inhibitors that are selective for a specific family member would represent highly desirable tools for deconvoluting the intricacies of JAK family biol.  Herein, we report the discovery of a potent JAK1 inhibitor, I, which displays ∼1000-fold selectivity over the other highly homologous JAK family members (detd. by biochem. assays), while also possessing good selectivity over other kinases (detd. by panel screening).  Moreover, this compd. was demonstrated to be orally bioavailable and possesses acceptable pharmacokinetic parameters.  In an in vivo study, the compd. was obsd. to dose dependently modulate the phosphorylation of STAT3 (a downstream marker of JAK1 inhibition).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5EjmOMjz01LVg90H21EOLACvtfcHk0liRUnJPDdeVpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKktbbP&md5=d595d4b2b993f5701cdffece39688556</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00076%26sid%3Dliteratum%253Aachs%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DDeegan%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGero%26aufirst%3DT.%26aulast%3DHarsch%26aufirst%3DA.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DKawatkar%26aufirst%3DA.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DThroner%26aufirst%3DS.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DVasbinder%26aufirst%3DM.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520novel%2520series%2520of%2520highly%2520selective%2520JAK1%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5235%26epage%3D5244%26doi%3D10.1021%2Facs.jmedchem.8b00076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STAT proteins: novel molecular targets for cancer drug discovery</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6613</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1038%2Fsj.onc.1204086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=11426647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsF2rsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6613-6626&author=J.+Turksonauthor=R.+Jove&title=STAT+proteins%3A+novel+molecular+targets+for+cancer+drug+discovery&doi=10.1038%2Fsj.onc.1204086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">STAT proteins: novel molecular targets for cancer drug discovery</span></div><div class="casAuthors">Turkson, James; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">6613-6626</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 101 refs.  Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic proteins with roles as signal messengers and transcription factors that participate in normal cellular responses to cytokines and growth factors.  Frequently, however, abnormal activity of certain STAT family members, particularly Stat3 and Stat5, is assocd. with a wide variety of human malignancies, including hematol., breast, head and neck, and prostate cancers.  Application of mol. biol. and pharmacol. tools in disease-relevant models has confirmed Stat3 as having a causal role in oncogenesis, and provided validation of Stat3 as a target for cancer drug discovery and therapeutic intervention.  Furthermore, a constitutively-active mutant form of Stat3 is sufficient to induce oncogenic transformation of cells, which form tumors in vivo.  Constitutive activation of Stat3 signaling is accompanied by upregulation of cyclin D1, c-Myc, and Bcl-x, changes consistent with subversion of normal cellular growth and survival control mechanisms.  Block of constitutive Stat3 signaling results in growth inhibition and apoptosis of Stat3-pos. tumor cells in vitro and in vivo.  The obsd. dependence of certain tumors on constitutive Stat3 signaling for growth and survival has wide implications for cancer therapy, offering the potential for preferential tumor cell killing.  This review evaluates constitutive Stat3 activation as a "cancer-causing" factor, and proposes a no. of mol. strategies for targeting Stat3 signaling for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoffTICt_aLhLVg90H21EOLACvtfcHk0liRUnJPDdeVpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsF2rsro%253D&md5=2011fb621ef70547ddbbef2ed253df98</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204086%26sid%3Dliteratum%253Aachs%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTAT%2520proteins%253A%2520novel%2520molecular%2520targets%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6613%26epage%3D6626%26doi%3D10.1038%2Fsj.onc.1204086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1038%2Fsj.onc.1205152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=11850821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvFGqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=1038-1047&author=A.+Zamoauthor=R.+Chiarleauthor=R.+Pivaauthor=J.+Howesauthor=Y.+Fanauthor=M.+Chilosiauthor=D.+E.+Levyauthor=G.+Inghirami&title=Anaplastic+lymphoma+kinase+%28ALK%29+activates+Stat3+and+protects+hematopoietic+cells+from+cell+death&doi=10.1038%2Fsj.onc.1205152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</span></div><div class="casAuthors">Zamo, Alberto; Chiarle, Roberto; Piva, Roberto; Howes, Jennifer; Fan, Yan; Chilosi, Marco; Levy, David E.; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1038-1047</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The anaplastic lymphoma kinase (ALK) gene is characteristically translocated in anaplastic large cell lymphomas (ALCL) and the juxtaposion of the ALK gene to multiple partners results in its constitutive protein tyrosine kinase activity.  We show here that expression of activated ALK induces the constitutive phosphorylation of Stat3 in transfected cells as well as in primary human ALCLs.  Furthermore, immunohistochem. studies demonstrate that among distinct human B and T cell lymphomas, activation of Stat3 nuclear translocation is uniquely assocd. with ALK expression.  NPM-ALK also binds and activates Jak3; however, Jak3 is not required for Stat3 activation or for cell transformation in vitro.  Moreover, src family kinases are not necessary for NPM-ALK-mediated Stat3 activation or transformation, suggesting that Stat3 may be phosphorylated directly by ALK.  To evaluate relevant targets of ALK-activated Stat3, we investigated the regulation of the anti-apoptotic protein Bcl-xL and its role in cell survival in NPM-ALK pos. cells.  NPM-ALK expression caused enhanced Bcl-xL transcription, largely mediated by Stat3.  Increased expression of Bcl-xL provided sufficient anti-apoptotic signals to protect cells from treatment with specific inhibitors of the Jaks/Stat pathway or the Brc-Abl kinase.  These studies support a pathogenic mechanism whereby stimulation of anti-apoptotic signals through activation of Stat3 contributes to the successful outgrowth of ALK pos. tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogI4o98Agys7Vg90H21EOLACvtfcHk0lgaOAx9Nq97lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvFGqs7g%253D&md5=c7b2e63cc7765563b6d30aa4bda2569f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205152%26sid%3Dliteratum%253Aachs%26aulast%3DZamo%26aufirst%3DA.%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DHowes%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DChilosi%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520activates%2520Stat3%2520and%2520protects%2520hematopoietic%2520cells%2520from%2520cell%2520death%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D1038%26epage%3D1047%26doi%3D10.1038%2Fsj.onc.1205152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sansone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the interleukin-6/Jak/stat pathway in human malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.31.8907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1200%2FJCO.2010.31.8907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=22355058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1SgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1005-1014&author=P.+Sansoneauthor=J.+Bromberg&title=Targeting+the+interleukin-6%2FJak%2Fstat+pathway+in+human+malignancies&doi=10.1200%2FJCO.2010.31.8907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the interleukin-6/Jak/Stat pathway in human malignancies</span></div><div class="casAuthors">Sansone, Pasquale; Bromberg, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1005-1014</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling.  Since this time, more than 2,500 articles have been published demonstrating the importance of this pathway in virtually all malignancies.  Although there are dozens of cytokines and cytokine receptors, four Jaks, and seven Stats, it seems that interleukin-6-mediated activation of Stat3 is a principal pathway implicated in promoting tumorigenesis.  This transcription factor regulates the expression of numerous crit. mediators of tumor formation and metastatic progression.  This review will examine the relative importance and function of this pathway in nonmalignant conditions as well as malignancies (including tumor intrinsic and extrinsic), the influence of other Stats, the development of inhibitors to this pathway, and the potential role of inhibitors in controlling or eradicating cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfUoiaYph-K7Vg90H21EOLACvtfcHk0lgaOAx9Nq97lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1SgsLo%253D&md5=38fca14c5a694cce722155b32f14c0ae</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.31.8907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.31.8907%26sid%3Dliteratum%253Aachs%26aulast%3DSansone%26aufirst%3DP.%26aulast%3DBromberg%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520interleukin-6%252FJak%252Fstat%2520pathway%2520in%2520human%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1005%26epage%3D1014%26doi%3D10.1200%2FJCO.2010.31.8907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reintgen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7001</span>– <span class="NLM_lpage">7010</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1038%2Fsj.onc.1205859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=12370822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFylur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=7001-7010&author=G.+Niuauthor=T.+Bowmanauthor=M.+Huangauthor=S.+Shiversauthor=D.+Reintgenauthor=A.+Daudauthor=A.+Changauthor=A.+Krakerauthor=R.+Joveauthor=H.+Yu&title=Roles+of+activated+Src+and+Stat3+signaling+in+melanoma+tumor+cell+growth&doi=10.1038%2Fsj.onc.1205859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</span></div><div class="casAuthors">Niu, Guilian; Bowman, Tammy; Huang, Mei; Shivers, Steve; Reintgen, Douglas; Daud, Adil; Chang, Alfred; Kraker, Alan; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">7001-7010</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of protein tyrosine kinases is prevalent in human cancers and previous studies have demonstrated that Stat3 signaling is a point of convergence for many of these tyrosine kinases.  Moreover, a crit. role for constitutive activation of Stat3 in tumor cell proliferation and survival has been established in diverse cancers.  However, the oncogenic signaling pathways in melanoma cells remain to be fully defined.  In this study, the authors demonstrate that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens examd.  Blocking Src tyrosine kinase activity, but not EGF receptor or JAK family kinases, leads to inhibition of Stat3 signaling in melanoma cell lines.  Consistent with a role of Src in the pathogenesis of melanoma, the authors show that c-Src tyrosine kinase is activated in melanoma cell lines.  Significantly, melanoma cells undergo apoptosis when either Src kinase activity or Stat3 signaling is inhibited.  Blockade of Src or Stat3 is also accompanied by down-regulation of expression of the anti-apoptotic genes, Bcl-xL and Mcl-1.  These findings demonstrate that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO46ilXC4-MLVg90H21EOLACvtfcHk0lgaOAx9Nq97lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFylur0%253D&md5=6d5f9f43c4ee07a1c2534165dd28fede</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205859%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DBowman%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DShivers%26aufirst%3DS.%26aulast%3DReintgen%26aufirst%3DD.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DRoles%2520of%2520activated%2520Src%2520and%2520Stat3%2520signaling%2520in%2520melanoma%2520tumor%2520cell%2520growth%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D7001%26epage%3D7010%26doi%3D10.1038%2Fsj.onc.1205859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Targeting STAT3 affects melanoma on multiple fronts</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1007/s10555-005-1580-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1007%2Fs10555-005-1580-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=15986140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2MXls1agsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=315-327&author=M.+Kortylewskiauthor=R.+Joveauthor=H.+Yu&title=Targeting+STAT3+affects+melanoma+on+multiple+fronts&doi=10.1007%2Fs10555-005-1580-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STAT3 affects melanoma on multiple fronts</span></div><div class="casAuthors">Kortylewski, Marcin; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">315-327</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  As a point of convergence for numerous oncogenic signaling pathways, STAT3 is constitutively-activated at 50 to 90% frequency in diverse human cancers, including melanoma.  A crit. role of STAT3 in tumor cell survival, proliferation, angiogenesis, metastasis and immune evasion has been recently demonstrated.  STAT3 contributes to tumor cell growth by regulating the expression of genes that are involved in cell survival and proliferation.  STAT3 promotes metastasis and angiogenesis by inducing expression of the metastatic gene, MMP-2, and the potent angiogenic gene, VEGF.  STAT3 participates in the regulation of tumor immune evasion by inhibiting expression of proinflammatory mediators while promoting expression of immune-suppressing factors, which in turn activates STAT3 signaling in dendritic cells leading to immune tolerance.  Thus, targeting STAT3 for therapy assaults cancer on multiple fronts.  Many of the studies that defined STAT3's role in oncogenesis were carried out in melanoma cells and tumor models.  In this review, we summarize the key role of STAT3 in cancer in general and melanoma in particular.  With the emergence of small-mol. drugs that directly inhibit STAT3 or the oncogenic signaling pathways upstream of STAT3 in melanoma, a promising novel approach for melanoma therapy is emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVSFnD9ExaqLVg90H21EOLACvtfcHk0li3llsAsDcM-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXls1agsbg%253D&md5=9c3739bf82951bb2f9da6a08ed08e15a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs10555-005-1580-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-005-1580-1%26sid%3Dliteratum%253Aachs%26aulast%3DKortylewski%26aufirst%3DM.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DTargeting%2520STAT3%2520affects%2520melanoma%2520on%2520multiple%2520fronts%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2005%26volume%3D24%26spage%3D315%26epage%3D327%26doi%3D10.1007%2Fs10555-005-1580-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1006/gyno.2000.5931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1006%2Fgyno.2000.5931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=11006034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslKns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2000&pages=67-73&author=M.+Huangauthor=C.+Pageauthor=R.+K.+Reynoldsauthor=J.+Lin&title=Constitutive+activation+of+stat+3+oncogene+product+in+human+ovarian+carcinoma+cells&doi=10.1006%2Fgyno.2000.5931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive Activation of Stat 3 Oncogene Product in Human Ovarian Carcinoma Cells</span></div><div class="casAuthors">Huang, Melinda; Page, Carmen; Reynolds, R. Kevin; Lin, Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-73</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Stat 3 functions in transducing signals from the cell's surface to its nucleus and activation of gene transcription.  Aberrations of Stat 3 in breast cancer have raised the possibility of its contribution to oncogenesis.  The goal was to examine ovarian cancer cell lines to det. whether Stat 3 plays a relevant role in ovarian carcinogenesis.  Protein lysates were extd. from normal ovarian surface epithelial cells and malignant cells.  Western blotting techniques were performed with phosphorylation-independent or phosphorylation-specific Stat 3 (Tyr 705) antibody.  Confirmation of Stat 3 activation was detd. by a luciferase reporter driven by a promoter contg. Stat 3-specific binding sites.  Bcl-xL and cyclin D1 were also analyzed by Western blotting.  MDAH 2774, OV-1063, Caov-3, and O.C. 22819 expressed high levels of phosphorylated Stat 3.  In contrast, A2780 and normal ovarian surface epithelial cells had little Stat 3 phosphorylation recognized.  Confirmation of persistent activation of Stat 3 activity was shown by transfection of cells with a Stat 3 luciferase reporter.  Potential downstream mediators of Stat 3 including Bcl-xL and cyclin D1 were also evaluated.  In cells expressing activated Stat 3, high levels of both Bcl-xL and cyclin D1 were detected, whereas in A2780 cells, which did not express activated Stat 3, only low levels of Bcl-xL and cyclin D1 were expressed.Conclusions.  Constitutive activation of Stat 3 is present in ovarian cancer lines but not in normal ovarian surface epithelial cells.  Activation of Stat 3 is a common event during oncogenic transformation upstream to both Bcl-xL and cyclin D1.  The relationship of this aberrancy of ovarian carcinoma harboring activated Stat 3 deserves further investigation.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3pODKA-r__7Vg90H21EOLACvtfcHk0li3llsAsDcM-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslKns7c%253D&md5=d992c9943608157e112466e3edebfd13</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1006%2Fgyno.2000.5931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgyno.2000.5931%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DR.%2BK.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DConstitutive%2520activation%2520of%2520stat%25203%2520oncogene%2520product%2520in%2520human%2520ovarian%2520carcinoma%2520cells%26jtitle%3DGynecol.%2520Oncol.%26date%3D2000%26volume%3D79%26spage%3D67%26epage%3D73%26doi%3D10.1006%2Fgyno.2000.5931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, M.</span></span> <span> </span><span class="NLM_article-title">Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1016/S0022-5347(05)64741-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2FS0022-5347%2805%2964741-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=12131365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtFWhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2002&pages=762-765&author=A.+Horiguchiauthor=M.+Oyaauthor=T.+Shimadaauthor=A.+Uchidaauthor=K.+Marumoauthor=M.+Murai&title=Activation+of+signal+transducer+and+activator+of+transcription+3+in+renal+cell+carcinoma%3A+a+study+of+incidence+and+its+association+with+pathological+features+and+clinical+outcome&doi=10.1016%2FS0022-5347%2805%2964741-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</span></div><div class="casAuthors">Horiguchi, Akio; Oya, Mototsugu; Shimada, Tetsuya; Uchida, Atsushi; Marumo, Ken; Murai, Masaru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">762-765</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: Signal transducer and activator of transcription 3 (STAT3) is known to have an important role in cytokine and growth factor signaling pathways.  In various types of human malignant tumors STAT3 has been shown to be constitutively activated due to aberrant prodn. of cytokines and growth factors.  The authors examd. the presence of STAT3 activation and its assocn. with pathol. features and clin. outcome in renal cell carcinoma cases.  Materials and Methods: the authors examd. 48 paraffin embedded renal cell carcinoma specimens and corresponding nonneoplastic kidney tissues for the activation status of STAT3 on immunohistochem. using anti-phospho-specific (p)-STAT3 antibody, which recognizes only activated STAT3.  Based on the percent of cells with pos. nuclear staining the activation status of STAT3 was detd. and categorized into 2 groups, including low - less than 10% and high - 90% or more tumor cells pos.  The assocns. of the activation status of STAT3 with pathol. features and clin. outcome were analyzed.  Results: Of 48 tumors 24 (50%) demonstrated high levels of nuclear immunostaining for p-STAT3, while the other 24 (50%) showed low levels.  Adjacent nonneoplastic kidney tissues showed only little immunostaining for p-STAT3.  A significant assocn. of high levels of p-STAT3 with metastasis was obsd.  No significant assocns. of p-STAT3 immunostaining with pathol. stage or grade were obsd.  A high level of p-STAT3 was a significant indicator of a poor prognosis on univariate and multivariate anal.  Conclusions: the authors' results indicate a high frequency of STAT3 activation in renal cell carcinoma, esp. in metastatic disease.  STAT3 activation was an independent prognostic variable in renal cell carcinoma cases.  The authors' results strongly suggest that the activation of STAT3 contributes to the development and progression of renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBk-RaURU1VLVg90H21EOLACvtfcHk0ljv7LjZV_AEsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtFWhurw%253D&md5=a8e5fe3f02f14b11202b78d40a42945b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2805%2964741-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252805%252964741-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoriguchi%26aufirst%3DA.%26aulast%3DOya%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DA.%26aulast%3DMarumo%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DM.%26atitle%3DActivation%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520in%2520renal%2520cell%2520carcinoma%253A%2520a%2520study%2520of%2520incidence%2520and%2520its%2520association%2520with%2520pathological%2520features%2520and%2520clinical%2520outcome%26jtitle%3DJ.%2520Urol.%26date%3D2002%26volume%3D168%26spage%3D762%26epage%3D765%26doi%3D10.1016%2FS0022-5347%2805%2964741-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corvinus, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriggl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsareva, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfitzner, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberb, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beug, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhlschläger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbhuber, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, K.</span></span> <span> </span><span class="NLM_article-title">Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1593/neo.04571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1593%2Fneo.04571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=16036105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvF2qu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=545-555&author=F.+M.+Corvinusauthor=C.+Orthauthor=R.+Morigglauthor=S.+A.+Tsarevaauthor=S.+Wagnerauthor=E.+B.+Pfitznerauthor=D.+Bausauthor=R.+Kaufmannauthor=L.+A.+Huberbauthor=K.+Zatloukalauthor=H.+Beugauthor=P.+%C3%96hlschl%C3%A4gerauthor=A.+Sch%C3%BCtzauthor=K.-J.+Halbhuberauthor=K.+Friedrich&title=Persistent+STAT3+activation+in+colon+cancer+is+associated+with+enhanced+cell+proliferation+and+tumor+growth&doi=10.1593%2Fneo.04571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth</span></div><div class="casAuthors">Corvinus, Florian M.; Orth, Carina; Moriggl, Richard; Tsareva, Svetlana A.; Wagner, Stefan; Pfitzner, Edith B.; Baus, Daniela; Kaufmann, Roland; Huber, Lukas A.; Zatloukal, Kurt; Beug, Hartmut; Oehlschlaeger, Peter; Schuetz, Alexander; Halbhuber, Karl-Juergen; Friedrich, Karlheinz</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-555</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Colorectal carcinoma (CRC) is a major cause of morbidity and mortality in Western countries.  It has so far been molecularly defined mainly by alterations of the Wnt pathway.  We show here for the first time that aberrant activities of the signal transducer and activator of transcription STAT3 actively contribute to this malignancy and, thus, are a potential therapeutic target for CRC.  Constitutive STAT3 activity was found to be abundant in dedifferentiated cancer cells and infiltrating lymphocytes of CRC samples, but not in non-neoplastic colon epithelium.  Cell lines derived from malignant colorectal tumors lost persistent STAT3 activity in culture.  However, implantation of colon carcinoma cells into nude mice resulted in restoration of STAT3 activity, suggesting a role of an extracellular stimulus within the tumor microenvironment as a trigger for STAT activation.  STAT3 activity in CRC cells triggered through interleukin-6 or through a constitutively active STAT3 mutant promoted cancer cell multiplication, whereas STAT3 inhibition through a dominant-neg. variant impaired IL-6-driven proliferation.  Blockade of STAT3 activation in CRC-derived xenograft tumors slowed down their development, arguing for a contribution of STAT3 to colorectal tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplNySx1-IGqLVg90H21EOLACvtfcHk0ljv7LjZV_AEsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvF2qu7k%253D&md5=6d74cb8a99173e589ceee0b54c7bd487</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1593%2Fneo.04571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.04571%26sid%3Dliteratum%253Aachs%26aulast%3DCorvinus%26aufirst%3DF.%2BM.%26aulast%3DOrth%26aufirst%3DC.%26aulast%3DMoriggl%26aufirst%3DR.%26aulast%3DTsareva%26aufirst%3DS.%2BA.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DPfitzner%26aufirst%3DE.%2BB.%26aulast%3DBaus%26aufirst%3DD.%26aulast%3DKaufmann%26aufirst%3DR.%26aulast%3DHuberb%26aufirst%3DL.%2BA.%26aulast%3DZatloukal%26aufirst%3DK.%26aulast%3DBeug%26aufirst%3DH.%26aulast%3D%25C3%2596hlschl%25C3%25A4ger%26aufirst%3DP.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DA.%26aulast%3DHalbhuber%26aufirst%3DK.-J.%26aulast%3DFriedrich%26aufirst%3DK.%26atitle%3DPersistent%2520STAT3%2520activation%2520in%2520colon%2520cancer%2520is%2520associated%2520with%2520enhanced%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D545%26epage%3D555%26doi%3D10.1593%2Fneo.04571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, Y.-L.</span></span> <span> </span><span class="NLM_article-title">Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1002/path.2041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1002%2Fpath.2041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=16917804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2006&pages=224-233&author=K.-C.+Changauthor=M.-H.+Wuauthor=D.+Jonesauthor=F.-F.+Chenauthor=Y.-L.+Tseng&title=Activation+of+STAT3+in+thymic+epithelial+tumours+correlates+with+tumour+type+and+clinical+behaviour&doi=10.1002%2Fpath.2041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour</span></div><div class="casAuthors">Chang, K.-C.; Wu, M.-H.; Jones, D.; Chen, F.-F.; Tseng, Y.-L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-233</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The STAT3 (signal transducers and activators of transcription 3) signalling pathway plays a pivotal role in oncogenesis and appears essential for postnatal maintenance of thymic architecture and thymocyte survival.  The assocn. of STAT3 activation with thymic epithelial tumors (TETs) and myasthenia gravis (MG) has not been elucidated.  In this study, 118 cases of TET and 25 non-neoplastic thymic tissue samples were evaluated for STAT3 and phospho-STAT3 (pSTAT3) expression immunohistochem.  In addn., 44 normal thymuses of different ages were included for comparison.  It was found that STAT3 activation in thymic epithelial cells (TECs), as evidenced by pSTAT3 expression and/or nuclear STAT3, was present in the majority of non-neoplastic thymuses (88%, 22/25), including those from young children, but not in fetal thymus.  In thymoma (n = 73), activated STAT3 was noted at a significantly higher frequency in the cases of lymphocyte-rich thymoma (ie types AB, B1, and B2, 46%, 23/50) in comparison with lymphocyte-depleted thymoma (types A and B3, 1/23) (p = 0.009).  Thymoma with activated STAT3 tended to present at an earlier stage, show complete resectability and less aggressive behavior, and have a higher correlation with MG than the STAT3-neg./inactive group (p < 0.05).  In contrast, thymic carcinoma with activated STAT3 (14/45, 31%) had significantly higher rates of unresectability, vascular invasion, and regional lymph node metastasis (p < 0.05).  These data provide the first evidence that constitutive STAT3 activation is seen in both benign and neoplastic thymic tissue and is assocd. with the persistence of thymic tissue and the presence of MG.  It is likely to be induced by different factors in thymoma and thymic carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGt8X77mhe7Vg90H21EOLACvtfcHk0li-7y9ZLlrYXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgur%252FI&md5=e3966221dfbda9697a2913b34fa8d1cb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fpath.2041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2041%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DK.-C.%26aulast%3DWu%26aufirst%3DM.-H.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DF.-F.%26aulast%3DTseng%26aufirst%3DY.-L.%26atitle%3DActivation%2520of%2520STAT3%2520in%2520thymic%2520epithelial%2520tumours%2520correlates%2520with%2520tumour%2520type%2520and%2520clinical%2520behaviour%26jtitle%3DJ.%2520Pathol.%26date%3D2006%26volume%3D210%26spage%3D224%26epage%3D233%26doi%3D10.1002%2Fpath.2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells</span>. <i>Acta Histochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.acthis.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.acthis.2011.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=21549414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2012&pages=151-158&author=Z.+Yinauthor=Y.+Zhangauthor=Y.+Liauthor=T.+Lvauthor=J.+Liuauthor=X.+Wang&title=Prognostic+significance+of+STAT3+expression+and+its+correlation+with+chemoresistance+of+non-small+cell+lung+cancer+cells&doi=10.1016%2Fj.acthis.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells</span></div><div class="casAuthors">Yin, Zhenjie; Zhang, Yan; Li, Yu; Lv, Tingting; Liu, Jie; Wang, Xinbo</div><div class="citationInfo"><span class="NLM_cas:title">Acta Histochemica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-158</span>CODEN:
                <span class="NLM_cas:coden">AHISA9</span>;
        ISSN:<span class="NLM_cas:issn">0065-1281</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Activation of signal transducer and activator of transcription 3 (STAT3) plays important roles in tumorigenesis and tumor development.  Previously, we have reported that overexpression of STAT3 potentiates growth, survival and radioresistance of non-small cell lung cancer (NSCLC) cells.  The aim of this study was to investigate the prognostic significance of STAT3 expression and its correlation with chemoresistance of NSCLC cells.  Semi-quant. RT-PCR was performed to detect the expression of STAT3 mRNA in 12 NSCLC and corresponding adjacent lung tissues.  Immunohistochem. was performed to detect the expression of STAT3 protein in 76 NSCLC tissue samples.  Addnl., the correlation between STAT3 expression and prognosis of NSCLC patients was statistically analyzed.  The role of STAT3 in chemoresistance of NSCLC cells was also assessed by the vector-based small interfering RNA.  The expression level of STAT3 mRNA in NSCLC tissues was significantly higher than that in corresponding adjacent lung tissues (P < 0.05).  Pos. immunostaining of STAT3 protein was mainly located in the cytoplasm of tumor cells.  The expression of STAT3 protein was significantly correlated with tumor differentiation, clin. stage and lymph node metastasis of NSCLC patients.  Moreover, the 5-yr overall survival rate of patients with high STAT3 expression (42.3%) was significantly lower than that of patients with low STAT3 expression (58.8%; P < 0.001).  Multivariate anal. using the Cox proportional hazard model showed that high STAT3 protein expression was an independent prognostic factor for NSCLC patients (P = 0.021).  Furthermore, two stably transfected cell lines (A549/shSTAT3 and SPC-A1/shSTAT3) were successfully established, and RNAi-mediated STAT3 inhibition could significantly increase the sensitivity of NSCLC cells to cisplatin by enhancing caspase-3-dependent apoptosis.  Together, the expression of STAT3 might be an independent prognostic marker for NSCLC patients and RNAi-mediated STAT3 inhibition would be a potential strategy for chemosensitization of NSCLC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjj5R2_p17K7Vg90H21EOLACvtfcHk0li-7y9ZLlrYXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKjs7w%253D&md5=232111e34d1e8297cd50235e791d601c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.acthis.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.acthis.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLv%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DPrognostic%2520significance%2520of%2520STAT3%2520expression%2520and%2520its%2520correlation%2520with%2520chemoresistance%2520of%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DActa%2520Histochem.%26date%3D2012%26volume%3D114%26spage%3D151%26epage%3D158%26doi%3D10.1016%2Fj.acthis.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidler, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danson, S. J.</span></span> <span> </span><span class="NLM_article-title">The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1038%2Fbjc.2015.233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=26151455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=365-371&author=S.+J.+Thomasauthor=J.+A.+Snowdenauthor=M.+P.+Zeidlerauthor=S.+J.+Danson&title=The+role+of+JAK%2FSTAT+signalling+in+the+pathogenesis%2C+prognosis+and+treatment+of+solid+tumours&doi=10.1038%2Fbjc.2015.233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumors</span></div><div class="casAuthors">Thomas, S. J.; Snowden, J. A.; Zeidler, M. P.; Danson, S. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-371</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant activation of intracellular signalling pathways confers malignant properties on cancer cells.  Targeting intracellular signalling pathways has been a productive strategy for drug development, with several drugs acting on signalling pathways already in use and more continually being developed.  The JAK/STAT signalling pathway provides an example of this paradigm in haematol. malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clin. effective JAK2 inhibitors, such as ruxolitinib.  It is now clear that many solid tumors also show activation of JAK/STAT signalling.  In this review, we focus on the role of JAK/STAT signalling in solid tumors, examg. the mol. mechanisms that cause inappropriate pathway activation and their cellular consequences.  We also discuss the degree to which activated JAK/STAT signalling contributes to oncogenesis.  Studies showing the effect of activation of JAK/STAT signalling upon prognosis in several tumor types are summarized.  Finally, we discuss the prospects for treating solid tumors using strategies targeting JAK/STAT signalling, including what can be learned from haematol. malignancies and the extent to which results in solid tumors might be expected to differ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZLyuJNOfIZrVg90H21EOLACvtfcHk0li-7y9ZLlrYXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7nJ&md5=d9c42818af6713ce510fea404982968e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.233%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BJ.%26aulast%3DSnowden%26aufirst%3DJ.%2BA.%26aulast%3DZeidler%26aufirst%3DM.%2BP.%26aulast%3DDanson%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520role%2520of%2520JAK%252FSTAT%2520signalling%2520in%2520the%2520pathogenesis%252C%2520prognosis%2520and%2520treatment%2520of%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D365%26epage%3D371%26doi%3D10.1038%2Fbjc.2015.233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, J. F.</span></span> <span> </span><span class="NLM_article-title">Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3846</span>– <span class="NLM_lpage">3856</span>, <span class="refDoi"> DOI: 10.1172/JCI31871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1172%2FJCI31871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=18060032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsValsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=3846-3856&author=S.+P.+Gaoauthor=K.+G.+Markauthor=K.+Leslieauthor=W.+Paoauthor=N.+Motoiauthor=W.+L.+Geraldauthor=W.+D.+Travisauthor=W.+Bornmannauthor=D.+Veachauthor=B.+Clarksonauthor=J.+F.+Bromberg&title=Mutations+in+the+EGFR+kinase+domain+mediate+STAT3+activation+via+IL-6+production+in+human+lung+adenocarcinomas&doi=10.1172%2FJCI31871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</span></div><div class="casAuthors">Gao, Sizhi Paul; Mark, Kavin G.; Leslie, Kenneth; Pao, William; Motoi, Noriko; Gerald, William L.; Travis, William D.; Bornmann, William; Veach, Darren; Clarkson, Bayard; Bromberg, Jacqueline F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3846-3856</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas.  PSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR.  Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis.  Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels.  In addn., redn. of IL-6 levels by RNA interference led to a decrease in tumorigenesis.  Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade.  Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased prodn. and release of IL-6.  Finally, immunohistochem. anal. revealed a pos. correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas.  Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-fCYAz8G9S7Vg90H21EOLACvtfcHk0liYAahPuKRcDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsValsL%252FO&md5=4043bc2cf3aecbfbfb3fbd8bf99d6aef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1172%2FJCI31871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31871%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.%2BP.%26aulast%3DMark%26aufirst%3DK.%2BG.%26aulast%3DLeslie%26aufirst%3DK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMotoi%26aufirst%3DN.%26aulast%3DGerald%26aufirst%3DW.%2BL.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DBromberg%26aufirst%3DJ.%2BF.%26atitle%3DMutations%2520in%2520the%2520EGFR%2520kinase%2520domain%2520mediate%2520STAT3%2520activation%2520via%2520IL-6%2520production%2520in%2520human%2520lung%2520adenocarcinomas%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D3846%26epage%3D3856%26doi%3D10.1172%2FJCI31871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1083/jcb.200703184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1083%2Fjcb.200703184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=17908914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOntb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2007&pages=129-138&author=L.+Sunauthor=K.+Maauthor=H.+Wangauthor=F.+Xiaoauthor=Y.+Gaoauthor=W.+Zhangauthor=K.+Wangauthor=X.+Gaoauthor=N.+Ipauthor=Z.+Wu&title=JAK1-STAT1-STAT3%2C+a+key+pathway+promoting+proliferation+and+preventing+premature+differentiation+of+myoblasts&doi=10.1083%2Fjcb.200703184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts</span></div><div class="casAuthors">Sun, Luguo; Ma, Kewei; Wang, Haixia; Xiao, Fang; Gao, Yan; Zhang, Wei; Wang, Kepeng; Gao, Xiang; Ip, Nancy; Wu, Zhenguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-138</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Skeletal muscle stem cell-derived myoblasts are mainly responsible for postnatal muscle growth and injury-induced muscle regeneration.  However, the cellular signaling pathways controlling the proliferation and differentiation of myoblasts are not fully understood.  We demonstrate that Janus kinase 1 (JAK1) is required for myoblast proliferation and that it also functions as a checkpoint to prevent myoblasts from premature differentiation.  Deliberate knockdown of JAK1 in both primary and immortalized myoblasts induces precocious myogenic differentiation with a concomitant redn. in cell proliferation.  This is caused, in part, by an accelerated induction of MyoD, myocyte enhancer-binding factor 2 (MEF2), p21Cip1, and p27Kip1, a faster down-regulation of Id1, and an increase in MEF2-dependent gene transcription.  Downstream of JAK1, of all the signal transducer and activator of transcriptions (STATs) present in myoblasts, we find that only STAT1 knockdown promotes myogenic differentiation in both primary and immortalized myoblasts.  Leukemia inhibitory factor stimulates myoblast proliferation and represses differentiation via JAK1-STAT1-STAT3.  Thus, JAK1-STAT1-STAT3 constitutes a signaling pathway that promotes myoblast proliferation and prevents premature myoblast differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2roS_PhxgIrVg90H21EOLACvtfcHk0liYAahPuKRcDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOntb3N&md5=b5501295e3a0b113030216299cd69e3a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200703184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200703184%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DIp%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DJAK1-STAT1-STAT3%252C%2520a%2520key%2520pathway%2520promoting%2520proliferation%2520and%2520preventing%2520premature%2520differentiation%2520of%2520myoblasts%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2007%26volume%3D179%26spage%3D129%26epage%3D138%26doi%3D10.1083%2Fjcb.200703184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">JAKs and STATs in immunity, immunodeficiency, and cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1202117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1056%2FNEJMra1202117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=23301733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=161-170&author=J.+J.+O%E2%80%99Sheaauthor=S.+M.+Hollandauthor=L.+M.+Staudt&title=JAKs+and+STATs+in+immunity%2C+immunodeficiency%2C+and+cancer&doi=10.1056%2FNEJMra1202117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">JAKs and STATs in immunity, immunodeficiency, and cancer</span></div><div class="casAuthors">O'Shea, John J.; Holland, Steven M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review highlights interferon-mediated gene regulation has resulted in a new framework for the study of cell signaling and JAKs STATs in immunity, immunodeficiency, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1n-UgWrlWrVg90H21EOLACvtfcHk0ljtZdbDRswQSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVyhuw%253D%253D&md5=5d87b67f72b721eb0ca9413adf92a7b9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1202117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1202117%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DJAKs%2520and%2520STATs%2520in%2520immunity%252C%2520immunodeficiency%252C%2520and%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D161%26epage%3D170%26doi%3D10.1056%2FNEJMra1202117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1080%2F13543776.2017.1252754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27774822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=145-161&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature+2013-2015%2C+part+2&doi=10.1080%2F13543776.2017.1252754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-161</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 2 covering J through Z.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xWVX0ADy67Vg90H21EOLACvtfcHk0ljtZdbDRswQSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI&md5=c75e5d123fd35306665e0713f801320c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252754%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202013-2015%252C%2520part%25202%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D145%26epage%3D161%26doi%3D10.1080%2F13543776.2017.1252754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span>; <span class="NLM_string-name">Shepard, S.</span>; <span class="NLM_string-name">Arvanitis, A. G.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Storace, L.</span>; <span class="NLM_string-name">Folmer, B.</span>; <span class="NLM_string-name">Shao, L.</span>; <span class="NLM_string-name">Zhu, W.</span>; <span class="NLM_string-name">Glenn, J.</span></span> <span> </span><span class="NLM_article-title">N-(hetero)aryl-pyrrolidine Derivatives of Pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and Pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus Kinase Inhibitors</span>. <span class="NLM_patent">WO 2010135650 A120101125</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+D.+Rodgers&author=S.+Shepard&author=A.+G.+Arvanitis&author=H.+Wang&author=L.+Storace&author=B.+Folmer&author=L.+Shao&author=W.+Zhu&author=J.+Glenn&title=N-%28hetero%29aryl-pyrrolidine+Derivatives+of+Pyrazol-4-yl-pyrrolo%5B2%2C3-d%5Dpyrimidines+and+Pyrrol-3-yl-pyrrolo%5B2%2C3-d%5Dpyrimidines+as+Janus+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26atitle%3DN-%2528hetero%2529aryl-pyrrolidine%2520Derivatives%2520of%2520Pyrazol-4-yl-pyrrolo%255B2%252C3-d%255Dpyrimidines%2520and%2520Pyrrol-3-yl-pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520Janus%2520Kinase%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nolen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, G.</span></span> <span> </span><span class="NLM_article-title">Regulation of protein kinases; controlling activity through activation segment conformation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.08.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.molcel.2004.08.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=15350212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFyhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=661-675&author=B.+Nolenauthor=S.+Taylorauthor=G.+Ghosh&title=Regulation+of+protein+kinases%3B+controlling+activity+through+activation+segment+conformation&doi=10.1016%2Fj.molcel.2004.08.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of protein kinases: Controlling activity through activation segment conformation</span></div><div class="casAuthors">Nolen, Brad; Taylor, Susan; Ghosh, Gourisankar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">661-675</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  There are currently at least 46 unique protein kinase crystal structures, 24 of which are available in an active state.  Here, the authors examine these structures using a structural bioinformatics approach to understand how the conformation of the activation segment controls kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAdRcy6kkUnbVg90H21EOLACvtfcHk0ljtZdbDRswQSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFyhsro%253D&md5=e1fc9a323c271a856ccd944a77c83a7f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.08.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.08.024%26sid%3Dliteratum%253Aachs%26aulast%3DNolen%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DG.%26atitle%3DRegulation%2520of%2520protein%2520kinases%253B%2520controlling%2520activity%2520through%2520activation%2520segment%2520conformation%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D661%26epage%3D675%26doi%3D10.1016%2Fj.molcel.2004.08.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span> <span> </span><span class="NLM_article-title">Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4805</span>– <span class="NLM_lpage">4808</span>, <span class="refDoi"> DOI: 10.1021/jm060522a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060522a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFGjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4805-4808&author=P.+D.+Lyneauthor=M.+L.+Lambauthor=J.+C.+Saeh&title=Accurate+prediction+of+the+relative+potencies+of+members+of+a+series+of+kinase+inhibitors+using+molecular+docking+and+MM-GBSA+scoring&doi=10.1021%2Fjm060522a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring</span></div><div class="casAuthors">Lyne, Paul D.; Lamb, Michelle L.; Saeh, Jamal C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4805-4808</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ability of mol. docking, using the program Glide and an MM-GBSA postdocking scoring protocol, to correctly rank a no. of congeneric kinase inhibitors was assessed.  The approach was successful for the cases considered and suggests that this may be useful for the design of inhibitors in the lead optimization phase of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVyYUu0E1ua7Vg90H21EOLACvtfcHk0lhXrQ80ZkFL2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFGjs7s%253D&md5=ea44ed5036a1569d191481bf10c74889</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm060522a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060522a%26sid%3Dliteratum%253Aachs%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26atitle%3DAccurate%2520prediction%2520of%2520the%2520relative%2520potencies%2520of%2520members%2520of%2520a%2520series%2520of%2520kinase%2520inhibitors%2520using%2520molecular%2520docking%2520and%2520MM-GBSA%2520scoring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4805%26epage%3D4808%26doi%3D10.1021%2Fjm060522a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aastrand, A. B. M.</span>, <span class="NLM_string-name">Grimster, N. P.</span>; <span class="NLM_string-name">Kawatkar, S.</span>; <span class="NLM_string-name">Kettle, J. G.</span>; <span class="NLM_string-name">Nilsson, M. K.</span></span>.; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L. L.</span>; <span class="NLM_string-name">Su, Q.</span>; <span class="NLM_string-name">Vasbinder, M. M.</span>; <span class="NLM_string-name">Winter-Holt, J. J.</span>; <span class="NLM_string-name">Wu, D.</span>; <span class="NLM_string-name">Yang, W.</span>; <span class="NLM_string-name">Grecu, T.</span>; <span class="NLM_string-name">McCabe, J.</span>; <span class="NLM_string-name">Woessner, R. D.</span>; <span class="NLM_string-name">Chuaqui, C. E.</span></span> , <span> </span><span class="NLM_article-title">Preparation of Substituted 2-(piperazin-1-yl)-N-[3-[2-[(1H-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl] Propanamide as Selective JAK1 Inhibitors for Treating Cancers and Immune Disorders</span>. <span class="NLM_patent">WO201750938</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+B.+M.+Aastrand&author=N.+P.+Grimster&author=S.+Kawatkar&author=J.+G.+Kettle&author=M.+K.+Nilssonauthor=L.+L.+Ruston&author=Q.+Su&author=M.+M.+Vasbinder&author=J.+J.+Winter-Holt&author=D.+Wu&author=W.+Yang&author=T.+Grecu&author=J.+McCabe&author=R.+D.+Woessner&author=C.+E.+Chuaqui&title=Preparation+of+Substituted+2-%28piperazin-1-yl%29-N-%5B3-%5B2-%5B%281H-pyrazol-4-yl%29amino%5Dpyrimidin-4-yl%5D-1H-indol-7-yl%5D+Propanamide+as+Selective+JAK1+Inhibitors+for+Treating+Cancers+and+Immune+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAastrand%26aufirst%3DA.%2BB.%2BM.%26aulast%3DRuston%26aufirst%3DL.%2BL.%26atitle%3DPreparation%2520of%2520Substituted%25202-%2528piperazin-1-yl%2529-N-%255B3-%255B2-%255B%25281H-pyrazol-4-yl%2529amino%255Dpyrimidin-4-yl%255D-1H-indol-7-yl%255D%2520Propanamide%2520as%2520Selective%2520JAK1%2520Inhibitors%2520for%2520Treating%2520Cancers%2520and%2520Immune%2520Disorders%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. É.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7048</span>, <span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+E.+Crossauthor=L.+A.+Dakinauthor=J.+%C3%89.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+M.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0lhgZmKTY1CFhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2B%25C3%2589.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lhgZmKTY1CFhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gideon A.  Gyebi</span>, <span class="hlFld-ContribAuthor ">Oludare M.  Ogunyemi</span>, <span class="hlFld-ContribAuthor ">Ibrahim M.  Ibrahim</span>, <span class="hlFld-ContribAuthor ">Saheed O.  Afolabi</span>, <span class="hlFld-ContribAuthor ">Joseph O.  Adebayo</span>. </span><span class="cited-content_cbyCitation_article-title">Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective. </span><span class="cited-content_cbyCitation_journal-name">Computers in Biology and Medicine</span><span> <strong>2021,</strong> <em>134 </em>, 104406. <a href="https://doi.org/10.1016/j.compbiomed.2021.104406" title="DOI URL">https://doi.org/10.1016/j.compbiomed.2021.104406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiomed.2021.104406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiomed.2021.104406%26sid%3Dliteratum%253Aachs%26jtitle%3DComputers%2520in%2520Biology%2520and%2520Medicine%26atitle%3DDual%252Btargeting%252Bof%252Bcytokine%252Bstorm%252Band%252Bviral%252Breplication%252Bin%252BCOVID-19%252Bby%252Bplant-derived%252Bsteroidal%252Bpregnanes%25253A%252BAn%252Bin%252Bsilico%252Bperspective%26aulast%3DGyebi%26aufirst%3DGideon%2BA.%26date%3D2021%26volume%3D134%26spage%3D104406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michela  Sperti</span>, <span class="hlFld-ContribAuthor ">Marta  Malavolta</span>, <span class="hlFld-ContribAuthor ">Gloria  Ciniero</span>, <span class="hlFld-ContribAuthor ">Simone  Borrelli</span>, <span class="hlFld-ContribAuthor ">Marco  Cavaglià</span>, <span class="hlFld-ContribAuthor ">Stefano  Muscat</span>, <span class="hlFld-ContribAuthor ">Jack Adam  Tuszynski</span>, <span class="hlFld-ContribAuthor ">Antonella  Afeltra</span>, <span class="hlFld-ContribAuthor ">Domenico Paolo Emanuele  Margiotta</span>, <span class="hlFld-ContribAuthor ">Luca  Navarini</span>. </span><span class="cited-content_cbyCitation_article-title">JAK inhibitors in immune-mediated rheumatic diseases: From a molecular perspective to clinical studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2021,</strong> <em>104 </em>, 107789. <a href="https://doi.org/10.1016/j.jmgm.2020.107789" title="DOI URL">https://doi.org/10.1016/j.jmgm.2020.107789</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2020.107789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2020.107789%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DJAK%252Binhibitors%252Bin%252Bimmune-mediated%252Brheumatic%252Bdiseases%25253A%252BFrom%252Ba%252Bmolecular%252Bperspective%252Bto%252Bclinical%252Bstudies%26aulast%3DSperti%26aufirst%3DMichela%26date%3D2021%26volume%3D104%26spage%3D107789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Si-Qi  Feng</span>, <span class="hlFld-ContribAuthor ">An-Qi  Li</span>, <span class="hlFld-ContribAuthor ">Jia-Hui  Zuo</span>, <span class="hlFld-ContribAuthor ">Dan-Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu-Jie  Xing</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Xie</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of new indole containing biaryl derivatives as potent antiproliferative agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104821. <a href="https://doi.org/10.1016/j.bioorg.2021.104821" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104821%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnew%252Bindole%252Bcontaining%252Bbiaryl%252Bderivatives%252Bas%252Bpotent%252Bantiproliferative%252Bagents%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2021%26volume%3D110%26spage%3D104821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaomeng  Xie</span>, <span class="hlFld-ContribAuthor ">Xiangyu  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaodan  Shi</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Kyle Vaughn  Laster</span>, <span class="hlFld-ContribAuthor ">Kangdong  Liu</span>, <span class="hlFld-ContribAuthor ">Zigang  Dong</span>, <span class="hlFld-ContribAuthor ">Dong Joon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Anwulignan is a novel JAK1 inhibitor that suppresses non‐small cell lung cancer growth. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular and Molecular Medicine</span><span> <strong>2021,</strong> <em>25 </em>
                                    (5)
                                     , 2645-2654. <a href="https://doi.org/10.1111/jcmm.16289" title="DOI URL">https://doi.org/10.1111/jcmm.16289</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jcmm.16289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjcmm.16289%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520and%2520Molecular%2520Medicine%26atitle%3DAnwulignan%252Bis%252Ba%252Bnovel%252BJAK1%252Binhibitor%252Bthat%252Bsuppresses%252Bnon%2525E2%252580%252590small%252Bcell%252Blung%252Bcancer%252Bgrowth%26aulast%3DXie%26aufirst%3DXiaomeng%26date%3D2021%26date%3D2021%26volume%3D25%26issue%3D5%26spage%3D2645%26epage%3D2654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Teodora  Djikic</span>, <span class="hlFld-ContribAuthor ">Zarko  Gagic</span>, <span class="hlFld-ContribAuthor ">Katarina  Nikolic</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Discovery of Kinase Inhibitors Using Docking Studies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 337-365. <a href="https://doi.org/10.1016/B978-0-12-822312-3.00009-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-822312-3.00009-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-822312-3.00009-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-822312-3.00009-6%26sid%3Dliteratum%253Aachs%26atitle%3DDesign%252Band%252BDiscovery%252Bof%252BKinase%252BInhibitors%252BUsing%252BDocking%252BStudies%26aulast%3DDjikic%26aufirst%3DTeodora%26date%3D2021%26spage%3D337%26epage%3D365%26pub%3DElsevier%26atitle%3DMolecular%252BDocking%252Bfor%252BComputer-Aided%252BDrug%252BDesign%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) X-ray crystal structure of <b>2</b> (yellow carbon atoms) bound to JAK1 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SM8">6SM8</a>) reveals a p-loop JAK1 selectivity pocket. Selected residues are shown as sticks. Hydrogen bonds are shown as dashed lines. (B) Overlay of <b>3</b> (green carbon atoms) with the X-ray crystal structure of JAK1 in complex with compound <b>2</b> suggested that substitutions of the 7-position of indole ring can reach the p-loop selectivity pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray structure of <b>5</b>-JAK1 complex (6SMB). The aminopyrimidine moiety maintains the key hydrogen bonds to the hinge. The amido-indole forms a bidentate hydrogen bond interaction with the side chain carboxylate of Asp1021. The methyl pyridine group forms several hydrophobic interactions in addition to a cation−π interaction with Lys908. Hydrogen bonds are shown as dashed lines. Compound <b>5</b> (yellow carbon atoms) overlays with the X-ray crystal structure of JAK1 in complex with compound <b>2</b> (green carbon atoms).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Plot of JAK1 biochemical potency vs human microsome CL<sub>int</sub>. Compound <b>9</b> was identified with a favorable balance of potency and properties. Dots were colored by ratio of IC<sub>50</sub>’s of JAK1 over JAK2 and sized by measured solubility at pH 7.4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray structure of <b>9</b>-JAK1 complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GGH">6GGH</a>). In addition to the retained interactions with the hinge and Aps1021, compound <b>9</b> also forms a salt-bridge interaction between the piperazine moiety and Asp1003. Hydrogen bonds are shown as dashed lines. Compound <b>9</b> (orange carbon atoms) overlays with the X-ray crystal structure of JAK1 in complex with compound <b>5</b> (yellow carbon atoms).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>21</b> enhances the antitumor activity of low-dose <b>22</b> (osimertinib) in an NCI-H1975 (T790M) NSCLC xenograft model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Plot of pSTAT3 and pEGFR signals in an NCI-H1975 mouse xenograft model with the treatment of <b>21</b> and <b>22</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/medium/jm9b01392_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Example Synthesis of Compound <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-9/acs.jmedchem.9b01392/20200507/images/large/jm9b01392_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01392&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (i) Pd(dppf)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>; 83%; (ii) NaOH, 50 °C, 81%; (b) TsOH·H<sub>2</sub>O, 130 °C, 75%; (c) Fe, NH<sub>4</sub>Cl, 74%; (d) HATU, iPrEt<sub>2</sub>N, 48%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i20">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52888" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52888" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hammarén, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtanen, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raivola, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span> <span> </span><span class="NLM_article-title">The regulation of JAKs in cytokine signaling and its breakdown in disease</span>. <i>Cytokine</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.cyto.2018.03.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.cyto.2018.03.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=29685781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFegtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2019&pages=48-63&author=H.+M.+Hammar%C3%A9nauthor=A.+T.+Virtanenauthor=J.+Raivolaauthor=O.+Silvennoinen&title=The+regulation+of+JAKs+in+cytokine+signaling+and+its+breakdown+in+disease&doi=10.1016%2Fj.cyto.2018.03.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The regulation of JAKs in cytokine signaling and its breakdown in disease</span></div><div class="casAuthors">Hammaren, Henrik M.; Virtanen, Anniina T.; Raivola, Juuli; Silvennoinen, Olli</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine+</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">48-63</span>CODEN:
                <span class="NLM_cas:coden">CYTIE9</span>;
        ISSN:<span class="NLM_cas:issn">1043-4666</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The JAK-STAT signal transduction pathway is responsible for mediating signals of over fifty cytokines, growth factors and hormones.  Signaling through the JAK-STAT pathway is regulated on multiple levels, including intramol. regulation by the JAK pseudokinase domain, and intermol. regulation by a host of regulatory proteins.  The advent of accessible genomic tools have provided a wealth of information on disease-assocd. mutations in the JAK-STAT pathway and its regulatory components.  The vast no. of these mutations in diseases ranging from immunodeficiencies and obesity to many cancers highlight the importance of correct regulation of JAK-STAT signaling for biol. processes such as hematopoiesis, regulation of the immune system, metab., and growth.  Simultaneously, JAK inhibitors are gaining traction in clin. use, both for treatment of diseases driven by JAK mutations, and for a host of inflammatory disorders, in which proinflammatory cytokine signaling through the JAK-STAT pathway is an integral part of pathogenesis.  The elucidation of mol. mechanisms in the pathogenesis of complex diseases has also, however, brought the limitations of our current understanding on the regulation of cytokine signaling to the foreground.  Indeed, deeper understanding of these regulatory mechanisms are a prerequisite for the development of the next generation of pharmacol. modulators of the JAK-STAT pathway.  In this review we discuss the current state of knowledge of the intra- and intermol. regulation of the JAK-STAT pathway, with a focus on diseases arising from disruptions in the regulatory app.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RzQKF2IxZbVg90H21EOLACvtfcHk0lgGGjpEdhOUJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFegtLg%253D&md5=f640078513fdd7e86a122d5d1172f76b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.cyto.2018.03.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cyto.2018.03.041%26sid%3Dliteratum%253Aachs%26aulast%3DHammar%25C3%25A9n%26aufirst%3DH.%2BM.%26aulast%3DVirtanen%26aufirst%3DA.%2BT.%26aulast%3DRaivola%26aufirst%3DJ.%26aulast%3DSilvennoinen%26aufirst%3DO.%26atitle%3DThe%2520regulation%2520of%2520JAKs%2520in%2520cytokine%2520signaling%2520and%2520its%2520breakdown%2520in%2520disease%26jtitle%3DCytokine%26date%3D2019%26volume%3D118%26spage%3D48%26epage%3D63%26doi%3D10.1016%2Fj.cyto.2018.03.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vakil, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment</span>. <i>Clin. Lymphoma, Myeloma Leuk.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">S37</span>– <span class="NLM_lpage">S45</span>, <span class="refDoi"> DOI: 10.1016/j.clml.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.clml.2011.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=22035746" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=S37-S45&author=E.+Vakilauthor=A.+Tefferi&title=BCR-ABL1%2D%2Dnegative+myeloproliferative+neoplasms%3A+a+review+of+molecular+biology%2C+diagnosis%2C+and+treatment&doi=10.1016%2Fj.clml.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.clml.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clml.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DVakil%26aufirst%3DE.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DBCR-ABL1--negative%2520myeloproliferative%2520neoplasms%253A%2520a%2520review%2520of%2520molecular%2520biology%252C%2520diagnosis%252C%2520and%2520treatment%26jtitle%3DClin.%2520Lymphoma%252C%2520Myeloma%2520Leuk.%26date%3D2011%26volume%3D11%26spage%3DS37%26epage%3DS45%26doi%3D10.1016%2Fj.clml.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, S. E.</span></span> <span> </span><span class="NLM_article-title">Biology and significance of the JAK/STAT signalling pathways</span>. <i>Growth Factors</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.3109/08977194.2012.660936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.3109%2F08977194.2012.660936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=22339650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=88-106&author=H.+Kiuauthor=S.+E.+Nicholson&title=Biology+and+significance+of+the+JAK%2FSTAT+signalling+pathways&doi=10.3109%2F08977194.2012.660936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Biology and significance of the JAK/STAT signalling pathways</span></div><div class="casAuthors">Kiu, Hiu; Nicholson, Sandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Growth Factors</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-106</span>CODEN:
                <span class="NLM_cas:coden">GRFAEC</span>;
        ISSN:<span class="NLM_cas:issn">0897-7194</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Since its discovery 2 decades ago, the activation of the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway by numerous cytokines and growth factors has resulted in it becoming 1 of the most well-studied intracellular signaling networks.  The field has progressed from the identification of the individual components to high-resoln. crystal structures of both JAK and STAT, and an understanding of the complexities of the mol. activation and deactivation cycle which results in a diverse, yet highly specific and regulated pattern of transcriptional responses.  While there is still more to learn, we now appreciate how disruption and deregulation of this pathway can result in clin. disease and look forward to adoption of the next generation of JAK inhibitors in routine clin. treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM2feFVqfQ77Vg90H21EOLACvtfcHk0lgGGjpEdhOUJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVahtbo%253D&md5=d81b34c514392de2c2179229633e9a55</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3109%2F08977194.2012.660936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08977194.2012.660936%26sid%3Dliteratum%253Aachs%26aulast%3DKiu%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DS.%2BE.%26atitle%3DBiology%2520and%2520significance%2520of%2520the%2520JAK%252FSTAT%2520signalling%2520pathways%26jtitle%3DGrowth%2520Factors%26date%3D2012%26volume%3D30%26spage%3D88%26epage%3D106%26doi%3D10.3109%2F08977194.2012.660936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenkopf, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brissette, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang-Poa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudlacz, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillie, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munchhof, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strelevitz, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanyam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whipple, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">8468</span>– <span class="NLM_lpage">8484</span>, <span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0ljV-WfRO-c2OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardanani, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Franco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrov, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson-Viitanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1002028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis&doi=10.1056%2FNEJMoa1002028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0ljV-WfRO-c2OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127%26doi%3D10.1056%2FNEJMoa1002028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papp, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Disch, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, J. M.</span></span> <span> </span><span class="NLM_article-title">A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span>. <i>Br. J. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1266</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1111/bjd.14403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1111%2Fbjd.14403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=26800231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2016&pages=1266-1276&author=K.+A.+Pappauthor=M.+A.+Menterauthor=M.+Ramanauthor=D.+Dischauthor=D.+E.+Schlichtingauthor=C.+Gaichauthor=W.+Maciasauthor=X.+Zhangauthor=J.+M.+Janes&title=A+randomized+phase+2b+trial+of+baricitinib%2C+an+oral+Janus+kinase+%28JAK%29+1%2FJAK2+inhibitor%2C+in+patients+with+moderate-to-severe+psoriasis&doi=10.1111%2Fbjd.14403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis</span></div><div class="casAuthors">Papp, K. A.; Menter, M. A.; Raman, M.; Disch, D.; Schlichting, D. E.; Gaich, C.; Macias, W.; Zhang, X.; Janes, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Dermatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1266-1276</span>CODEN:
                <span class="NLM_cas:coden">BJDEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0007-0963</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Background : Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.  Objectives : To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.  Methods : Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 wk (Part A).  Dose adjustment for 12 addnl. weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score.  The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 wk for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population.  Results : At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75.  All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 wk and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-mg and 10-mg groups at 8 and 12 wk.  More than 81% of PASI-75 responders maintained their scores through 24 wk.  During Part A, study discontinuations due to adverse events (AEs) were 0%, 0%, 2·8%, 6·3% and 5·8% and treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, resp.  No opportunistic infections were obsd. in any treatment group.  Dose-dependent changes in lab. values were obsd.  Conclusions : Patients with moderate-to-severe psoriasis treated with baricitinib for 12 wk achieved significant improvements in PASI-75.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqVPv2558vrrVg90H21EOLACvtfcHk0lj1qtbVMs7h6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSiurfN&md5=37df34807683b4742548f192f99654f6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fbjd.14403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjd.14403%26sid%3Dliteratum%253Aachs%26aulast%3DPapp%26aufirst%3DK.%2BA.%26aulast%3DMenter%26aufirst%3DM.%2BA.%26aulast%3DRaman%26aufirst%3DM.%26aulast%3DDisch%26aufirst%3DD.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DGaich%26aufirst%3DC.%26aulast%3DMacias%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DJanes%26aufirst%3DJ.%2BM.%26atitle%3DA%2520randomized%2520phase%25202b%2520trial%2520of%2520baricitinib%252C%2520an%2520oral%2520Janus%2520kinase%2520%2528JAK%2529%25201%252FJAK2%2520inhibitor%252C%2520in%2520patients%2520with%2520moderate-to-severe%2520psoriasis%26jtitle%3DBr.%2520J.%2520Dermatol.%26date%3D2016%26volume%3D174%26spage%3D1266%26epage%3D1276%26doi%3D10.1111%2Fbjd.14403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kremer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludivico, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogulec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardillo, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rooney, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macias, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span> <span> </span><span class="NLM_article-title">Baricitinib in patients with refractory rheumatoid arthritis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">1243</span>– <span class="NLM_lpage">1252</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1507247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1056%2FNEJMoa1507247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27028914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=1243-1252&author=M.+C.+Genoveseauthor=J.+Kremerauthor=O.+Zamaniauthor=C.+Ludivicoauthor=M.+Krogulecauthor=L.+Xieauthor=S.+D.+Beattieauthor=A.+E.+Kochauthor=T.+E.+Cardilloauthor=T.+P.+Rooneyauthor=W.+L.+Maciasauthor=S.+de+Bonoauthor=D.+E.+Schlichtingauthor=J.+S.+Smolen&title=Baricitinib+in+patients+with+refractory+rheumatoid+arthritis&doi=10.1056%2FNEJMoa1507247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib in patients with refractory rheumatoid arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Kremer, Joel; Zamani, Omid; Ludivico, Charles; Krogulec, Marek; Xie, Li; Beattie, Scott D.; Koch, Alisa E.; Cardillo, Tracy E.; Rooney, Terence P.; Macias, William L.; de Bono, Stephanie; Schlichting, Douglas E.; Smolen, Josef S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1243-1252</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced disease activity in patients with rheumatoid arthritis who had not previously received treatment with biol. disease-modifying antirheumatic drugs (DMARDs).  METHODS In this phase 3 study involving 527 patients with an inadequate response to or unacceptable side effects assocd. with one or more tumor necrosis factor inhibitors, other biol. DMARDs, or both, we randomly assigned the patients in a 1:1:1 ratio to baricitinib at a dose of 2 or 4 mg daily or placebo for 24 wk.  End points, tested hierarchically at week 12 to control type 1 error, were the American College of Rheumatol. 20% (ACR20) response (primary end point), the Health Assessment Questionnaire-Disability Index (HAQ-DI) score, the 28-joint Disease Activity Score based on C-reactive protein level (DAS28-CRP), and a Simplified Disease Activity Index (SDAI) score of 3.3 or less (on a scale of 0.1 to 86.0, with a score of 3.3 or less indicating remission).  Comparisons with placebo were made first with the 4-mg dose of baricitinib and then with the 2-mg dose.  RESULTS Significantly more patients receiving baricitinib at the 4-mg dose than those receiving placebo had an ACR20 response at week 12 (55% vs. 27%, P<0.001).  Differences between the higher-dose baricitinib group and the placebo group were also significant for the HAQ-DI score and the DAS28-CRP but not for an SDAI score of 3.3 or less.  Adverse-event rates through 24 wk were higher for patients receiving the 2-mg dose of baricitinib and those receiving the 4-mg dose than for patients receiving placebo (71% and 77%, resp., vs. 64%), including infections (44% and 40%, vs. 31%).  The rates of serious adverse events were 4%, 10%, and 7% in the three groups, resp.  Two nonmelanoma skin cancers and two major adverse cardiovascular events, including a fatal stroke, occurred in the higher-dose group.  Baricitinib was assocd. with a small redn. in neutrophil levels and increases in serum creatinine and low-d. lipoprotein cholesterol levels.  CONCLUSIONS In patients with rheumatoid arthritis and an inadequate response to biol. DMARDs, baricitinib at a daily dose of 4 mg was assocd. with clin. improvement at 12 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj72FQTLOsQLVg90H21EOLACvtfcHk0lj1qtbVMs7h6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kisr3E&md5=d7d317ee88fae38379b3b07c420349f6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1507247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1507247%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKremer%26aufirst%3DJ.%26aulast%3DZamani%26aufirst%3DO.%26aulast%3DLudivico%26aufirst%3DC.%26aulast%3DKrogulec%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DBeattie%26aufirst%3DS.%2BD.%26aulast%3DKoch%26aufirst%3DA.%2BE.%26aulast%3DCardillo%26aufirst%3DT.%2BE.%26aulast%3DRooney%26aufirst%3DT.%2BP.%26aulast%3DMacias%26aufirst%3DW.%2BL.%26aulast%3Dde%2BBono%26aufirst%3DS.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26atitle%3DBaricitinib%2520in%2520patients%2520with%2520refractory%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D1243%26epage%3D1252%26doi%3D10.1056%2FNEJMoa1507247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Codding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubrzycka-Sienkiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardiel, M. H.</span></span> <span> </span><span class="NLM_article-title">Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">932</span>– <span class="NLM_lpage">942</span>, <span class="refDoi"> DOI: 10.1002/art.40054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1002%2Fart.40054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=28118538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVelsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=932-942&author=M.+C.+Genoveseauthor=M.+Greenwaldauthor=C.+Coddingauthor=A.+Zubrzycka-Sienkiewiczauthor=A.+J.+Kivitzauthor=A.+Wangauthor=K.+Shayauthor=X.+Wangauthor=J.+P.+Gargauthor=M.+H.+Cardiel&title=Peficitinib%2C+a+JAK+inhibitor%2C+in+combination+with+limited+conventional+synthetic+disease-modifying+antirheumatic+drugs+in+the+treatment+of+moderate-to-severe+rheumatoid+arthritis&doi=10.1002%2Fart.40054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis</span></div><div class="casAuthors">Genovese, Mark C.; Greenwald, Maria; Codding, Christine; Zubrzycka-Sienkiewicz, Anna; Kivitz, Alan J.; Wang, Annie; Shay, Kathyjo; Wang, Xuegong; Garg, Jay P.; Cardiel, Mario H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">932-942</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with limited conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with moderate-to-severe rheumatoid arthritis (RA).  Methods : In this randomized, double-blind, phase IIb trial, patients with RA (n = 289) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg or matching placebo once daily for 12 wk.  The primary end point was the percentage of patients who met the American College of Rheumatol. 20% improvement criteria (achieved an ACR20 response) at week 12.  Results : ACR20 response rates at week 12 were 22.0%, 36.8%, 48.3% (P < 0.05), 56.3% (P < 0.01), and 29.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, resp.  Patients in the peficitinib 100 mg and 150 mg groups achieved a rapid and statistically significant ACR20 response compared with those in the placebo group (P < 0.05), reaching statistical significance by week 2.  Overall, the incidence of adverse events (AEs) was similar between patients receiving peficitinib and those receiving placebo.  The most common AEs were upper respiratory tract infection (5% [n = 15]), nausea (4% [n = 12]), and urinary tract infection (4% [n = 10]).  There was 1 case of herpes zoster in the placebo group, and 1 serious infection (limb abscess) in the peficitinib 25 mg group.  There were no incidences of grade 2 or higher neutropenia or lymphopenia.  Conclusion : In patients with moderate-to-severe RA, orally administered once-daily peficitinib in combination with limited csDMARDs resulted in a dose-dependent ACR20 response rate over 12 wk with satisfactory tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAtngQf8klmrVg90H21EOLACvtfcHk0liKIzJ8Tt2cEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVelsr0%253D&md5=761c5b89cdbbe60108a1bceb1d699ecd</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fart.40054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.40054%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DGreenwald%26aufirst%3DM.%26aulast%3DCodding%26aufirst%3DC.%26aulast%3DZubrzycka-Sienkiewicz%26aufirst%3DA.%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DShay%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGarg%26aufirst%3DJ.%2BP.%26aulast%3DCardiel%26aufirst%3DM.%2BH.%26atitle%3DPeficitinib%252C%2520a%2520JAK%2520inhibitor%252C%2520in%2520combination%2520with%2520limited%2520conventional%2520synthetic%2520disease-modifying%2520antirheumatic%2520drugs%2520in%2520the%2520treatment%2520of%2520moderate-to-severe%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D932%26epage%3D942%26doi%3D10.1002%2Fart.40054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez-Ureña, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poiley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shay, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zubrzycka-Sienkiewicz, A.</span></span> <span> </span><span class="NLM_article-title">Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">719</span>, <span class="refDoi"> DOI: 10.1002/art.39955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1002%2Fart.39955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27748083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltVSrtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2017&pages=709-719&author=A.+J.+Kivitzauthor=S.+R.+Gutierrez-Ure%C3%B1aauthor=J.+Poileyauthor=M.+C.+Genoveseauthor=R.+Kristyauthor=K.+Shayauthor=X.+Wangauthor=J.+P.+Gargauthor=A.+Zubrzycka-Sienkiewicz&title=Peficitinib%2C+a+JAK+inhibitor%2C+in+the+treatment+of+moderate-to-severe+rheumatoid+arthritis+in+patients+with+an+inadequate+response+to+methotrexate&doi=10.1002%2Fart.39955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate</span></div><div class="casAuthors">Kivitz, A. J.; Gutierrez-Urena, S. R.; Poiley, J.; Genovese, M. C.; Kristy, R.; Shay, K.; Wang, X.; Garg, J. P.; Zubrzycka-Sienkiewicz, A.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">709-719</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy and safety of orally administered once-daily peficitinib in combination with methotrexate (MTX) in patients with moderate-to-severe rheumatoid arthritis (RA) who had an inadequate response to MTX.  Methods: In this multinational, phase IIb, randomized, double-blind, placebo-controlled, dose-ranging trial, patients with RA (n = 378) were treated with peficitinib 25 mg, 50 mg, 100 mg, or 150 mg plus MTX, or matching placebo plus MTX once daily for 12 wk.  The primary end point was the percentage of patients who met the American College of Rheumatol. 20% improvement criteria (achieved an ACR20 response) at week 12.  Results: ACR20 response rates at week 12 were 43.9%, 61.5% (P < 0.05 vs. placebo), 46.4%, 57.7%, and 44.4% in the peficitinib 25 mg, 50 mg, 100 mg, 150 mg, and placebo groups, resp.  Significant decreases from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level were seen in the peficitinib 50 mg (P < 0.05) and 150 mg (P < 0.01) groups compared with placebo at week 12.  Overall, the incidence of adverse events (AEs) was similar between peficitinib and placebo.  The most common AEs were urinary tract infection (n = 22 [6%]), upper respiratory tract infection (n = 16 [4%]), and diarrhea (n = 16 [4%]).  There were 3 cases of herpes zoster infection (2 in the peficitinib 100 mg group and 1 in the 150 mg group) and 2 cases of serious infection (viral infection in the peficitinib 100 mg group and erysipelas in the 150 mg group).  Conclusion: The ACR20 response rate in the group receiving peficitinib 50 mg plus MTX was significantly different compared with the rate in patients receiving placebo, but there were no apparent dose-dependent responses, and the placebo response rate was high.  Peficitinib plus MTX in patients with moderate-to-severe RA was well tolerated, with limited safety signals emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsFnyDl8xZ4LVg90H21EOLACvtfcHk0liKIzJ8Tt2cEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltVSrtro%253D&md5=20630f376b7459166317e00024145613</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Fart.39955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39955%26sid%3Dliteratum%253Aachs%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DGutierrez-Ure%25C3%25B1a%26aufirst%3DS.%2BR.%26aulast%3DPoiley%26aufirst%3DJ.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DKristy%26aufirst%3DR.%26aulast%3DShay%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGarg%26aufirst%3DJ.%2BP.%26aulast%3DZubrzycka-Sienkiewicz%26aufirst%3DA.%26atitle%3DPeficitinib%252C%2520a%2520JAK%2520inhibitor%252C%2520in%2520the%2520treatment%2520of%2520moderate-to-severe%2520rheumatoid%2520arthritis%2520in%2520patients%2520with%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2017%26volume%3D69%26spage%3D709%26epage%3D719%26doi%3D10.1002%2Fart.39955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1080%2F13543776.2017.1252753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27774824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVagtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=127-143&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature+2013-2015%2C+part+1&doi=10.1080%2F13543776.2017.1252753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-143</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 1 covering A through to I.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwhs64lbsS9rVg90H21EOLACvtfcHk0ljxX3lUnXCrvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVagtr7I&md5=90dbe8bc6e86ac19fe512baf6ed82ef7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252753%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202013-2015%252C%2520part%25201%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D127%26epage%3D143%26doi%3D10.1080%2F13543776.2017.1252753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smolen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinblatt, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burmester, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerwein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Othman, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangan, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jungerwirth, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate</span>. <i>Arthritis Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">2857</span>– <span class="NLM_lpage">2866</span>, <span class="refDoi"> DOI: 10.1002/art.39808</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1002%2Fart.39808" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27390150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGgsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=2857-2866&author=M.+C.+Genoveseauthor=J.+S.+Smolenauthor=M.+E.+Weinblattauthor=G.+R.+Burmesterauthor=S.+Meerweinauthor=H.+S.+Campauthor=L.+Wangauthor=A.+A.+Othmanauthor=N.+Khanauthor=A.+L.+Panganauthor=S.+Jungerwirth&title=Efficacy+and+safety+of+ABT-494%2C+a+selective+JAK-1+inhibitor%2C+in+a+phase+IIb+study+in+patients+with+rheumatoid+arthritis+and+an+inadequate+response+to+methotrexate&doi=10.1002%2Fart.39808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate</span></div><div class="casAuthors">Genovese, Mark C.; Smolen, Josef S.; Weinblatt, Michael E.; Burmester, Gerd R.; Meerwein, Sebastian; Camp, Heidi S.; Wang, Li; Othman, Ahmed A.; Khan, Nasser; Pangan, Aileen L.; Jungerwirth, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2857-2866</span>CODEN:
                <span class="NLM_cas:coden">ARRHBO</span>;
        ISSN:<span class="NLM_cas:issn">2326-5191</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To evaluate the efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).  Methods : Three hundred RA patients receiving stable doses of MTX were randomly assigned equally to receive immediate-release ABT-494 at 3, 6, 12, or 18 mg twice daily, 24 mg once daily, or placebo for 12 wk.  The primary efficacy end point was the proportion of patients meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at week 12, as detd. using the last observation carried forward method.  Results : At week 12, the proportion of ACR20 responses was higher with ABT-494 (62%, 68%, 80%, 64%, and 76% for the 3, 6, 12, 18, and 24 mg doses, resp.) than with placebo (46%) (using nonresponder imputation) (P < 0.05 for the 6, 12, and 24 mg doses).  There was a significant dose-response relationship among all ABT-494 doses (P < 0.001).  The proportions of patients achieving ACR50 and ACR70 responses were significantly higher for all ABT-494 doses (except the 12 mg dose for the ACR70 response) than for placebo, as were changes in the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP).  Rapid improvement was demonstrated by significant differences in ACR20 response rates and changes in the DAS28-CRP for all doses compared with placebo at week 2 (the first postbaseline visit).  The incidence of adverse events was similar across groups; most were mild, and infections were the most frequent.  One serious infection (community-acquired pneumonia) occurred with ABT-494 at 12 mg.  There were dose-dependent increases in high-d. lipoprotein (HDL) and low-d. lipoprotein (LDL) cholesterol, but the LDL cholesterol:HDL cholesterol ratios were unchanged through week 12.  Mean Hb levels remained stable at lower doses, but decreases were obsd. at higher doses.  Conclusion : This study evaluated a broad range of doses of ABT-494 in RA patients with an inadequate response to MTX.  ABT-494 demonstrated efficacy, with a safety and tolerability profile similar to that of other JAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0MsK02mgIbVg90H21EOLACvtfcHk0ljxX3lUnXCrvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGgsL3I&md5=5d4bf383496b2153fede781caf6ba0c7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fart.39808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.39808%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DBurmester%26aufirst%3DG.%2BR.%26aulast%3DMeerwein%26aufirst%3DS.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DOthman%26aufirst%3DA.%2BA.%26aulast%3DKhan%26aufirst%3DN.%26aulast%3DPangan%26aufirst%3DA.%2BL.%26aulast%3DJungerwirth%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520ABT-494%252C%2520a%2520selective%2520JAK-1%2520inhibitor%252C%2520in%2520a%2520phase%2520IIb%2520study%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520and%2520an%2520inadequate%2520response%2520to%2520methotrexate%26jtitle%3DArthritis%2520Rheumatol.%26date%3D2016%26volume%3D68%26spage%3D2857%26epage%3D2866%26doi%3D10.1002%2Fart.39808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vazquez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaila, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohbach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trzupek, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitton-Fry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">TenBrink, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heasley, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parikh, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duclos, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caspers, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banker, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symanowicz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telliez, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unwalla, R.</span></span> <span> </span><span class="NLM_article-title">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1130</span>– <span class="NLM_lpage">1152</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01598</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01598" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1130-1152&author=M.+L.+Vazquezauthor=N.+Kailaauthor=J.+W.+Strohbachauthor=J.+D.+Trzupekauthor=M.+F.+Brownauthor=M.+E.+Flanaganauthor=M.+J.+Mitton-Fryauthor=T.+A.+Johnsonauthor=R.+E.+TenBrinkauthor=E.+P.+Arnoldauthor=A.+Basakauthor=S.+E.+Heasleyauthor=S.+Kwonauthor=J.+Langilleauthor=M.+D.+Parikhauthor=S.+H.+Griffinauthor=J.+M.+Casavantauthor=B.+A.+Duclosauthor=A.+E.+Fenwickauthor=T.+M.+Harrisauthor=S.+Hanauthor=N.+Caspersauthor=M.+E.+Dowtyauthor=X.+Yangauthor=M.+E.+Bankerauthor=M.+Hegenauthor=P.+T.+Symanowiczauthor=L.+Liauthor=L.+Wangauthor=T.+H.+Linauthor=J.+Jussifauthor=J.+D.+Clarkauthor=J.-B.+Telliezauthor=R.+P.+Robinsonauthor=R.+Unwalla&title=Identification+of+N-%7Bcis-3-%5BMethyl%287H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%29amino%5Dcyclobutyl%7Dpropane-1-sulfonamide+%28PF-04965842%29%3A+a+selective+JAK1+clinical+candidate+for+the+treatment+of+autoimmune+diseases&doi=10.1021%2Facs.jmedchem.7b01598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases</span></div><div class="casAuthors">Vazquez, Michael L.; Kaila, Neelu; Strohbach, Joseph W.; Trzupek, John D.; Brown, Matthew F.; Flanagan, Mark E.; Mitton-Fry, Mark J.; Johnson, Timothy A.; TenBrink, Ruth E.; Arnold, Eric P.; Basak, Arindrajit; Heasley, Steven E.; Kwon, Soojin; Langille, Jonathan; Parikh, Mihir D.; Griffin, Sarah H.; Casavant, Jeffrey M.; Duclos, Brian A.; Fenwick, Ashley E.; Harris, Thomas M.; Han, Seungil; Caspers, Nicole; Dowty, Martin E.; Yang, Xin; Banker, Mary Ellen; Hegen, Martin; Symanowicz, Peter T.; Li, Li; Wang, Lu; Lin, Tsung H.; Jussif, Jason; Clark, James D.; Telliez, Jean-Baptiste; Robinson, Ralph P.; Unwalla, Ray</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1130-1152</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are intracellular tyrosine kinases that mediate the signaling of numerous cytokines and growth factors involved in the regulation of immunity, inflammation, and hematopoiesis.  As JAK1 pairs with JAK2, JAK3, and TYK2, a JAK1-selective inhibitor would be expected to inhibit many cytokines involved in inflammation and immune function while avoiding inhibition of the JAK2 homodimer regulating erythropoietin and thrombopoietin signaling.  The authors' efforts began with tofacitinib, an oral JAK inhibitor approved for the treatment of rheumatoid arthritis.  Through modification of the 3-aminopiperidine linker in tofacitinib, the authors discovered highly selective JAK1 inhibitors with nanomolar potency in a human whole blood assay.  Improvements in JAK1 potency and selectivity were achieved via structural modifications suggested by x-ray crystallog. anal.  After demonstrating efficacy in a rat adjuvant-induced arthritis (rAIA) model, PF-04965842 (25) was nominated as a clin. candidate for the treatment of JAK1-mediated autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNdiJFIHI-YLVg90H21EOLACvtfcHk0liPFxG2Ng0D0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Wnsw%253D%253D&md5=45c6d1b0eee7ab9d5dfc8ea168607a8b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01598%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez%26aufirst%3DM.%2BL.%26aulast%3DKaila%26aufirst%3DN.%26aulast%3DStrohbach%26aufirst%3DJ.%2BW.%26aulast%3DTrzupek%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DMitton-Fry%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DArnold%26aufirst%3DE.%2BP.%26aulast%3DBasak%26aufirst%3DA.%26aulast%3DHeasley%26aufirst%3DS.%2BE.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DLangille%26aufirst%3DJ.%26aulast%3DParikh%26aufirst%3DM.%2BD.%26aulast%3DGriffin%26aufirst%3DS.%2BH.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DDuclos%26aufirst%3DB.%2BA.%26aulast%3DFenwick%26aufirst%3DA.%2BE.%26aulast%3DHarris%26aufirst%3DT.%2BM.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBanker%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DSymanowicz%26aufirst%3DP.%2BT.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DT.%2BH.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DClark%26aufirst%3DJ.%2BD.%26aulast%3DTelliez%26aufirst%3DJ.-B.%26aulast%3DRobinson%26aufirst%3DR.%2BP.%26aulast%3DUnwalla%26aufirst%3DR.%26atitle%3DIdentification%2520of%2520N-%257Bcis-3-%255BMethyl%25287H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%255Dcyclobutyl%257Dpropane-1-sulfonamide%2520%2528PF-04965842%2529%253A%2520a%2520selective%2520JAK1%2520clinical%2520candidate%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1130%26epage%3D1152%26doi%3D10.1021%2Facs.jmedchem.7b01598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Rompaey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galien, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Aar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement-Lacroix, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelles, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smets, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepescheux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christophe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrath, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandeghinste, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vayssiere, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brys, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van ’t Klooster, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyen, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">3568</span>– <span class="NLM_lpage">3577</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1201348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.4049%2Fjimmunol.1201348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=24006460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=3568-3577&author=L.+Van%0ARompaeyauthor=R.+Galienauthor=E.+M.+van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Nellesauthor=B.+Smetsauthor=L.+Lepescheuxauthor=T.+Christopheauthor=K.+Conrathauthor=N.+Vandeghinsteauthor=B.+Vayssiereauthor=S.+De+Vosauthor=S.+Fletcherauthor=R.+Brysauthor=G.+van+%E2%80%99t+Kloosterauthor=J.+H.+M.+Feyenauthor=C.+Menet&title=Preclinical+characterization+of+GLPG0634%2C+a+selective+inhibitor+of+JAK1%2C+for+the+treatment+of+inflammatory+diseases&doi=10.4049%2Fjimmunol.1201348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Van Rompaey, Luc; Galien, Rene; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Nelles, Luc; Smets, Bart; Lepescheux, Lien; Christophe, Thierry; Conrath, Katja; Vandeghinste, Nick; Vayssiere, Beatrice; De Vos, Steve; Fletcher, Stephen; Brys, Reginald; van 't Klooster, Gerben; Feyen, Jean H. M.; Menet, Christel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3568-3577</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">The JAKs receive continued interest as therapeutic targets for autoimmune, inflammatory, and oncol. diseases.  JAKs play crit. roles in the development and biol. of the hematopoietic system, as evidenced by mouse and human genetics.  JAK1 is crit. for the signal transduction of many type I and type II inflammatory cytokine receptors.  In a search for JAK small mol. inhibitors, GLPG0634 was identified as a lead compd. belonging to a novel class of JAK inhibitors.  It displayed a JAK1/JAK2 inhibitor profile in biochem. assays, but subsequent studies in cellular and whole blood assays revealed a selectivity of ∼30-fold for JAK1- over JAK2-dependent signaling.  GLPG0634 dose-dependently inhibited Th1 and Th2 differentiation and to a lesser extent the differentiation of Th17 cells in vitro.  GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repression of Mx2 expression in leukocytes.  Oral dosing of GLPG0634 in a therapeutic set-up in a collagen-induced arthritis model in rodents resulted in a significant dose-dependent redn. of the disease progression.  Paw swelling, bone and cartilage degrdn., and levels of inflammatory cytokines were reduced by GLPG0634 treatment.  Efficacy of GLPG0634 in the collagen-induced arthritis models was comparable to the results obtained with etanercept.  In conclusion, the JAK1 selective inhibitor GLPG0634 is a promising novel therapeutic with potential for oral treatment of rheumatoid arthritis and possibly other immune-inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOIeLPk4kdvbVg90H21EOLACvtfcHk0liPFxG2Ng0D0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsV2nsLzI&md5=01042ebac904fecbcdffe494e456c199</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1201348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1201348%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DSmets%26aufirst%3DB.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DConrath%26aufirst%3DK.%26aulast%3DVandeghinste%26aufirst%3DN.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DDe%2BVos%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DS.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3Dvan%2B%25E2%2580%2599t%2BKlooster%26aufirst%3DG.%26aulast%3DFeyen%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMenet%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520GLPG0634%252C%2520a%2520selective%2520inhibitor%2520of%2520JAK1%252C%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D3568%26epage%3D3577%26doi%3D10.4049%2Fjimmunol.1201348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammoliti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Ramos, M.</span></span> <span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+J.+Menetauthor=O.+Mammolitiauthor=M.+L%C3%B3pez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of γc cytokine (γc = common γ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0lgknRVI87XnjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DL%25C3%25B3pez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Menet, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rompaey, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geney, R.</span></span> <span> </span><span class="NLM_article-title">Advances in the discovery of selective JAK inhibitors</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1016/B978-0-444-62652-3.00004-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2FB978-0-444-62652-3.00004-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=23384668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=153-223&author=C.+J.+Menetauthor=L.+V.+Rompaeyauthor=R.+Geney&title=Advances+in+the+discovery+of+selective+JAK+inhibitors&doi=10.1016%2FB978-0-444-62652-3.00004-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the discovery of selective JAK inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Van Rompaey, Luc; Geney, Raphael</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">153-223</span>CODEN:
                <span class="NLM_cas:coden">PMDCAY</span>;
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  This article discusses the advances in the discovery of selective JAK inhibitors.  JAK inhibitor includes JAK1, JAK2 and JAK3 and tyrosine kinase2.  Medicinal chem. and structural biol. fronts in designing and synthesizing selective or mixed JAK small-mol. inhibitors were discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTg_zxiK5GGLVg90H21EOLACvtfcHk0lgknRVI87XnjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFGrtr8%253D&md5=3d7e6f0481e3a891c84c49ece6421d74</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FB978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DRompaey%26aufirst%3DL.%2BV.%26aulast%3DGeney%26aufirst%3DR.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520of%2520selective%2520JAK%2520inhibitors%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D52%26spage%3D153%26epage%3D223%26doi%3D10.1016%2FB978-0-444-62652-3.00004-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6524</span>– <span class="NLM_lpage">6528</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2009.10.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=19857966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6524-6528&author=S.+Ioannidisauthor=M.+L.+Lambauthor=A.+M.+Daviesauthor=L.+Almeidaauthor=M.+Suauthor=G.+Bebernitzauthor=M.+Yeauthor=K.+Bellauthor=M.+Alimzhanovauthor=M.+Zinda&title=Discovery+of+pyrazol-3-ylamino+pyrazines+as+novel+JAK2+inhibitors&doi=10.1016%2Fj.bmcl.2009.10.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Davies, Audrey M.; Almeida, Lynsie; Su, Mei; Bebernitz, Geraldine; Ye, Minwei; Bell, Kirsten; Alimzhanov, Marat; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6524-6528</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pyridineethyl- and pyrimidineethyl-substituted pyrazoleaminopyrazines such as I (R = Me; X = N) and I (R = H; X = CH) are prepd. as selective JAK2 kinase inhibitors for potential use as anticancer agents; the GI50 values for their JAK2 and JAK3 kinase inhibition are detd.  The activities of selected pyridineethyl- and pyrimidineethyl-substituted pyrazoleaminopyrazines in a functional phosphorylation model in mice and their inhibition of aurora B kinase, cyclin-dependent kinase 2, and TrkA are detd.; the pharmacokinetics and pharmacodynamics of I (R = Me; X = N) and of I (R = H; X = CH) in rats and beagles are also detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY1tQ0K-v7orVg90H21EOLACvtfcHk0lgyRGbUWyqGJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGisLvE&md5=3029e4300eb84ea19f704264c8753df6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.054%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520pyrazol-3-ylamino%2520pyrazines%2520as%2520novel%2520JAK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6524%26epage%3D6528%26doi%3D10.1016%2Fj.bmcl.2009.10.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1669</span>– <span class="NLM_lpage">1673</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2010.01.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=20144546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlehsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1669-1673&author=S.+Ioannidisauthor=M.+L.+Lambauthor=L.+Almeidaauthor=H.+Guanauthor=B.+Pengauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Alimzhanovauthor=M.+Zinda&title=Replacement+of+pyrazol-3-yl+amine+hinge+binder+with+thiazol-2-yl+amine%3A+Discovery+of+potent+and+selective+JAK2+inhibitors&doi=10.1016%2Fj.bmcl.2010.01.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Almeida, Lynsie; Guan, Huiping; Peng, Bo; Bebernitz, Geraldine; Bell, Kirsten; Alimzhanov, Marat; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1669-1673</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Thiazol-2-yl amine was identified as an isosteric replacement for pyrazol-3-yl amine during the efforts to identify potent and selective JAK2 inhibitors.  The rationale, synthesis and biol. evaluation of several analogs I (X = N, CH; R1 = MeO, 4-morpholinyl, 4-methyl-1-piperazinyl; R2 = H, F; R3 = Me, CN) is reported, along with the in vivo evaluation of the lead compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE4-bwWDreyrVg90H21EOLACvtfcHk0lgyRGbUWyqGJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlehsbY%253D&md5=a9b1f0cdc19311aca0a314325a1cbc56</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.091%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DReplacement%2520of%2520pyrazol-3-yl%2520amine%2520hinge%2520binder%2520with%2520thiazol-2-yl%2520amine%253A%2520Discovery%2520of%2520potent%2520and%2520selective%2520JAK2%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1669%26epage%3D1673%26doi%3D10.1016%2Fj.bmcl.2010.01.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2958</span>– <span class="NLM_lpage">2961</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.03.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2011.03.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=21493067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVCmtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2958-2961&author=T.+Wangauthor=S.+Ioannidisauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=M.+L.+Lambauthor=D.+A.+Scottauthor=M.+Suauthor=H.-J.+Zhangauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Zinda&title=In+vitro+and+in+vivo+evaluation+of+6-aminopyrazolyl-pyridine-3-carbonitriles+as+JAK2+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2011.03.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors</span></div><div class="casAuthors">Wang, Tao; Ioannidis, Stephanos; Almeida, Lynsie; Block, Michael H.; Davies, Audrey M.; Lamb, Michelle L.; Scott, David A.; Su, Mei; Zhang, Hai-Jun; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2958-2961</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthesis and biol. evaluation of a series of 6-aminopyrazolylpyridine-3-carbonitriles as JAK2 kinase inhibitors was reported.  Biochem. screening, followed by profile optimization, resulted in JAK2 inhibitors exhibiting good kinase selectivity, pharmacokinetic properties, phys. properties and pharmacodynamic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGzJYyPhqN_bVg90H21EOLACvtfcHk0lgyRGbUWyqGJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVCmtb0%253D&md5=e9b8a9e58e36a6976490bdb84a8043b6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.053%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DScott%26aufirst%3DD.%2BA.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.-J.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%25206-aminopyrazolyl-pyridine-3-carbonitriles%2520as%2520JAK2%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2958%26epage%3D2961%26doi%3D10.1016%2Fj.bmcl.2011.03.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degrace, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3105</span>– <span class="NLM_lpage">3110</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2013.02.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=23562594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltlOhtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3105-3110&author=H.+Guanauthor=M.+L.+Lambauthor=B.+Pengauthor=S.+Huangauthor=N.+Degraceauthor=J.+Readauthor=S.+Hussainauthor=J.+Wuauthor=C.+Rivardauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=M.+Zindaauthor=S.+Ioannidis&title=Discovery+of+novel+Jak2-Stat+pathway+inhibitors+with+extended+residence+time+on+target&doi=10.1016%2Fj.bmcl.2013.02.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target</span></div><div class="casAuthors">Guan, Huiping; Lamb, Michelle L.; Peng, Bo; Huang, Shan; DeGrace, Nancy; Read, Jon; Hussain, Syeed; Wu, Jiaquan; Rivard, Caroline; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Minwei; Zinda, Michael; Ioannidis, Stephanos</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3105-3110</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncol.  In this Letter, the authors communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivs.  The rationale, synthesis and biol. evaluation of these derivs. are reported.  Two lead analogs from this series, (I) and (II), displayed prolonged residence time on Jak2, at enzymic level.  Although (I) and (II) exhibited moderate selectivity in a selected kinase panel, the authors chose to test these inhibitors in vivo as a consequence to their long residence time.  However, extended inhibition of Jak2 due to the long residence time, in the form of inhibiting phosphorylation of downstream Stat5, was not recapitulated in an in vivo setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEqzh5WfofE7Vg90H21EOLACvtfcHk0ljYLHBVxYUh3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltlOhtrk%253D&md5=dee4662399d073c0d1a5f8dddcd9682a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.111%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DH.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DDegrace%26aufirst%3DN.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DHussain%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26aulast%3DIoannidis%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520novel%2520Jak2-Stat%2520pathway%2520inhibitors%2520with%2520extended%2520residence%2520time%2520on%2520target%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3105%26epage%3D3110%26doi%3D10.1016%2Fj.bmcl.2013.02.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioannidis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1021/jm401546n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401546n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=144-158&author=Q.+Suauthor=S.+Ioannidisauthor=C.+Chuaquiauthor=L.+Almeidaauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Blockauthor=T.+Howardauthor=S.+Huangauthor=D.+Huszarauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=J.+Shiauthor=M.+Suauthor=M.+Yeauthor=M.+Zinda&title=Discovery+of+1-methyl-1H-imidazole+derivatives+as+potent+Jak2+inhibitors&doi=10.1021%2Fjm401546n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-Methyl-1H-imidazole Derivatives as Potent Jak2 Inhibitors</span></div><div class="casAuthors">Su, Qibin; Ioannidis, Stephanos; Chuaqui, Claudio; Almeida, Lynsie; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Block, Michael; Howard, Tina; Huang, Shan; Huszar, Dennis; Read, Jon A.; Rivard Costa, Caroline; Shi, Jie; Su, Mei; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure based design, synthesis, and biol. evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described.  Using the C-ring fragment from our first clin. candidate AZD1480 (I), optimization of the series led to the discovery of compd. II, a potent, orally bioavailable Jak2 inhibitor.  Compd. II displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells.  Compd. II demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczgU5RpFv1bVg90H21EOLACvtfcHk0ljYLHBVxYUh3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltLnL&md5=88c57119ec77d084a91a1123fd9dea86</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm401546n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401546n%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DBlock%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25201-methyl-1H-imidazole%2520derivatives%2520as%2520potent%2520Jak2%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D144%26epage%3D158%26doi%3D10.1021%2Fjm401546n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deegan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steuber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toader, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Identification of azabenzimidazoles as potent JAK1 selective inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.bmcl.2015.11.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=26614408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFagsLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=60-67&author=M.+M.+Vasbinderauthor=M.+Alimzhanovauthor=M.+Augustinauthor=G.+Bebernitzauthor=K.+Bellauthor=C.+Chuaquiauthor=T.+Deeganauthor=A.+D.+Fergusonauthor=K.+Goodwinauthor=D.+Huszarauthor=A.+Kawatkarauthor=S.+Kawatkarauthor=J.+Readauthor=J.+Shiauthor=S.+Steinbacherauthor=H.+Steuberauthor=Q.+Suauthor=D.+Toaderauthor=H.+Wangauthor=R.+Woessnerauthor=A.+Wuauthor=M.+Yeauthor=M.+Zinda&title=Identification+of+azabenzimidazoles+as+potent+JAK1+selective+inhibitors&doi=10.1016%2Fj.bmcl.2015.11.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of azabenzimidazoles as potent JAK1 selective inhibitors</span></div><div class="casAuthors">Vasbinder, Melissa M.; Alimzhanov, Marat; Augustin, Martin; Bebernitz, Geraldine; Bell, Kirsten; Chuaqui, Claudio; Deegan, Tracy; Ferguson, Andrew D.; Goodwin, Kelly; Huszar, Dennis; Kawatkar, Aarti; Kawatkar, Sameer; Read, Jon; Shi, Jie; Steinbacher, Stefan; Steuber, Holger; Su, Qibin; Toader, Dorin; Wang, Haixia; Woessner, Richard; Wu, Allan; Ye, Minwei; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-67</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have identified a class of azabenzimidazoles as potent and selective JAK1 inhibitors.  Investigations into the SAR are presented along with the structural features required to achieve selectivity for JAK1 vs. other JAK family members.  An example from the series demonstrated highly selective inhibition of JAK1 vs. JAK2 and JAK3, along with inhibition of pSTAT3 in vivo, enabling it to serve as a JAK1 selective tool compd. to further probe the biol. of JAK1 selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQjKE058gZrVg90H21EOLACvtfcHk0liLmmDtaR1d5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFagsLrL&md5=49f2cc63e15dcdf539fb7195a9c6224a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.031%26sid%3Dliteratum%253Aachs%26aulast%3DVasbinder%26aufirst%3DM.%2BM.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DDeegan%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGoodwin%26aufirst%3DK.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DKawatkar%26aufirst%3DA.%26aulast%3DKawatkar%26aufirst%3DS.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSteuber%26aufirst%3DH.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520azabenzimidazoles%2520as%2520potent%2520JAK1%2520selective%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D60%26epage%3D67%26doi%3D10.1016%2Fj.bmcl.2015.11.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alimzhanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bebernitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deegan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gero, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huszar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawatkar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivard
Costa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Throner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toader, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasbinder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinda, M.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of a novel series of highly selective JAK1 kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5235</span>– <span class="NLM_lpage">5244</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00076</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00076" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKktbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5235-5244&author=N.+P.+Grimsterauthor=E.+Andersonauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=C.+Chuaquiauthor=T.+Deeganauthor=A.+D.+Fergusonauthor=T.+Geroauthor=A.+Harschauthor=D.+Huszarauthor=A.+Kawatkarauthor=J.+G.+Kettleauthor=P.+Lyneauthor=J.+A.+Readauthor=C.+Rivard%0ACostaauthor=L.+Rustonauthor=P.+Schroederauthor=J.+Shiauthor=Q.+Suauthor=S.+Thronerauthor=D.+Toaderauthor=M.+Vasbinderauthor=R.+Woessnerauthor=H.+Wangauthor=A.+Wuauthor=M.+Yeauthor=W.+Zhengauthor=M.+Zinda&title=Discovery+and+optimization+of+a+novel+series+of+highly+selective+JAK1+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.8b00076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors</span></div><div class="casAuthors">Grimster, Neil P.; Anderson, Erica; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Chuaqui, Claudio; Deegan, Tracy; Ferguson, Andrew D.; Gero, Thomas; Harsch, Andreas; Huszar, Dennis; Kawatkar, Aarti; Kettle, Jason G.; Lyne, Paul; Read, Jon A.; Rivard Costa, Caroline; Ruston, Linette; Schroeder, Patricia; Shi, Jie; Su, Qibin; Throner, Scott; Toader, Dorin; Vasbinder, Melissa; Woessner, Richard; Wang, Haixia; Wu, Allan; Ye, Minwei; Zheng, Weijia; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5235-5244</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) have been demonstrated to be crit. in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases.  The JAK family consists of four highly homologous members: JAK1-3 and TYK2.  The development of small-mol. inhibitors that are selective for a specific family member would represent highly desirable tools for deconvoluting the intricacies of JAK family biol.  Herein, we report the discovery of a potent JAK1 inhibitor, I, which displays ∼1000-fold selectivity over the other highly homologous JAK family members (detd. by biochem. assays), while also possessing good selectivity over other kinases (detd. by panel screening).  Moreover, this compd. was demonstrated to be orally bioavailable and possesses acceptable pharmacokinetic parameters.  In an in vivo study, the compd. was obsd. to dose dependently modulate the phosphorylation of STAT3 (a downstream marker of JAK1 inhibition).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5EjmOMjz01LVg90H21EOLACvtfcHk0liLmmDtaR1d5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKktbbP&md5=d595d4b2b993f5701cdffece39688556</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00076%26sid%3Dliteratum%253Aachs%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DAnderson%26aufirst%3DE.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DDeegan%26aufirst%3DT.%26aulast%3DFerguson%26aufirst%3DA.%2BD.%26aulast%3DGero%26aufirst%3DT.%26aulast%3DHarsch%26aufirst%3DA.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DKawatkar%26aufirst%3DA.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DLyne%26aufirst%3DP.%26aulast%3DRead%26aufirst%3DJ.%2BA.%26aulast%3DRivard%2BCosta%26aufirst%3DC.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DThroner%26aufirst%3DS.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DVasbinder%26aufirst%3DM.%26aulast%3DWoessner%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520novel%2520series%2520of%2520highly%2520selective%2520JAK1%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5235%26epage%3D5244%26doi%3D10.1021%2Facs.jmedchem.8b00076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turkson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span> <span> </span><span class="NLM_article-title">STAT proteins: novel molecular targets for cancer drug discovery</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6613</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1038%2Fsj.onc.1204086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=11426647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsF2rsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6613-6626&author=J.+Turksonauthor=R.+Jove&title=STAT+proteins%3A+novel+molecular+targets+for+cancer+drug+discovery&doi=10.1038%2Fsj.onc.1204086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">STAT proteins: novel molecular targets for cancer drug discovery</span></div><div class="casAuthors">Turkson, James; Jove, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">6613-6626</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with 101 refs.  Signal Transducers and Activators of Transcription (STATs) are a family of cytoplasmic proteins with roles as signal messengers and transcription factors that participate in normal cellular responses to cytokines and growth factors.  Frequently, however, abnormal activity of certain STAT family members, particularly Stat3 and Stat5, is assocd. with a wide variety of human malignancies, including hematol., breast, head and neck, and prostate cancers.  Application of mol. biol. and pharmacol. tools in disease-relevant models has confirmed Stat3 as having a causal role in oncogenesis, and provided validation of Stat3 as a target for cancer drug discovery and therapeutic intervention.  Furthermore, a constitutively-active mutant form of Stat3 is sufficient to induce oncogenic transformation of cells, which form tumors in vivo.  Constitutive activation of Stat3 signaling is accompanied by upregulation of cyclin D1, c-Myc, and Bcl-x, changes consistent with subversion of normal cellular growth and survival control mechanisms.  Block of constitutive Stat3 signaling results in growth inhibition and apoptosis of Stat3-pos. tumor cells in vitro and in vivo.  The obsd. dependence of certain tumors on constitutive Stat3 signaling for growth and survival has wide implications for cancer therapy, offering the potential for preferential tumor cell killing.  This review evaluates constitutive Stat3 activation as a "cancer-causing" factor, and proposes a no. of mol. strategies for targeting Stat3 signaling for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoffTICt_aLhLVg90H21EOLACvtfcHk0li4Tat4SBvNqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsF2rsro%253D&md5=2011fb621ef70547ddbbef2ed253df98</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204086%26sid%3Dliteratum%253Aachs%26aulast%3DTurkson%26aufirst%3DJ.%26aulast%3DJove%26aufirst%3DR.%26atitle%3DSTAT%2520proteins%253A%2520novel%2520molecular%2520targets%2520for%2520cancer%2520drug%2520discovery%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6613%26epage%3D6626%26doi%3D10.1038%2Fsj.onc.1204086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarle, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chilosi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span> <span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1038</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1038%2Fsj.onc.1205152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=11850821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvFGqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=1038-1047&author=A.+Zamoauthor=R.+Chiarleauthor=R.+Pivaauthor=J.+Howesauthor=Y.+Fanauthor=M.+Chilosiauthor=D.+E.+Levyauthor=G.+Inghirami&title=Anaplastic+lymphoma+kinase+%28ALK%29+activates+Stat3+and+protects+hematopoietic+cells+from+cell+death&doi=10.1038%2Fsj.onc.1205152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death</span></div><div class="casAuthors">Zamo, Alberto; Chiarle, Roberto; Piva, Roberto; Howes, Jennifer; Fan, Yan; Chilosi, Marco; Levy, David E.; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1038-1047</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The anaplastic lymphoma kinase (ALK) gene is characteristically translocated in anaplastic large cell lymphomas (ALCL) and the juxtaposion of the ALK gene to multiple partners results in its constitutive protein tyrosine kinase activity.  We show here that expression of activated ALK induces the constitutive phosphorylation of Stat3 in transfected cells as well as in primary human ALCLs.  Furthermore, immunohistochem. studies demonstrate that among distinct human B and T cell lymphomas, activation of Stat3 nuclear translocation is uniquely assocd. with ALK expression.  NPM-ALK also binds and activates Jak3; however, Jak3 is not required for Stat3 activation or for cell transformation in vitro.  Moreover, src family kinases are not necessary for NPM-ALK-mediated Stat3 activation or transformation, suggesting that Stat3 may be phosphorylated directly by ALK.  To evaluate relevant targets of ALK-activated Stat3, we investigated the regulation of the anti-apoptotic protein Bcl-xL and its role in cell survival in NPM-ALK pos. cells.  NPM-ALK expression caused enhanced Bcl-xL transcription, largely mediated by Stat3.  Increased expression of Bcl-xL provided sufficient anti-apoptotic signals to protect cells from treatment with specific inhibitors of the Jaks/Stat pathway or the Brc-Abl kinase.  These studies support a pathogenic mechanism whereby stimulation of anti-apoptotic signals through activation of Stat3 contributes to the successful outgrowth of ALK pos. tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogI4o98Agys7Vg90H21EOLACvtfcHk0lha7WvaW9MXOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvFGqs7g%253D&md5=c7b2e63cc7765563b6d30aa4bda2569f</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205152%26sid%3Dliteratum%253Aachs%26aulast%3DZamo%26aufirst%3DA.%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DHowes%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DChilosi%26aufirst%3DM.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520activates%2520Stat3%2520and%2520protects%2520hematopoietic%2520cells%2520from%2520cell%2520death%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D1038%26epage%3D1047%26doi%3D10.1038%2Fsj.onc.1205152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sansone, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, J.</span></span> <span> </span><span class="NLM_article-title">Targeting the interleukin-6/Jak/stat pathway in human malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1014</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.31.8907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1200%2FJCO.2010.31.8907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=22355058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmt1SgsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=1005-1014&author=P.+Sansoneauthor=J.+Bromberg&title=Targeting+the+interleukin-6%2FJak%2Fstat+pathway+in+human+malignancies&doi=10.1200%2FJCO.2010.31.8907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the interleukin-6/Jak/Stat pathway in human malignancies</span></div><div class="casAuthors">Sansone, Pasquale; Bromberg, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1005-1014</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling.  Since this time, more than 2,500 articles have been published demonstrating the importance of this pathway in virtually all malignancies.  Although there are dozens of cytokines and cytokine receptors, four Jaks, and seven Stats, it seems that interleukin-6-mediated activation of Stat3 is a principal pathway implicated in promoting tumorigenesis.  This transcription factor regulates the expression of numerous crit. mediators of tumor formation and metastatic progression.  This review will examine the relative importance and function of this pathway in nonmalignant conditions as well as malignancies (including tumor intrinsic and extrinsic), the influence of other Stats, the development of inhibitors to this pathway, and the potential role of inhibitors in controlling or eradicating cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfUoiaYph-K7Vg90H21EOLACvtfcHk0lg1LaxKwbEmKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmt1SgsLo%253D&md5=38fca14c5a694cce722155b32f14c0ae</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.31.8907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.31.8907%26sid%3Dliteratum%253Aachs%26aulast%3DSansone%26aufirst%3DP.%26aulast%3DBromberg%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520interleukin-6%252FJak%252Fstat%2520pathway%2520in%2520human%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D1005%26epage%3D1014%26doi%3D10.1200%2FJCO.2010.31.8907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reintgen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7001</span>– <span class="NLM_lpage">7010</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205859</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1038%2Fsj.onc.1205859" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=12370822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFylur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=7001-7010&author=G.+Niuauthor=T.+Bowmanauthor=M.+Huangauthor=S.+Shiversauthor=D.+Reintgenauthor=A.+Daudauthor=A.+Changauthor=A.+Krakerauthor=R.+Joveauthor=H.+Yu&title=Roles+of+activated+Src+and+Stat3+signaling+in+melanoma+tumor+cell+growth&doi=10.1038%2Fsj.onc.1205859"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of activated Src and Stat3 signaling in melanoma tumor cell growth</span></div><div class="casAuthors">Niu, Guilian; Bowman, Tammy; Huang, Mei; Shivers, Steve; Reintgen, Douglas; Daud, Adil; Chang, Alfred; Kraker, Alan; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">7001-7010</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activation of protein tyrosine kinases is prevalent in human cancers and previous studies have demonstrated that Stat3 signaling is a point of convergence for many of these tyrosine kinases.  Moreover, a crit. role for constitutive activation of Stat3 in tumor cell proliferation and survival has been established in diverse cancers.  However, the oncogenic signaling pathways in melanoma cells remain to be fully defined.  In this study, the authors demonstrate that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens examd.  Blocking Src tyrosine kinase activity, but not EGF receptor or JAK family kinases, leads to inhibition of Stat3 signaling in melanoma cell lines.  Consistent with a role of Src in the pathogenesis of melanoma, the authors show that c-Src tyrosine kinase is activated in melanoma cell lines.  Significantly, melanoma cells undergo apoptosis when either Src kinase activity or Stat3 signaling is inhibited.  Blockade of Src or Stat3 is also accompanied by down-regulation of expression of the anti-apoptotic genes, Bcl-xL and Mcl-1.  These findings demonstrate that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO46ilXC4-MLVg90H21EOLACvtfcHk0lg1LaxKwbEmKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFylur0%253D&md5=6d5f9f43c4ee07a1c2534165dd28fede</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205859&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205859%26sid%3Dliteratum%253Aachs%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DBowman%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DShivers%26aufirst%3DS.%26aulast%3DReintgen%26aufirst%3DD.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DChang%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DRoles%2520of%2520activated%2520Src%2520and%2520Stat3%2520signaling%2520in%2520melanoma%2520tumor%2520cell%2520growth%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D7001%26epage%3D7010%26doi%3D10.1038%2Fsj.onc.1205859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kortylewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jove, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span> <span> </span><span class="NLM_article-title">Targeting STAT3 affects melanoma on multiple fronts</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1007/s10555-005-1580-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1007%2Fs10555-005-1580-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=15986140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2MXls1agsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=315-327&author=M.+Kortylewskiauthor=R.+Joveauthor=H.+Yu&title=Targeting+STAT3+affects+melanoma+on+multiple+fronts&doi=10.1007%2Fs10555-005-1580-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting STAT3 affects melanoma on multiple fronts</span></div><div class="casAuthors">Kortylewski, Marcin; Jove, Richard; Yu, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">315-327</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  As a point of convergence for numerous oncogenic signaling pathways, STAT3 is constitutively-activated at 50 to 90% frequency in diverse human cancers, including melanoma.  A crit. role of STAT3 in tumor cell survival, proliferation, angiogenesis, metastasis and immune evasion has been recently demonstrated.  STAT3 contributes to tumor cell growth by regulating the expression of genes that are involved in cell survival and proliferation.  STAT3 promotes metastasis and angiogenesis by inducing expression of the metastatic gene, MMP-2, and the potent angiogenic gene, VEGF.  STAT3 participates in the regulation of tumor immune evasion by inhibiting expression of proinflammatory mediators while promoting expression of immune-suppressing factors, which in turn activates STAT3 signaling in dendritic cells leading to immune tolerance.  Thus, targeting STAT3 for therapy assaults cancer on multiple fronts.  Many of the studies that defined STAT3's role in oncogenesis were carried out in melanoma cells and tumor models.  In this review, we summarize the key role of STAT3 in cancer in general and melanoma in particular.  With the emergence of small-mol. drugs that directly inhibit STAT3 or the oncogenic signaling pathways upstream of STAT3 in melanoma, a promising novel approach for melanoma therapy is emerging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVSFnD9ExaqLVg90H21EOLACvtfcHk0lg1LaxKwbEmKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXls1agsbg%253D&md5=9c3739bf82951bb2f9da6a08ed08e15a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs10555-005-1580-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-005-1580-1%26sid%3Dliteratum%253Aachs%26aulast%3DKortylewski%26aufirst%3DM.%26aulast%3DJove%26aufirst%3DR.%26aulast%3DYu%26aufirst%3DH.%26atitle%3DTargeting%2520STAT3%2520affects%2520melanoma%2520on%2520multiple%2520fronts%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2005%26volume%3D24%26spage%3D315%26epage%3D327%26doi%3D10.1007%2Fs10555-005-1580-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span> <span> </span><span class="NLM_article-title">Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1006/gyno.2000.5931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1006%2Fgyno.2000.5931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=11006034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslKns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2000&pages=67-73&author=M.+Huangauthor=C.+Pageauthor=R.+K.+Reynoldsauthor=J.+Lin&title=Constitutive+activation+of+stat+3+oncogene+product+in+human+ovarian+carcinoma+cells&doi=10.1006%2Fgyno.2000.5931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Constitutive Activation of Stat 3 Oncogene Product in Human Ovarian Carcinoma Cells</span></div><div class="casAuthors">Huang, Melinda; Page, Carmen; Reynolds, R. Kevin; Lin, Jiayuh</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-73</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Stat 3 functions in transducing signals from the cell's surface to its nucleus and activation of gene transcription.  Aberrations of Stat 3 in breast cancer have raised the possibility of its contribution to oncogenesis.  The goal was to examine ovarian cancer cell lines to det. whether Stat 3 plays a relevant role in ovarian carcinogenesis.  Protein lysates were extd. from normal ovarian surface epithelial cells and malignant cells.  Western blotting techniques were performed with phosphorylation-independent or phosphorylation-specific Stat 3 (Tyr 705) antibody.  Confirmation of Stat 3 activation was detd. by a luciferase reporter driven by a promoter contg. Stat 3-specific binding sites.  Bcl-xL and cyclin D1 were also analyzed by Western blotting.  MDAH 2774, OV-1063, Caov-3, and O.C. 22819 expressed high levels of phosphorylated Stat 3.  In contrast, A2780 and normal ovarian surface epithelial cells had little Stat 3 phosphorylation recognized.  Confirmation of persistent activation of Stat 3 activity was shown by transfection of cells with a Stat 3 luciferase reporter.  Potential downstream mediators of Stat 3 including Bcl-xL and cyclin D1 were also evaluated.  In cells expressing activated Stat 3, high levels of both Bcl-xL and cyclin D1 were detected, whereas in A2780 cells, which did not express activated Stat 3, only low levels of Bcl-xL and cyclin D1 were expressed.Conclusions.  Constitutive activation of Stat 3 is present in ovarian cancer lines but not in normal ovarian surface epithelial cells.  Activation of Stat 3 is a common event during oncogenic transformation upstream to both Bcl-xL and cyclin D1.  The relationship of this aberrancy of ovarian carcinoma harboring activated Stat 3 deserves further investigation.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3pODKA-r__7Vg90H21EOLACvtfcHk0lhEhGC8Y103RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslKns7c%253D&md5=d992c9943608157e112466e3edebfd13</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1006%2Fgyno.2000.5931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgyno.2000.5931%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DR.%2BK.%26aulast%3DLin%26aufirst%3DJ.%26atitle%3DConstitutive%2520activation%2520of%2520stat%25203%2520oncogene%2520product%2520in%2520human%2520ovarian%2520carcinoma%2520cells%26jtitle%3DGynecol.%2520Oncol.%26date%3D2000%26volume%3D79%26spage%3D67%26epage%3D73%26doi%3D10.1006%2Fgyno.2000.5931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horiguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oya, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marumo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murai, M.</span></span> <span> </span><span class="NLM_article-title">Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</span>. <i>J. Urol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">762</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1016/S0022-5347(05)64741-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2FS0022-5347%2805%2964741-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=12131365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtFWhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2002&pages=762-765&author=A.+Horiguchiauthor=M.+Oyaauthor=T.+Shimadaauthor=A.+Uchidaauthor=K.+Marumoauthor=M.+Murai&title=Activation+of+signal+transducer+and+activator+of+transcription+3+in+renal+cell+carcinoma%3A+a+study+of+incidence+and+its+association+with+pathological+features+and+clinical+outcome&doi=10.1016%2FS0022-5347%2805%2964741-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome</span></div><div class="casAuthors">Horiguchi, Akio; Oya, Mototsugu; Shimada, Tetsuya; Uchida, Atsushi; Marumo, Ken; Murai, Masaru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">762-765</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose: Signal transducer and activator of transcription 3 (STAT3) is known to have an important role in cytokine and growth factor signaling pathways.  In various types of human malignant tumors STAT3 has been shown to be constitutively activated due to aberrant prodn. of cytokines and growth factors.  The authors examd. the presence of STAT3 activation and its assocn. with pathol. features and clin. outcome in renal cell carcinoma cases.  Materials and Methods: the authors examd. 48 paraffin embedded renal cell carcinoma specimens and corresponding nonneoplastic kidney tissues for the activation status of STAT3 on immunohistochem. using anti-phospho-specific (p)-STAT3 antibody, which recognizes only activated STAT3.  Based on the percent of cells with pos. nuclear staining the activation status of STAT3 was detd. and categorized into 2 groups, including low - less than 10% and high - 90% or more tumor cells pos.  The assocns. of the activation status of STAT3 with pathol. features and clin. outcome were analyzed.  Results: Of 48 tumors 24 (50%) demonstrated high levels of nuclear immunostaining for p-STAT3, while the other 24 (50%) showed low levels.  Adjacent nonneoplastic kidney tissues showed only little immunostaining for p-STAT3.  A significant assocn. of high levels of p-STAT3 with metastasis was obsd.  No significant assocns. of p-STAT3 immunostaining with pathol. stage or grade were obsd.  A high level of p-STAT3 was a significant indicator of a poor prognosis on univariate and multivariate anal.  Conclusions: the authors' results indicate a high frequency of STAT3 activation in renal cell carcinoma, esp. in metastatic disease.  STAT3 activation was an independent prognostic variable in renal cell carcinoma cases.  The authors' results strongly suggest that the activation of STAT3 contributes to the development and progression of renal cell carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBk-RaURU1VLVg90H21EOLACvtfcHk0lhEhGC8Y103RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtFWhurw%253D&md5=a8e5fe3f02f14b11202b78d40a42945b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2FS0022-5347%2805%2964741-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-5347%252805%252964741-6%26sid%3Dliteratum%253Aachs%26aulast%3DHoriguchi%26aufirst%3DA.%26aulast%3DOya%26aufirst%3DM.%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DUchida%26aufirst%3DA.%26aulast%3DMarumo%26aufirst%3DK.%26aulast%3DMurai%26aufirst%3DM.%26atitle%3DActivation%2520of%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520in%2520renal%2520cell%2520carcinoma%253A%2520a%2520study%2520of%2520incidence%2520and%2520its%2520association%2520with%2520pathological%2520features%2520and%2520clinical%2520outcome%26jtitle%3DJ.%2520Urol.%26date%3D2002%26volume%3D168%26spage%3D762%26epage%3D765%26doi%3D10.1016%2FS0022-5347%2805%2964741-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corvinus, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriggl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsareva, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfitzner, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberb, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zatloukal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beug, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhlschläger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halbhuber, K.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedrich, K.</span></span> <span> </span><span class="NLM_article-title">Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth</span>. <i>Neoplasia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">545</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1593/neo.04571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1593%2Fneo.04571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=16036105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvF2qu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=545-555&author=F.+M.+Corvinusauthor=C.+Orthauthor=R.+Morigglauthor=S.+A.+Tsarevaauthor=S.+Wagnerauthor=E.+B.+Pfitznerauthor=D.+Bausauthor=R.+Kaufmannauthor=L.+A.+Huberbauthor=K.+Zatloukalauthor=H.+Beugauthor=P.+%C3%96hlschl%C3%A4gerauthor=A.+Sch%C3%BCtzauthor=K.-J.+Halbhuberauthor=K.+Friedrich&title=Persistent+STAT3+activation+in+colon+cancer+is+associated+with+enhanced+cell+proliferation+and+tumor+growth&doi=10.1593%2Fneo.04571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth</span></div><div class="casAuthors">Corvinus, Florian M.; Orth, Carina; Moriggl, Richard; Tsareva, Svetlana A.; Wagner, Stefan; Pfitzner, Edith B.; Baus, Daniela; Kaufmann, Roland; Huber, Lukas A.; Zatloukal, Kurt; Beug, Hartmut; Oehlschlaeger, Peter; Schuetz, Alexander; Halbhuber, Karl-Juergen; Friedrich, Karlheinz</div><div class="citationInfo"><span class="NLM_cas:title">Neoplasia (Ann Arbor, MI, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-555</span>CODEN:
                <span class="NLM_cas:coden">NEOPFL</span>;
        ISSN:<span class="NLM_cas:issn">1522-8002</span>.
    
            (<span class="NLM_cas:orgname">Neoplasia Press Inc.</span>)
        </div><div class="casAbstract">Colorectal carcinoma (CRC) is a major cause of morbidity and mortality in Western countries.  It has so far been molecularly defined mainly by alterations of the Wnt pathway.  We show here for the first time that aberrant activities of the signal transducer and activator of transcription STAT3 actively contribute to this malignancy and, thus, are a potential therapeutic target for CRC.  Constitutive STAT3 activity was found to be abundant in dedifferentiated cancer cells and infiltrating lymphocytes of CRC samples, but not in non-neoplastic colon epithelium.  Cell lines derived from malignant colorectal tumors lost persistent STAT3 activity in culture.  However, implantation of colon carcinoma cells into nude mice resulted in restoration of STAT3 activity, suggesting a role of an extracellular stimulus within the tumor microenvironment as a trigger for STAT activation.  STAT3 activity in CRC cells triggered through interleukin-6 or through a constitutively active STAT3 mutant promoted cancer cell multiplication, whereas STAT3 inhibition through a dominant-neg. variant impaired IL-6-driven proliferation.  Blockade of STAT3 activation in CRC-derived xenograft tumors slowed down their development, arguing for a contribution of STAT3 to colorectal tumor growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplNySx1-IGqLVg90H21EOLACvtfcHk0lhEhGC8Y103RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvF2qu7k%253D&md5=6d74cb8a99173e589ceee0b54c7bd487</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1593%2Fneo.04571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.04571%26sid%3Dliteratum%253Aachs%26aulast%3DCorvinus%26aufirst%3DF.%2BM.%26aulast%3DOrth%26aufirst%3DC.%26aulast%3DMoriggl%26aufirst%3DR.%26aulast%3DTsareva%26aufirst%3DS.%2BA.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DPfitzner%26aufirst%3DE.%2BB.%26aulast%3DBaus%26aufirst%3DD.%26aulast%3DKaufmann%26aufirst%3DR.%26aulast%3DHuberb%26aufirst%3DL.%2BA.%26aulast%3DZatloukal%26aufirst%3DK.%26aulast%3DBeug%26aufirst%3DH.%26aulast%3D%25C3%2596hlschl%25C3%25A4ger%26aufirst%3DP.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DA.%26aulast%3DHalbhuber%26aufirst%3DK.-J.%26aulast%3DFriedrich%26aufirst%3DK.%26atitle%3DPersistent%2520STAT3%2520activation%2520in%2520colon%2520cancer%2520is%2520associated%2520with%2520enhanced%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D545%26epage%3D555%26doi%3D10.1593%2Fneo.04571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, Y.-L.</span></span> <span> </span><span class="NLM_article-title">Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour</span>. <i>J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1002/path.2041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1002%2Fpath.2041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=16917804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2006&pages=224-233&author=K.-C.+Changauthor=M.-H.+Wuauthor=D.+Jonesauthor=F.-F.+Chenauthor=Y.-L.+Tseng&title=Activation+of+STAT3+in+thymic+epithelial+tumours+correlates+with+tumour+type+and+clinical+behaviour&doi=10.1002%2Fpath.2041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour</span></div><div class="casAuthors">Chang, K.-C.; Wu, M.-H.; Jones, D.; Chen, F.-F.; Tseng, Y.-L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-233</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-3417</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The STAT3 (signal transducers and activators of transcription 3) signalling pathway plays a pivotal role in oncogenesis and appears essential for postnatal maintenance of thymic architecture and thymocyte survival.  The assocn. of STAT3 activation with thymic epithelial tumors (TETs) and myasthenia gravis (MG) has not been elucidated.  In this study, 118 cases of TET and 25 non-neoplastic thymic tissue samples were evaluated for STAT3 and phospho-STAT3 (pSTAT3) expression immunohistochem.  In addn., 44 normal thymuses of different ages were included for comparison.  It was found that STAT3 activation in thymic epithelial cells (TECs), as evidenced by pSTAT3 expression and/or nuclear STAT3, was present in the majority of non-neoplastic thymuses (88%, 22/25), including those from young children, but not in fetal thymus.  In thymoma (n = 73), activated STAT3 was noted at a significantly higher frequency in the cases of lymphocyte-rich thymoma (ie types AB, B1, and B2, 46%, 23/50) in comparison with lymphocyte-depleted thymoma (types A and B3, 1/23) (p = 0.009).  Thymoma with activated STAT3 tended to present at an earlier stage, show complete resectability and less aggressive behavior, and have a higher correlation with MG than the STAT3-neg./inactive group (p < 0.05).  In contrast, thymic carcinoma with activated STAT3 (14/45, 31%) had significantly higher rates of unresectability, vascular invasion, and regional lymph node metastasis (p < 0.05).  These data provide the first evidence that constitutive STAT3 activation is seen in both benign and neoplastic thymic tissue and is assocd. with the persistence of thymic tissue and the presence of MG.  It is likely to be induced by different factors in thymoma and thymic carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhGt8X77mhe7Vg90H21EOLACvtfcHk0lj188FsY0bS6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgur%252FI&md5=e3966221dfbda9697a2913b34fa8d1cb</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fpath.2041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2041%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DK.-C.%26aulast%3DWu%26aufirst%3DM.-H.%26aulast%3DJones%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DF.-F.%26aulast%3DTseng%26aufirst%3DY.-L.%26atitle%3DActivation%2520of%2520STAT3%2520in%2520thymic%2520epithelial%2520tumours%2520correlates%2520with%2520tumour%2520type%2520and%2520clinical%2520behaviour%26jtitle%3DJ.%2520Pathol.%26date%3D2006%26volume%3D210%26spage%3D224%26epage%3D233%26doi%3D10.1002%2Fpath.2041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells</span>. <i>Acta Histochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">158</span>, <span class="refDoi"> DOI: 10.1016/j.acthis.2011.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.acthis.2011.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=21549414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKjs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2012&pages=151-158&author=Z.+Yinauthor=Y.+Zhangauthor=Y.+Liauthor=T.+Lvauthor=J.+Liuauthor=X.+Wang&title=Prognostic+significance+of+STAT3+expression+and+its+correlation+with+chemoresistance+of+non-small+cell+lung+cancer+cells&doi=10.1016%2Fj.acthis.2011.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells</span></div><div class="casAuthors">Yin, Zhenjie; Zhang, Yan; Li, Yu; Lv, Tingting; Liu, Jie; Wang, Xinbo</div><div class="citationInfo"><span class="NLM_cas:title">Acta Histochemica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-158</span>CODEN:
                <span class="NLM_cas:coden">AHISA9</span>;
        ISSN:<span class="NLM_cas:issn">0065-1281</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">Activation of signal transducer and activator of transcription 3 (STAT3) plays important roles in tumorigenesis and tumor development.  Previously, we have reported that overexpression of STAT3 potentiates growth, survival and radioresistance of non-small cell lung cancer (NSCLC) cells.  The aim of this study was to investigate the prognostic significance of STAT3 expression and its correlation with chemoresistance of NSCLC cells.  Semi-quant. RT-PCR was performed to detect the expression of STAT3 mRNA in 12 NSCLC and corresponding adjacent lung tissues.  Immunohistochem. was performed to detect the expression of STAT3 protein in 76 NSCLC tissue samples.  Addnl., the correlation between STAT3 expression and prognosis of NSCLC patients was statistically analyzed.  The role of STAT3 in chemoresistance of NSCLC cells was also assessed by the vector-based small interfering RNA.  The expression level of STAT3 mRNA in NSCLC tissues was significantly higher than that in corresponding adjacent lung tissues (P < 0.05).  Pos. immunostaining of STAT3 protein was mainly located in the cytoplasm of tumor cells.  The expression of STAT3 protein was significantly correlated with tumor differentiation, clin. stage and lymph node metastasis of NSCLC patients.  Moreover, the 5-yr overall survival rate of patients with high STAT3 expression (42.3%) was significantly lower than that of patients with low STAT3 expression (58.8%; P < 0.001).  Multivariate anal. using the Cox proportional hazard model showed that high STAT3 protein expression was an independent prognostic factor for NSCLC patients (P = 0.021).  Furthermore, two stably transfected cell lines (A549/shSTAT3 and SPC-A1/shSTAT3) were successfully established, and RNAi-mediated STAT3 inhibition could significantly increase the sensitivity of NSCLC cells to cisplatin by enhancing caspase-3-dependent apoptosis.  Together, the expression of STAT3 might be an independent prognostic marker for NSCLC patients and RNAi-mediated STAT3 inhibition would be a potential strategy for chemosensitization of NSCLC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjj5R2_p17K7Vg90H21EOLACvtfcHk0lj188FsY0bS6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKjs7w%253D&md5=232111e34d1e8297cd50235e791d601c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.acthis.2011.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.acthis.2011.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLv%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DPrognostic%2520significance%2520of%2520STAT3%2520expression%2520and%2520its%2520correlation%2520with%2520chemoresistance%2520of%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DActa%2520Histochem.%26date%3D2012%26volume%3D114%26spage%3D151%26epage%3D158%26doi%3D10.1016%2Fj.acthis.2011.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeidler, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danson, S. J.</span></span> <span> </span><span class="NLM_article-title">The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1038/bjc.2015.233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1038%2Fbjc.2015.233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=26151455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2015&pages=365-371&author=S.+J.+Thomasauthor=J.+A.+Snowdenauthor=M.+P.+Zeidlerauthor=S.+J.+Danson&title=The+role+of+JAK%2FSTAT+signalling+in+the+pathogenesis%2C+prognosis+and+treatment+of+solid+tumours&doi=10.1038%2Fbjc.2015.233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumors</span></div><div class="casAuthors">Thomas, S. J.; Snowden, J. A.; Zeidler, M. P.; Danson, S. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-371</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aberrant activation of intracellular signalling pathways confers malignant properties on cancer cells.  Targeting intracellular signalling pathways has been a productive strategy for drug development, with several drugs acting on signalling pathways already in use and more continually being developed.  The JAK/STAT signalling pathway provides an example of this paradigm in haematol. malignancies, with the identification of JAK2 mutations in myeloproliferative neoplasms leading to the development of specific clin. effective JAK2 inhibitors, such as ruxolitinib.  It is now clear that many solid tumors also show activation of JAK/STAT signalling.  In this review, we focus on the role of JAK/STAT signalling in solid tumors, examg. the mol. mechanisms that cause inappropriate pathway activation and their cellular consequences.  We also discuss the degree to which activated JAK/STAT signalling contributes to oncogenesis.  Studies showing the effect of activation of JAK/STAT signalling upon prognosis in several tumor types are summarized.  Finally, we discuss the prospects for treating solid tumors using strategies targeting JAK/STAT signalling, including what can be learned from haematol. malignancies and the extent to which results in solid tumors might be expected to differ.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZLyuJNOfIZrVg90H21EOLACvtfcHk0lj188FsY0bS6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7nJ&md5=d9c42818af6713ce510fea404982968e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2015.233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2015.233%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%2BJ.%26aulast%3DSnowden%26aufirst%3DJ.%2BA.%26aulast%3DZeidler%26aufirst%3DM.%2BP.%26aulast%3DDanson%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520role%2520of%2520JAK%252FSTAT%2520signalling%2520in%2520the%2520pathogenesis%252C%2520prognosis%2520and%2520treatment%2520of%2520solid%2520tumours%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2015%26volume%3D113%26spage%3D365%26epage%3D371%26doi%3D10.1038%2Fbjc.2015.233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mark, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Travis, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarkson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromberg, J. F.</span></span> <span> </span><span class="NLM_article-title">Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3846</span>– <span class="NLM_lpage">3856</span>, <span class="refDoi"> DOI: 10.1172/JCI31871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1172%2FJCI31871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=18060032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsValsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2007&pages=3846-3856&author=S.+P.+Gaoauthor=K.+G.+Markauthor=K.+Leslieauthor=W.+Paoauthor=N.+Motoiauthor=W.+L.+Geraldauthor=W.+D.+Travisauthor=W.+Bornmannauthor=D.+Veachauthor=B.+Clarksonauthor=J.+F.+Bromberg&title=Mutations+in+the+EGFR+kinase+domain+mediate+STAT3+activation+via+IL-6+production+in+human+lung+adenocarcinomas&doi=10.1172%2FJCI31871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas</span></div><div class="casAuthors">Gao, Sizhi Paul; Mark, Kavin G.; Leslie, Kenneth; Pao, William; Motoi, Noriko; Gerald, William L.; Travis, William D.; Bornmann, William; Veach, Darren; Clarkson, Bayard; Bromberg, Jacqueline F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3846-3856</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas.  PSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR.  Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis.  Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels.  In addn., redn. of IL-6 levels by RNA interference led to a decrease in tumorigenesis.  Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade.  Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased prodn. and release of IL-6.  Finally, immunohistochem. anal. revealed a pos. correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas.  Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-fCYAz8G9S7Vg90H21EOLACvtfcHk0lgDIq7-QhnUig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsValsL%252FO&md5=4043bc2cf3aecbfbfb3fbd8bf99d6aef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1172%2FJCI31871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI31871%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DS.%2BP.%26aulast%3DMark%26aufirst%3DK.%2BG.%26aulast%3DLeslie%26aufirst%3DK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMotoi%26aufirst%3DN.%26aulast%3DGerald%26aufirst%3DW.%2BL.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DVeach%26aufirst%3DD.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DBromberg%26aufirst%3DJ.%2BF.%26atitle%3DMutations%2520in%2520the%2520EGFR%2520kinase%2520domain%2520mediate%2520STAT3%2520activation%2520via%2520IL-6%2520production%2520in%2520human%2520lung%2520adenocarcinomas%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2007%26volume%3D117%26spage%3D3846%26epage%3D3856%26doi%3D10.1172%2FJCI31871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1083/jcb.200703184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1083%2Fjcb.200703184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=17908914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOntb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2007&pages=129-138&author=L.+Sunauthor=K.+Maauthor=H.+Wangauthor=F.+Xiaoauthor=Y.+Gaoauthor=W.+Zhangauthor=K.+Wangauthor=X.+Gaoauthor=N.+Ipauthor=Z.+Wu&title=JAK1-STAT1-STAT3%2C+a+key+pathway+promoting+proliferation+and+preventing+premature+differentiation+of+myoblasts&doi=10.1083%2Fjcb.200703184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">JAK1-STAT1-STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts</span></div><div class="casAuthors">Sun, Luguo; Ma, Kewei; Wang, Haixia; Xiao, Fang; Gao, Yan; Zhang, Wei; Wang, Kepeng; Gao, Xiang; Ip, Nancy; Wu, Zhenguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-138</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Skeletal muscle stem cell-derived myoblasts are mainly responsible for postnatal muscle growth and injury-induced muscle regeneration.  However, the cellular signaling pathways controlling the proliferation and differentiation of myoblasts are not fully understood.  We demonstrate that Janus kinase 1 (JAK1) is required for myoblast proliferation and that it also functions as a checkpoint to prevent myoblasts from premature differentiation.  Deliberate knockdown of JAK1 in both primary and immortalized myoblasts induces precocious myogenic differentiation with a concomitant redn. in cell proliferation.  This is caused, in part, by an accelerated induction of MyoD, myocyte enhancer-binding factor 2 (MEF2), p21Cip1, and p27Kip1, a faster down-regulation of Id1, and an increase in MEF2-dependent gene transcription.  Downstream of JAK1, of all the signal transducer and activator of transcriptions (STATs) present in myoblasts, we find that only STAT1 knockdown promotes myogenic differentiation in both primary and immortalized myoblasts.  Leukemia inhibitory factor stimulates myoblast proliferation and represses differentiation via JAK1-STAT1-STAT3.  Thus, JAK1-STAT1-STAT3 constitutes a signaling pathway that promotes myoblast proliferation and prevents premature myoblast differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2roS_PhxgIrVg90H21EOLACvtfcHk0lgDIq7-QhnUig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOntb3N&md5=b5501295e3a0b113030216299cd69e3a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200703184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200703184%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DMa%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DGao%26aufirst%3DX.%26aulast%3DIp%26aufirst%3DN.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DJAK1-STAT1-STAT3%252C%2520a%2520key%2520pathway%2520promoting%2520proliferation%2520and%2520preventing%2520premature%2520differentiation%2520of%2520myoblasts%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2007%26volume%3D179%26spage%3D129%26epage%3D138%26doi%3D10.1083%2Fjcb.200703184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">JAKs and STATs in immunity, immunodeficiency, and cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1202117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1056%2FNEJMra1202117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=23301733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVyhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=161-170&author=J.+J.+O%E2%80%99Sheaauthor=S.+M.+Hollandauthor=L.+M.+Staudt&title=JAKs+and+STATs+in+immunity%2C+immunodeficiency%2C+and+cancer&doi=10.1056%2FNEJMra1202117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">JAKs and STATs in immunity, immunodeficiency, and cancer</span></div><div class="casAuthors">O'Shea, John J.; Holland, Steven M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-170</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review highlights interferon-mediated gene regulation has resulted in a new framework for the study of cell signaling and JAKs STATs in immunity, immunodeficiency, and cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1n-UgWrlWrVg90H21EOLACvtfcHk0lgDIq7-QhnUig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVyhuw%253D%253D&md5=5d87b67f72b721eb0ca9413adf92a7b9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1202117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1202117%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DHolland%26aufirst%3DS.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DJAKs%2520and%2520STATs%2520in%2520immunity%252C%2520immunodeficiency%252C%2520and%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D161%26epage%3D170%26doi%3D10.1056%2FNEJMra1202117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åstrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimster, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woessner, R.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1252754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1080%2F13543776.2017.1252754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=27774822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=145-161&author=J.+G.+Kettleauthor=A.+%C3%85strandauthor=M.+Catleyauthor=N.+P.+Grimsterauthor=M.+Nilssonauthor=Q.+Suauthor=R.+Woessner&title=Inhibitors+of+JAK-family+kinases%3A+an+update+on+the+patent+literature+2013-2015%2C+part+2&doi=10.1080%2F13543776.2017.1252754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2</span></div><div class="casAuthors">Kettle, Jason G.; Astrand, Annika; Catley, Matthew; Grimster, Neil P.; Nilsson, Magnus; Su, Qibin; Woessner, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-161</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are crit. in cytokine signalling and are strongly linked to both cancer and inflammatory diseases.  There are currently two launched JAK inhibitors for the treatment of human conditions: tofacitinib for Rheumatoid arthritis (RA) and ruxolitinib for myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera.  This review covers patents claiming activity against one or more JAK family members in the period 2013-2015 inclusive, and covers 95 patents from 42 applicants, split over two parts.  The authors have ordered recent patents according to the primary applicant's name, with part 2 covering J through Z.  Inhibition of JAK-family kinases is an area of growing interest, catalyzed by the maturity of data on marketed inhibitors ruxolitinib and tofacitinib in late stage clin. trials.  Many applicants are pursuing traditional fast-follower strategies around these inhibitors, with a range of chem. strategies adopted.  The challenge will be to show sufficient differentiation to the originator compds., since dose limiting toxicities with such agents appear to be on target and mechanism-related and also considering that such agents may be available as generic compds. by the time follower agents reach market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3xWVX0ADy67Vg90H21EOLACvtfcHk0lhkmRzngcDpPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhsl2htrnI&md5=c75e5d123fd35306665e0713f801320c</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1252754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1252754%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3D%25C3%2585strand%26aufirst%3DA.%26aulast%3DCatley%26aufirst%3DM.%26aulast%3DGrimster%26aufirst%3DN.%2BP.%26aulast%3DNilsson%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DWoessner%26aufirst%3DR.%26atitle%3DInhibitors%2520of%2520JAK-family%2520kinases%253A%2520an%2520update%2520on%2520the%2520patent%2520literature%25202013-2015%252C%2520part%25202%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D145%26epage%3D161%26doi%3D10.1080%2F13543776.2017.1252754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span>; <span class="NLM_string-name">Shepard, S.</span>; <span class="NLM_string-name">Arvanitis, A. G.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Storace, L.</span>; <span class="NLM_string-name">Folmer, B.</span>; <span class="NLM_string-name">Shao, L.</span>; <span class="NLM_string-name">Zhu, W.</span>; <span class="NLM_string-name">Glenn, J.</span></span> <span> </span><span class="NLM_article-title">N-(hetero)aryl-pyrrolidine Derivatives of Pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and Pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus Kinase Inhibitors</span>. <span class="NLM_patent">WO 2010135650 A120101125</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+D.+Rodgers&author=S.+Shepard&author=A.+G.+Arvanitis&author=H.+Wang&author=L.+Storace&author=B.+Folmer&author=L.+Shao&author=W.+Zhu&author=J.+Glenn&title=N-%28hetero%29aryl-pyrrolidine+Derivatives+of+Pyrazol-4-yl-pyrrolo%5B2%2C3-d%5Dpyrimidines+and+Pyrrol-3-yl-pyrrolo%5B2%2C3-d%5Dpyrimidines+as+Janus+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26atitle%3DN-%2528hetero%2529aryl-pyrrolidine%2520Derivatives%2520of%2520Pyrazol-4-yl-pyrrolo%255B2%252C3-d%255Dpyrimidines%2520and%2520Pyrrol-3-yl-pyrrolo%255B2%252C3-d%255Dpyrimidines%2520as%2520Janus%2520Kinase%2520Inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nolen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, G.</span></span> <span> </span><span class="NLM_article-title">Regulation of protein kinases; controlling activity through activation segment conformation</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">675</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2004.08.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=10.1016%2Fj.molcel.2004.08.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=15350212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFyhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=661-675&author=B.+Nolenauthor=S.+Taylorauthor=G.+Ghosh&title=Regulation+of+protein+kinases%3B+controlling+activity+through+activation+segment+conformation&doi=10.1016%2Fj.molcel.2004.08.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of protein kinases: Controlling activity through activation segment conformation</span></div><div class="casAuthors">Nolen, Brad; Taylor, Susan; Ghosh, Gourisankar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">661-675</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  There are currently at least 46 unique protein kinase crystal structures, 24 of which are available in an active state.  Here, the authors examine these structures using a structural bioinformatics approach to understand how the conformation of the activation segment controls kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAdRcy6kkUnbVg90H21EOLACvtfcHk0lhkmRzngcDpPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFyhsro%253D&md5=e1fc9a323c271a856ccd944a77c83a7f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.08.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.08.024%26sid%3Dliteratum%253Aachs%26aulast%3DNolen%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DG.%26atitle%3DRegulation%2520of%2520protein%2520kinases%253B%2520controlling%2520activity%2520through%2520activation%2520segment%2520conformation%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D661%26epage%3D675%26doi%3D10.1016%2Fj.molcel.2004.08.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lyne, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeh, J. C.</span></span> <span> </span><span class="NLM_article-title">Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4805</span>– <span class="NLM_lpage">4808</span>, <span class="refDoi"> DOI: 10.1021/jm060522a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060522a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFGjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4805-4808&author=P.+D.+Lyneauthor=M.+L.+Lambauthor=J.+C.+Saeh&title=Accurate+prediction+of+the+relative+potencies+of+members+of+a+series+of+kinase+inhibitors+using+molecular+docking+and+MM-GBSA+scoring&doi=10.1021%2Fjm060522a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Accurate Prediction of the Relative Potencies of Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring</span></div><div class="casAuthors">Lyne, Paul D.; Lamb, Michelle L.; Saeh, Jamal C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4805-4808</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ability of mol. docking, using the program Glide and an MM-GBSA postdocking scoring protocol, to correctly rank a no. of congeneric kinase inhibitors was assessed.  The approach was successful for the cases considered and suggests that this may be useful for the design of inhibitors in the lead optimization phase of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVyYUu0E1ua7Vg90H21EOLACvtfcHk0lhkmRzngcDpPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFGjs7s%253D&md5=ea44ed5036a1569d191481bf10c74889</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm060522a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060522a%26sid%3Dliteratum%253Aachs%26aulast%3DLyne%26aufirst%3DP.%2BD.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DSaeh%26aufirst%3DJ.%2BC.%26atitle%3DAccurate%2520prediction%2520of%2520the%2520relative%2520potencies%2520of%2520members%2520of%2520a%2520series%2520of%2520kinase%2520inhibitors%2520using%2520molecular%2520docking%2520and%2520MM-GBSA%2520scoring%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4805%26epage%3D4808%26doi%3D10.1021%2Fjm060522a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aastrand, A. B. M.</span>, <span class="NLM_string-name">Grimster, N. P.</span>; <span class="NLM_string-name">Kawatkar, S.</span>; <span class="NLM_string-name">Kettle, J. G.</span>; <span class="NLM_string-name">Nilsson, M. K.</span></span>.; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L. L.</span>; <span class="NLM_string-name">Su, Q.</span>; <span class="NLM_string-name">Vasbinder, M. M.</span>; <span class="NLM_string-name">Winter-Holt, J. J.</span>; <span class="NLM_string-name">Wu, D.</span>; <span class="NLM_string-name">Yang, W.</span>; <span class="NLM_string-name">Grecu, T.</span>; <span class="NLM_string-name">McCabe, J.</span>; <span class="NLM_string-name">Woessner, R. D.</span>; <span class="NLM_string-name">Chuaqui, C. E.</span></span> , <span> </span><span class="NLM_article-title">Preparation of Substituted 2-(piperazin-1-yl)-N-[3-[2-[(1H-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl] Propanamide as Selective JAK1 Inhibitors for Treating Cancers and Immune Disorders</span>. <span class="NLM_patent">WO201750938</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+B.+M.+Aastrand&author=N.+P.+Grimster&author=S.+Kawatkar&author=J.+G.+Kettle&author=M.+K.+Nilssonauthor=L.+L.+Ruston&author=Q.+Su&author=M.+M.+Vasbinder&author=J.+J.+Winter-Holt&author=D.+Wu&author=W.+Yang&author=T.+Grecu&author=J.+McCabe&author=R.+D.+Woessner&author=C.+E.+Chuaqui&title=Preparation+of+Substituted+2-%28piperazin-1-yl%29-N-%5B3-%5B2-%5B%281H-pyrazol-4-yl%29amino%5Dpyrimidin-4-yl%5D-1H-indol-7-yl%5D+Propanamide+as+Selective+JAK1+Inhibitors+for+Treating+Cancers+and+Immune+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAastrand%26aufirst%3DA.%2BB.%2BM.%26aulast%3DRuston%26aufirst%3DL.%2BL.%26atitle%3DPreparation%2520of%2520Substituted%25202-%2528piperazin-1-yl%2529-N-%255B3-%255B2-%255B%25281H-pyrazol-4-yl%2529amino%255Dpyrimidin-4-yl%255D-1H-indol-7-yl%255D%2520Propanamide%2520as%2520Selective%2520JAK1%2520Inhibitors%2520for%2520Treating%2520Cancers%2520and%2520Immune%2520Disorders%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. É.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7048</span>, <span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+E.+Crossauthor=L.+A.+Dakinauthor=J.+%C3%89.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+M.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0lhUZyviO_J3GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2B%25C3%2589.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0liK-sQc0_ctxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SM8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6SM8','PDB','6SM8'); return false;">PDB: 6SM8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GGH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GGH','PDB','6GGH'); return false;">PDB: 6GGH</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i16"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01392">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_00516"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01392?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01392</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Compound synthesis, characterization, crystallographic information, kinase panel selectivity data, additional DMPK data, compound purity data, and NMR spectra of selected compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of the compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_001.pdf">jm9b01392_si_001.pdf (1.91 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01392/suppl_file/jm9b01392_si_002.csv">jm9b01392_si_002.csv (2.06 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01392&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-9%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01392%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01392" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6f78ebf63cac","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
